Safety and Tumor Responses with Lambrolizumab (Ant

New England Journal of Medicine
369, 134-144
DOI: 10.1056/nejmoa1305133

Citation Report

#	Article	IF	Citations
1	Pathology of Hematopoietic Stem Cell Transplantation. , 0, , 260-293.		0
2	Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions. Journal of Immunology, 2008, 181, 7660-7669.	0.4	181
3	Combination Checkpoint Blockade â€" Taking Melanoma Immunotherapy to the Next Level. New England Journal of Medicine, 2013, 369, 187-189.	13.9	65
4	Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors. , 2013, 1, 11.		56
5	Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity, 2013, 39, 1-10.	6.6	4,815
6	Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies. European Journal of Cancer, 2013, 49, 2968-2971.	1.3	84
7	Zebrafish cancer: the state of the art and the path forward. Nature Reviews Cancer, 2013, 13, 624-636.	12.8	349
8	The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma. Clinical Cancer Research, 2013, 19, 5320-5328.	3.2	226
9	Metastatic melanoma: New paradigms of treatment and new toxicities. European Journal of Cancer, Supplement, 2013, 11, 278-280.	2.2	1
10	Molecular Pathways: Coexpression of Immune Checkpoint Molecules: Signaling Pathways and Implications for Cancer Immunotherapy. Clinical Cancer Research, 2013, 19, 4917-4924.	3.2	244
11	Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with antiâ€"PD-L1 immunotherapy in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20212-20217.	3.3	1,482
12	Management of Primary Cutaneous and Metastatic Melanoma. Seminars in Oncology Nursing, 2013, 29, 195-205.	0.7	14
13	Turning Tumors into Vaccines: Co-opting the Innate Immune System. Immunity, 2013, 39, 27-37.	6.6	93
14	Microenvironmental regulation of tumor progression and metastasis. Nature Medicine, 2013, 19, 1423-1437.	15.2	5,730
15	Challenging resistance mechanisms to therapies for metastatic melanoma. Trends in Pharmacological Sciences, 2013, 34, 656-666.	4.0	90
16	CNS Metastases in Breast Cancer: Old Challenge, New Frontiers. Clinical Cancer Research, 2013, 19, 6404-6418.	3.2	162
17	Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy. Cancer Immunology Research, 2013, 1, 373-377.	1.6	100
18	Antibody Therapeutics in Cancer. Science, 2013, 341, 1192-1198.	6.0	474

#	Article	IF	Citations
19	CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients. Clinical Cancer Research, 2013, 19, 5300-5309.	3.2	596
20	ASCO 2013â€"treatment of metastatic melanoma: is it still a story of success?. Memo - Magazine of European Medical Oncology, 2013, 6, 244-246.	0.3	0
21	Neoadjuvant treatment of melanoma: case reports and review. Experimental Hematology and Oncology, 2013, 2, 30.	2.0	7
22	Immunotherapy and the concept of a clinical cure. European Journal of Cancer, 2013, 49, 2965-2967.	1.3	41
23	Immunotherapy at Large: Balancing tumor immunity and inflammatory pathology. Nature Medicine, 2013, 19, 1100-1101.	15.2	30
24	Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. European Journal of Cancer, 2013, 49, 3229-3241.	1.3	40
25	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nature Reviews Clinical Oncology, 2013, 10, 588-598.	12.5	177
26	GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability. Cancer Immunology Research, 2013, 1, 320-331.	1.6	135
27	HLA ligandome tumor antigen discovery for personalized vaccine approach. Expert Review of Vaccines, 2013, 12, 1211-1217.	2.0	87
29	Anti-PD-1 approachesâ€"important steps forward in metastatic melanoma. Nature Reviews Clinical Oncology, 2013, 10, 365-365.	12.5	10
30	Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer. Cancer Immunology Research, 2013, 1, 85-91.	1.6	161
31	The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be. Clinical Cancer Research, 2013, 19, 5283-5291.	3.2	54
32	Emerging BRAF inhibitors for melanoma. Expert Opinion on Emerging Drugs, 2013, 18, 431-443.	1.0	5
33	Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma. Journal of Clinical Oncology, 2013, 31, 4311-4318.	0.8	515
34	AACR Cancer Progress Report 2013. Clinical Cancer Research, 2013, 19, S1-S98.	3.2	55
35	Immunotherapy in Lung Cancer: â€œB7-Bombersâ€•and Other New Developments. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 810-821.	0.8	6
36	Impact of MAPK Pathway Activation in BRAFV600 Melanoma on T Cell and Dendritic Cell Function. Frontiers in Immunology, 2013, 4, 346.	2.2	36
37	Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes. OncoImmunology, 2013, 2, e26014.	2.1	20

#	Article	IF	Citations
38	Renal Cell Carcinoma. Journal of Immunotherapy, 2013, 36, 459-461.	1.2	3
39	T Cells and Costimulation in Cancer. Cancer Journal (Sudbury, Mass), 2013, 19, 473-482.	1.0	22
40	Drug development: Releasing the brakes. Nature, 2013, 504, S6-S8.	13.7	17
41	Lysophosphatidic Acid Inhibits CD8 T-cell Activation and Control of Tumor Progression. Cancer Immunology Research, 2013, 1, 245-255.	1.6	71
42	Dabrafenib for treatment of BRAF-mutant melanoma. Pharmacogenomics and Personalized Medicine, 2013, 7, 21.	0.4	14
43	TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. Frontiers in Immunology, 2013, 4, 363.	2.2	70
44	Role of T Cell Receptor Affinity in the Efficacy and Specificity of Adoptive T Cell Therapies. Frontiers in Immunology, 2013, 4, 244.	2.2	79
45	Programmed Cell Death 1-Directed Immunotherapy for Enhancing T-Cell Function. Cold Spring Harbor Symposia on Quantitative Biology, 2013, 78, 239-247.	2.0	38
46	Melanoma: From Melanocyte to Genetic Alterations and Clinical Options. Scientifica, 2013, 2013, 1-22.	0.6	80
47	Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies. Clinical Pharmacology and Therapeutics, 2013, 95, 24-31.	2.3	75
48	Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. OncoImmunology, 2013, 2, e27010.	2.1	45
49	Human Vaccines & Immunotherapeutics: News. Human Vaccines and Immunotherapeutics, 2013, 9, 1395-1398.	1.4	1
50	Immune alterations in malignant melanoma and current immunotherapy concepts. Expert Opinion on Biological Therapy, 2013, 13, 1413-1427.	1.4	19
51	Vemurafenib-Induced Pulmonary Injury. Onkologie, 2013, 36, 685-686.	1.1	7
52	Adoptive Cell Transfer for Patients with Metastatic Melanoma: The Potential and Promise of Cancer Immunotherapy. Cancer Control, 2013, 20, 289-297.	0.7	95
53	Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity. Clinical Pharmacology: Advances and Applications, 2013, 5, 1.	0.8	8
54	PD-1 Blockade in Chronically HIV-1-Infected Humanized Mice Suppresses Viral Loads. PLoS ONE, 2013, 8, e77780.	1.1	85
55	Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. Frontiers in Immunology, 2013, 4, 417.	2.2	62

#	Article	IF	Citations
56	Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients. Clinical and Developmental Immunology, 2013, 2013, 1-8.	3.3	9
57	Melanoma vaccines: trials and tribulations. Vaccine (Auckland, N Z), 0, , 57.	1.7	12
58	Treating Metastatic Melanoma in 2014: What Just Happened and What Is Next?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 16-19.	1.8	1
59	Frontline Approach to Metastatic BRAF-Mutant Melanoma Diagnosis, Molecular Evaluation, and Treatment Choice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e412-e421.	1.8	4
60	Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights. Journal of Receptor, Ligand and Channel Research, 2014, , 1.	0.7	2
61	New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Management and Research, 2014, 6, 63.	0.9	68
62	Avoidance of Cancer Cell Destruction by the Immune System. , 2014, , 434-443.		0
63	Therapeutic cancer vaccines and combination immunotherapies involving vaccination. ImmunoTargets and Therapy, 2014, 3, 135.	2.7	9
64	Genetic Diversity of the KIR/HLA System and Outcome of Patients with Metastatic Colorectal Cancer Treated with Chemotherapy. PLoS ONE, 2014, 9, e84940.	1.1	40
65	Systemic CD8+ T Cell-Mediated Tumoricidal Effects by Intratumoral Treatment of Oncolytic Herpes Simplex Virus with the Agonistic Monoclonal Antibody for Murine Glucocorticoid-Induced Tumor Necrosis Factor Receptor. PLoS ONE, 2014, 9, e104669.	1.1	12
66	Ask ACCC's Community Resource Centers: Pancreatic Cancer. Oncology Issues, 2014, 29, 60-62.	0.0	0
67	Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmacogenomics and Personalized Medicine, 2014, 7, 357.	0.4	60
68	New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy. Drug, Healthcare and Patient Safety, 2014, 6, 77.	1.0	32
69	Pathways and therapeutic targets in melanoma. Oncotarget, 2014, 5, 1701-1752.	0.8	202
70	PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. OncoTargets and Therapy, 2014, 7, 1349.	1.0	37
71	Colorectal cancer and immunity: What we know and perspectives. World Journal of Gastroenterology, 2014, 20, 3738.	1.4	105
72	PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases. Journal of Cancer, 2014, 5, 166-172.	1.2	140
73	Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Design, Development and Therapy, 2014, 8, 775.	2.0	32

#	Article	IF	Citations
74	The Importance of a Biopsychosocial Approach in Melanoma ResearchExperiences from a Single-center Multidisciplinary Melanoma Working Group in Middle-Europe. Acta Dermato-Venereologica, 2014, 96, 51-4.	0.6	1
75	The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy. Immune Network, 2014, 14, 265.	1.6	78
76	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
77	Pancreatic Cancer Fostered Immunosuppression Privileges Tumor Growth and Progression. Journal of Clinical & Cellular Immunology, 2014, 05, .	1.5	3
78	PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. Journal of Clinical Investigation, 2014, 124, 2246-2259.	3.9	892
80	Interactions between Siglec-7/9 receptors and ligands influence NK cellâ€“dependent tumor immunosurveillance. Journal of Clinical Investigation, 2014, 124, 1810-1820.	3.9	340
81	New Agents and New Targets for Renal Cell Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e222-e227.	1.8	26
82	Precision Cancer Medicine: The Future Is Now, Only Better. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 61-69.	1.8	38
83	Trial watch. OncoImmunology, 2014, 3, e29030.	2.1	51
84	Awareness and understanding of cancer immunotherapy in Europe. Human Vaccines and Immunotherapeutics, 2014, 10, 1828-1835.	1.4	6
85	The Use of Anti-CD40 mAb in Cancer. Current Topics in Microbiology and Immunology, 2014, 405, 165-207.	0.7	21
86	AACR Cancer Progress Report 2014. Clinical Cancer Research, 2014, 20, S1-S112.	3.2	48
87	Tumor cell lysates as immunogenic sources for cancer vaccine design. Human Vaccines and Immunotherapeutics, 2014, 10, 3261-3269.	1.4	126
88	PD-1 and PD-L1 antibodies for melanoma. Human Vaccines and Immunotherapeutics, 2014, 10, 3111-3116.	1.4	54
89	Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer. Expert Review of Vaccines, 2014, 13, 87-116.	2.0	3
90	Biomarkers in melanoma: where are we now?. Melanoma Management, 2014, 1, 139-150.	0.1	1
91	Trial watch: IDO inhibitors in cancer therapy. OncoImmunology, 2014, 3, e957994.	2.1	223
92	Trial Watch. OncoImmunology, 2014, 3, e27297.	2.1	99

#	Article	IF	Citations
93	<scp>PD</scp>â€1 expression on peripheral blood Tâ€cell subsets correlates with prognosis in nonâ€small cell lung cancer. Cancer Science, 2014, 105, 1229-1235.	1.7	64
94	Economic evaluation of therapeutic cancer vaccines and immunotherapy: A systematic review. Human Vaccines and Immunotherapeutics, 2014, 10, 3415-3424.	1.4	39
95	Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. Expert Opinion on Biological Therapy, 2014, 14, 663-686.	1.4	17
96	Drugs that Act on the Immune System. Side Effects of Drugs Annual, 2014, , 561-590.	0.6	1
97	New Strategies in Ewing Sarcoma: Lost in Translation?. Clinical Cancer Research, 2014, 20, 3050-3056.	3.2	28
98	Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. , 2014, 2, 33.		52
99	Melanoma immunotherapy. Cancer Biology and Therapy, 2014, 15, 665-674.	1.5	73
100	Exomics and immunogenics. OncoImmunology, 2014, 3, e27817.	2.1	178
101	High sensitivity of cancer exome-based CD8 T cell neo-antigen identification. OncoImmunology, 2014, 3, e28836.	2.1	85
102	Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. OncoImmunology, 2014, 3, e27560.	2.1	38
104	Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma. , 2014, 2, 41.		80
105	Anti-PD-1 antibodies for the treatment of B-cell lymphoma. OncoImmunology, 2014, 3, e28101.	2.1	5
106	Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer. Journal of the National Cancer Institute, 2014, 106, .	3.0	298
107	Programmed Death-1 Impairs Secondary Effector Lung CD8+ T Cells during Respiratory Virus Reinfection. Journal of Immunology, 2014, 193, 5108-5117.	0.4	39
108	Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity. Cell Death and Disease, 2014, 5, e1568-e1568.	2.7	42
109	Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. Blood Cancer Journal, 2014, 4, e236-e236.	2.8	54
110	Indomethacin to the Rescue of TRAIL-Resistant Melanomas. Journal of Investigative Dermatology, 2014, 134, 1198-1199.	0.3	4
111	DC-HIL + CD14 + HLA-DR no/low Cells Are a Potential Blood Marker and Therapeutic Target for Melanoma. Journal of Investigative Dermatology, 2014, 134, 2839-2842.	0.3	11

#	Article	IF	Citations
112	Antibodies to watch in 2014. MAbs, 2014, 6, 5-14.	2.6	90
113	Successes and Limitations of Targeted Cancer Therapy in Melanoma. Progress in Tumor Research, 2014, 41, 78-88.	0.1	4
114	Sentinel lymph node biopsy in melanoma: controversies and current guidelines. Future Oncology, 2014, 10, 429-442.	1.1	14
115	Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor. Molecular Therapy, 2014, 22, 1211-1220.	3.7	145
116	Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. Modern Pathology, 2014, 27, 1193-1202.	2.9	18
117	Agonistic CD200R1 DNA Aptamers Are Potent Immunosuppressants That Prolong Allogeneic Skin Graft Survival. Molecular Therapy - Nucleic Acids, 2014, 3, e190.	2.3	17
118	Overcoming tumor-mediated immunosuppression. Immunotherapy, 2014, 6, 973-988.	1.0	38
119	The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade. Clinical Cancer Research, 2014, 20, 4982-4984.	3.2	80
120	The inducible caspase-9 suicide gene system as a Ã¢â‚¬Å“safety switchÃ¢â‚¬Â•to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Frontiers in Pharmacology, 2014, 5, 235.	1.6	280
121	Is vaccine research still relevant for metastatic melanoma?. Melanoma Management, 2014, 1, 91-94.	0.1	5
122	BRAF and beyond: Tailoring strategies for the individual melanoma patient. Journal of Carcinogenesis, 2014, 13, 1.	2.5	19
123	The MEK inhibitor trametinib for the treatment of advanced melanoma. Expert Opinion on Orphan Drugs, 2014, 2, 1341-1349.	0.5	0
125	Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?. Laboratory Investigation, 2014, 94, 13-30.	1.7	63
126	Immune checkpoints in cancer clinical trials. Chinese Journal of Cancer, 2014, 33, 434-444.	4.9	96
127	ÃŽÂ³ÃŽÂ´Ã¢â‚¬â€°T Lymphocytes as a First Line of Immune Defense: Old and New Ways of Antigen Recognition and Implications for Cancer Immunotherapy. Frontiers in Immunology, 2014, 5, 575.	2.2	57
128	Treating advanced melanoma: current insights and opportunities. Cancer Management and Research, 2014, 6, 349.	0.9	33
129	High-risk cutaneous melanoma follow-up: time for more intensive surveillance?. Melanoma Management, 2014, 1, 7-10.	0.1	1
131	A Chemically Defined Trifunctional Antibodyâ€“Cytokineâ€“Drug Conjugate with Potent Antitumor Activity. Molecular Cancer Therapeutics, 2014, 13, 2641-2652.	1.9	32

#	Article	IF	Citations
132	New treatments for metastatic melanoma. Cmaj, 2014, 186, 754-760.	0.9	9
133	Targeting CD8⁺T-cell tolerance for cancer immunotherapy. Immunotherapy, 2014, 6, 833-852.	1.0	41
134	Does vaccine-primed pancreatic cancer offer better candidates for immune-based therapies?. Immunotherapy, 2014, 6, 1017-1020.	1.0	10
135	The adaptation model of immunity. Immunotherapy, 2014, 6, 59-70.	1.0	11
136	Therapeutic cancer vaccines: a long and winding road to success. Expert Review of Vaccines, 2014, 13, 131-144.	2.0	12
137	Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma. Cancer Immunology Research, 2014, 2, 1051-1058.	1.6	74
138	Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex. Open Biology, 2014, 4, 140030.	1.5	11
139	CD160 expression defines a uniquely exhausted subset of T lymphocytes in HTLV-1 infection. Biochemical and Biophysical Research Communications, 2014, 453, 379-384.	1.0	14
140	Immunotherapy in pediatric malignancies: current status and future perspectives. Future Oncology, 2014, 10, 1659-1678.	1.1	11
141	Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy. Future Oncology, 2014, 10, 1779-1794.	1.1	12
142	Reâ€adapting T cells for cancer therapy: from mouse models to clinical trials. Immunological Reviews, 2014, 257, 145-164.	2.8	67
143	Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2965-2970.	1.1	432
144	Nano-Oncologicals. Advances in Delivery Science and Technology, 2014, , .	0.4	7
145	<scp>TCR</scp> repertoires of intratumoral Tâ€cell subsets. Immunological Reviews, 2014, 257, 72-82.	2.8	59
146	Targeted therapy in melanoma: the era of personalized medicine. Diagnostic Histopathology, 2014, 20, 425-430.	0.2	1
147	Isolated limb perfusion for inâ€transit melanoma metastases: Melphalan or TNFâ€melphalan perfusion?. Journal of Surgical Oncology, 2014, 109, 338-347.	0.8	26
148	PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature, 2014, 515, 568-571.	13.7	5,429
149	Cosmic triangles and black-hole masses. Nature, 2014, 515, 498-499.	13.7	0

#	Article	IF	Citations
150	Antitumour immunity gets a boost. Nature, 2014, 515, 496-498.	13.7	90
151	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014, 515, 563-567.	13.7	4,342
152	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature, 2014, 515, 577-581.	13.7	1,705
153	High-Dose IL2 in Metastatic Melanoma: Better Survival in Patients Immunized with Antigens from Autologous Tumor Cell Lines. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 53-57.	0.7	14
154	Î³Î´ T cells for cancer immunotherapy. OncoImmunology, 2014, 3, e27572.	2.1	158
155	IgEâ€based immunotherapy of cancer: challenges and chances. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 137-149.	2.7	29
156	Antitumor CD8⁺T cells in hepatocellular carcinoma: Present but exhausted. Hepatology, 2014, 59, 1232-1234.	3.6	17
157	Animal models of vitiligo: Matching the model to the question. Dermatologica Sinica, 2014, 32, 240-247.	0.2	24
158	Rush Hour Traffic: Directing T Cells to Tumor. Journal of the National Cancer Institute, 2014, 106, dju301-dju301.	3.0	0
159	Intralesional immunotherapy for melanoma. Journal of Surgical Oncology, 2014, 109, 320-326.	0.8	54
160	Major therapeutic developments and current challenges in advanced melanoma. British Journal of Dermatology, 2014, 170, 36-44.	1.4	20
161	Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nature Communications, 2014, 5, 5241.	5.8	780
162	Harnessing the PD-1 Pathway in Renal Cell Carcinoma: Current Evidence and Future Directions. BioDrugs, 2014, 28, 513-526.	2.2	7
163	Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma. JAMA - Journal of the American Medical Association, 2014, 312, 1744.	3.8	312
164	Molecular Determinants of Head and Neck Cancer. , 2014, , .		2
165	Dabrafenib for the treatment of melanoma. Expert Opinion on Pharmacotherapy, 2014, 15, 1043-1050.	0.9	4
168	Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab. Clinical Cancer Research, 2014, 20, 3310-3318.	3.2	29
169	Strategies for modern biomarker and drug development in oncology. Journal of Hematology and Oncology, 2014, 7, 70.	6.9	98

#	Article	IF	Citations
170	Melanoma brain metastasis globally reconfigures chemokine and cytokine profiles in patient cerebrospinal fluid. Melanoma Research, 2014, 24, 120-130.	0.6	30
171	Animal models for viral infection and cell exhaustion. Current Opinion in HIV and AIDS, 2014, 9, 492-499.	1.5	5
172	Sentinel node followed by completion lymph node dissection versus nodal observation. Melanoma Research, 2014, 24, 291-294.	0.6	25
173	Emerging new anticancer therapies in 2013. Current Opinion in Oncology, 2014, 26, 357-362.	1.1	2
174	The role of systemic therapies in the management of melanoma brain metastases. Current Opinion in Oncology, 2014, 26, 222-229.	1.1	19
175	Where to start with systemic melanoma therapy?. Melanoma Management, 2014, 1, 15-18.	0.1	0
176	Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression. OncoImmunology, 2014, 3, e28499.	2.1	68
177	Hepatic yttrium-90 radioembolization for metastatic melanoma. Melanoma Research, 2014, 24, 244-251.	0.6	23
178	Implementing combinatorial immunotherapeutic regimens against cancer. OncoImmunology, 2014, 3, e27588.	2.1	13
179	The perspective of immunotherapy. Current Opinion in Oncology, 2014, 26, 204-214.	1.1	64
180	B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis. Journal of Thoracic Oncology, 2014, 9, 1036-1040.	0.5	208
181	Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation. Cancer Journal (Sudbury, Mass), 2014, 20, 256-261.	1.0	131
182	Current Systemic Therapies for Melanoma. Dermatologic Surgery, 2014, 40, 948-963.	0.4	29
183	Perspectives for immunotherapy in glioblastoma treatment. Current Opinion in Oncology, 2014, 26, 608-614.	1.1	26
184	Harnessing the immune system for cancer therapy. Current Opinion in Oncology, 2014, 26, 600-607.	1.1	25
185	Distinctive features of CD4+ T cell dysfunction in chronic viral infections. Current Opinion in HIV and AIDS, 2014, 9, 446-451.	1.5	41
186	Subverting the B7-H1/PD-1 Pathway in Advanced Melanoma and Kidney Cancer. Cancer Journal (Sudbury,) Tj ETQq0 0 0 rgBT /Overlock 1	1.0	17
187	Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma. Clinical Cancer Research, 2014, 20, 4390-4399.	3.2	36

#	Article	IF	Citations
188	Immune Cellâ€“Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation. Cancer Discovery, 2014, 4, 674-687.	7.7	226
189	Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. OncoImmunology, 2014, 3, e962401.	2.1	37
190	Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity. OncoImmunology, 2014, 3, e955684.	2.1	44
191	HIV-1 Tat Protein Induces PD-L1 (B7-H1) Expression on Dendritic Cells through Tumor Necrosis Factor Alpha- and Toll-Like Receptor 4-Mediated Mechanisms. Journal of Virology, 2014, 88, 6672-6689.	1.5	48
192	Targeted therapies for cutaneous T-cell lymphomas. Expert Review of Hematology, 2014, 7, 481-493.	1.0	6
193	Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1. Frontiers in Immunology, 2014, 5, 206.	2.2	108
194	Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma. Human Vaccines and Immunotherapeutics, 2014, 10, 970-976.	1.4	47
195	Immunotherapeutic implications of the immunophenotype of pediatric brain tumors. OncoImmunology, 2014, 3, e27256.	2.1	5
196	Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. OncoImmunology, 2014, 3, e29244.	2.1	83
197	Armed Therapeutic Viruses â€“ A Disruptive Therapy on the Horizon of Cancer Immunotherapy. Frontiers in Immunology, 2014, 5, 74.	2.2	39
198	Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade. Cancer Immunology Research, 2014, 2, 643-654.	1.6	226
199	Early Carcinogenesis Involves the Establishment of Immune Privilege via Intrinsic and Extrinsic Regulation of Indoleamine 2,3-dioxygenase-1: Translational Implications in Cancer Immunotherapy. Frontiers in Immunology, 2014, 5, 438.	2.2	12
200	Detection of Binding of a Synthetic Granzyme B-like Peptide Fluorescent Conjugate within Platelet-like Structures in Cancer-related Peripheral Blood Specimens and Tissue Sections. Journal of Fluorescence, 2014, 24, 1473-1479.	1.3	2
201	Immunoguiding, the Final Frontier in the Immunotherapy of Cancer. , 2014, , 37-51.		0
202	Extracranial oligometastatic renal cell carcinoma: current management and future directions. Future Oncology, 2014, 10, 761-774.	1.1	27
203	Drug development: A chance of survival. Nature, 2014, 515, S118-S120.	13.7	8
204	Evaluating biomarkers in melanoma. Frontiers in Oncology, 2014, 4, 383.	1.3	38
205	Combination Therapies for the Treatment of Advanced Melanoma: A Review of Current Evidence. Biochemistry Research International, 2014, 2014, 1-9.	1.5	18

#	Article	IF	Citations
206	Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an â€œInnocent Bystanderâ€• Toxins, 2014, 6, 914-933.	1.5	62
207	T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors. Clinical Cancer Research, 2014, 20, 1768-1778.	3.2	81
208	Untreated Stage IV Melanoma Patients Exhibit Abnormal Monocyte Phenotypes and Decreased Functional Capacity. Cancer Immunology Research, 2014, 2, 241-248.	1.6	29
209	Immunotherapy of hepatocellular carcinoma. Hepatic Oncology, 2014, 1, 433-446.	4.2	5
210	Adverse events of targeted therapies. Current Opinion in Oncology, 2014, 26, 395-402.	1.1	13
211	Coinhibitory receptors and CD8 T cell exhaustion in chronic infections. Current Opinion in HIV and AIDS, 2014, 9, 439-445.	1.5	64
212	Blockade of the B7-H1/PD-1 Pathway as a Basis for Combination Anticancer Therapy. Cancer Journal (Sudbury, Mass), 2014, 20, 290-295.	1.0	32
213	Cutaneous melanoma. Lancet, The, 2014, 383, 816-827.	6.3	465
214	New drug targets in metastatic melanoma. Journal of Pathology, 2014, 232, 134-141.	2.1	50
215	Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncology, The, 2014, 15, 69-77.	5.1	518
216	Adjuvant chemotherapy for rectal cancerâ€”an unresolved issue. Nature Reviews Clinical Oncology, 2014, 11, 182-184.	12.5	22
217	Potential of New Therapies like Anti-PD1 in Kidney Cancer. Current Treatment Options in Oncology, 2014, 15, 137-146.	1.3	39
218	Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Critical Care, 2014, 18, R3.	2.5	236
219	Regulatory T cells in cancer immunotherapy. Current Opinion in Immunology, 2014, 27, 1-7.	2.4	612
220	Human relevance of NRAS/BRAF mouse melanoma models. European Journal of Cell Biology, 2014, 93, 82-86.	1.6	19
221	Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities. Critical Reviews in Oncology/Hematology, 2014, 89, 140-165.	2.0	148
222	Immunotherapy for solid tumorsâ€”a review for surgeons. Journal of Surgical Research, 2014, 187, 525-535.	0.8	16
223	Targeted therapies in gastroesophageal cancer. European Journal of Cancer, 2014, 50, 1247-1258.	1.3	45

#	Article	IF	Citations
224	Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Current Opinion in Immunology, 2014, 27, 89-97.	2.4	111
225	Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer, 2014, 120, 1695-1701.	2.0	195
227	Regulation of the anti-tumour immune response by cancer-associated fibroblasts. Seminars in Cancer Biology, 2014, 25, 69-77.	4.3	214
228	Programmed death-1 pathway in cancer and autoimmunity. Clinical Immunology, 2014, 153, 145-152.	1.4	218
229	Anti-vascular endothelial growth factor receptor (VEGFR) 2 autoantibody identification in glioblastoma patient using single B cell-based antibody gene cloning. Immunology Letters, 2014, 159, 15-22.	1.1	6
230	Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape. Cancer Immunology Research, 2014, 2, 393-398.	1.6	278
231	Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. Immunotherapy, 2014, 6, 459-475.	1.0	88
232	Recent Clinical Advances in Lung Cancer Management. Journal of Clinical Oncology, 2014, 32, 973-982.	0.8	203
233	A cure for HIV: is it in sight?. Expert Review of Anti-Infective Therapy, 2014, 12, 783-791.	2.0	22
234	Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia, 2014, 28, 993-1000.	3.3	92
235	Immune Modulation in Cancer with Antibodies. Annual Review of Medicine, 2014, 65, 185-202.	5.0	455
236	Checkpoint blocking antibodies in cancer immunotherapy. FEBS Letters, 2014, 588, 368-376.	1.3	227
237	Interplay between DNA repair and inflammation, and the link to cancer. Critical Reviews in Biochemistry and Molecular Biology, 2014, 49, 116-139.	2.3	128
238	Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nature Reviews Cancer, 2014, 14, 135-146.	12.8	925
239	Beyond Sipuleucel-T: Immune Approaches to Treating Prostate Cancer. Current Treatment Options in Oncology, 2014, 15, 115-126.	1.3	13
240	Mitigating the toxic effects of anticancer immunotherapy. Nature Reviews Clinical Oncology, 2014, 11, 91-99.	12.5	189
241	Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends in Immunology, 2014, 35, 51-60.	2.9	513
242	Immunotherapy for prostate cancer: recent developments and future challenges. Cancer and Metastasis Reviews, 2014, 33, 641-655.	2.7	53

#	Article	IF	Citations
243	Molecularly targeted cancer therapy: some lessons from the past decade. Trends in Pharmacological Sciences, 2014, 35, 41-50.	4.0	255
244	Resistance to RAF Inhibitors Revisited. Journal of Investigative Dermatology, 2014, 134, 319-325.	0.3	62
245	Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nature Reviews Clinical Oncology, 2014, 11, 24-37.	12.5	380
246	The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opinion on Therapeutic Targets, 2014, 18, 1-14.	1.5	38
247	Immunotherapy for Malignant Pleural Mesothelioma. Current Status and Future Prospects. American Journal of Respiratory Cell and Molecular Biology, 2014, 50, 870-875.	1.4	23
248	Sex disparities in melanoma outcomes: The role of biology. Archives of Biochemistry and Biophysics, 2014, 563, 42-50.	1.4	53
249	Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clinical and Translational Immunology, 2014, 3, e22.	1.7	64
250	Immunotherapy and Radiation. Seminars in Oncology, 2014, 41, 702-713.	0.8	8
251	The melanoma revolution: From UV carcinogenesis to a new era in therapeutics. Science, 2014, 346, 945-949.	6.0	328
252	Smart therapeutic strategies in immuno-oncology. Nature Reviews Clinical Oncology, 2014, 11, 181-182.	12.5	20
253	Pembrolizumab: First Global Approval. Drugs, 2014, 74, 1973-1981.	4.9	134
254	Current management of advanced melanoma: a transformed landscape. ANZ Journal of Surgery, 2014, 84, 612-617.	0.3	13
255	Anti-PD1 Following Ipilimumab for Mucosal Melanoma: Durable Tumor Response Associated with Severe Hypothyroidism and Rhabdomyolysis. Cancer Immunology Research, 2014, 2, 15-18.	1.6	95
256	Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. New England Journal of Medicine, 2014, 371, 1867-1876.	13.9	1,824
257	Specificity Delivers: Therapeutic Role of Tumor Antigen-Specific Antibodies in Pancreatic Cancer. Seminars in Oncology, 2014, 41, 559-575.	0.8	3
258	Current Perspectives on Immunotherapy. Seminars in Oncology, 2014, 41, S14-S29.	0.8	28
259	PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Annals of Oncology, 2014, 25, 2433-2442.	0.6	119
260	The Optimal Partnership of Radiation and Immunotherapy: from Preclinical Studies to Clinical Translation. Radiation Research, 2014, 182, 170-181.	0.7	80

#	Article	IF	Citations
261	A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy. Journal of Immunology, 2014, 193, 4739-4747.	0.4	24
262	Molecular Diagnostics for Dermatology. , 2014, , .		2
263	The Curative Outcome of Radioimmunotherapy in a Mouse Breast Cancer Model Relies on mTOR Signaling. Radiation Research, 2014, 182, 219.	0.7	29
264	Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. Blood, 2014, 123, 2172-2180.	0.6	23
265	Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects. Clinical Cancer Research, 2014, 20, 6258-6268.	3.2	88
266	Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?. Cancer Immunology Research, 2014, 2, 831-838.	1.6	270
267	Immunotherapy advances for glioblastoma. Neuro-Oncology, 2014, 16, 1441-1458.	0.6	164
268	The Carcinoma-Associated Fibroblast Expressing Fibroblast Activation Protein and Escape from Immune Surveillance. Cancer Immunology Research, 2014, 2, 187-193.	1.6	223
269	MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells. Cancer Immunology Research, 2014, 2, 351-360.	1.6	122
270	Antibody-Based Immunotherapy for Malignant Glioma. Seminars in Oncology, 2014, 41, 496-510.	0.8	11
271	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, The, 2014, 384, 1109-1117.	6.3	1,588
272	Acquired and intrinsic resistance in cancer immunotherapy. Molecular Oncology, 2014, 8, 1132-1139.	2.1	153
273	Vaccine therapies for patients with glioblastoma. Journal of Neuro-Oncology, 2014, 119, 531-546.	1.4	32
274	Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?. Expert Review of Anticancer Therapy, 2014, 14, 1173-1187.	1.1	25
275	Tracking Cellular and Immune Therapies in Cancer. Advances in Cancer Research, 2014, 124, 257-296.	1.9	25
276	Immune modulation for cancer therapy. British Journal of Cancer, 2014, 111, 2214-2219.	2.9	128
277	LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses. Cancer Research, 2014, 74, 3418-3428.	0.4	270
278	T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?. Nature Reviews Immunology, 2014, 14, 768-774.	10.6	248

#	Article	IF	Citations
279	No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients. Molecular Oncology, 2014, 8, 1140-1158.	2.1	47
280	Adjuvant Interferon in Melanoma: Is Duration of Therapy Important?. Journal of Clinical Oncology, 2014, 32, 171-173.	0.8	6
281	Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents. Expert Opinion on Biological Therapy, 2014, 14, 955-967.	1.4	20
282	Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion. Journal of Immunology, 2014, 193, 1525-1530.	0.4	149
283	Programmed Cell Death Ligand 1 Expression in Osteosarcoma. Cancer Immunology Research, 2014, 2, 690-698.	1.6	182
284	Management of melanoma. British Medical Bulletin, 2014, 111, 149-162.	2.7	61
285	Systemic treatment for BRAF-mutant melanoma: where do we go next?. Lancet Oncology, The, 2014, 15, e371-e381.	5.1	130
286	Therapeutic Antibodies in Breast Cancer. Seminars in Oncology, 2014, 41, 576-588.	0.8	3
287	CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models. Cancer Research, 2014, 74, 5057-5069.	0.4	1,030
288	The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity. Journal of Immunology, 2014, 193, 3835-3841.	0.4	178
289	The nature and management of metastatic melanoma after progression on <scp>BRAF</scp> inhibitors: Effects of extended <scp>BRAF</scp> inhibition. Cancer, 2014, 120, 3142-3153.	2.0	65
291	Opportunistic infections in patients treated with immunotherapy for cancer. , 2014, 2, 19.		98
292	The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer. , 2014, 2, .		110
293	Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade. Cancer Research, 2014, 74, 5458-5468.	0.4	1,014
294	Unusual Presentations of Melanoma. Surgical Clinics of North America, 2014, 94, 1059-1073.	0.5	8
295	Indications and Options for Systemic Therapy in Melanoma. Surgical Clinics of North America, 2014, 94, 1049-1058.	0.5	12
296	Surgical Treatment Options for Stage IV Melanoma. Surgical Clinics of North America, 2014, 94, 1075-1089.	0.5	10
297	PD-1 and Tim-3 Regulate the Expansion of Tumor Antigenâ€“Specific CD8+ T Cells Induced by Melanoma Vaccines. Cancer Research, 2014, 74, 1045-1055.	0.4	179

#	Article	IF	Citations
299	American association for cancer research â€" AACR congress 2014. Oncologie, 2014, 16, 341-366.	0.2	0
300	Stromal Fibroblasts and the Immune Microenvironment: Partners in Mammary Gland Biology and Pathology?. Journal of Mammary Gland Biology and Neoplasia, 2014, 19, 169-182.	1.0	31
301	Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunology, Immunotherapy, 2014, 63, 449-58.	2.0	253
303	Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Research and Treatment, 2014, 146, 15-24.	1.1	472
304	Cytokine responsiveness of CD8+ T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. , 2014, 2, 10.		29
305	Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. , 2014, 2, 14.		108
306	Metastatic melanoma to the liver: A contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer, 2014, 120, 781-789.	2.0	79
307	Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications. Seminars in Oncology, 2014, 41, 174-184.	0.8	147
308	Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and Challenges. Journal of Clinical Oncology, 2014, 32, 2248-2254.	0.8	184
309	Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Antiâ€"PD-1 Therapy. Clinical Cancer Research, 2014, 20, 5064-5074.	3.2	2,050
310	Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RASâ€"RAF Mutations. Clinical Cancer Research, 2014, 20, 4251-4261.	3.2	60
311	Therapeutic vaccines for cancer: an overview of clinical trials. Nature Reviews Clinical Oncology, 2014, 11, 509-524.	12.5	636
312	What Is the Role of Chemotherapy in the Treatment of Melanoma?. Current Treatment Options in Oncology, 2014, 15, 321-335.	1.3	20
313	Microenvironmental Clues for Glioma Immunotherapy. Current Neurology and Neuroscience Reports, 2014, 14, 440.	2.0	51
314	Tumor antigen discovery through translation of the cancer genome. Immunologic Research, 2014, 58, 292-299.	1.3	13
315	The upregulation of programmed death 1 on peripheral blood T cells of glioma is correlated with disease progression. Tumor Biology, 2014, 35, 2923-2929.	0.8	30
316	Rectal Melanoma with Multiple Metastases: A Rare and Aggressive Tumor. Rare Cancers and Therapy, 2014, 2, 11-16.	0.2	3
317	What have we learned from cancer immunotherapy in the last 3Âyears?. Journal of Translational Medicine, 2014, 12, 141.	1.8	28

#	Article	IF	Citations
318	Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer. Journal of Translational Medicine, 2014, 12, 61.	1.8	66
319	MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. Journal of Translational Medicine, 2014, 12, 97.	1.8	69
320	Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer. Clinical Pharmacology and Therapeutics, 2014, 96, 214-223.	2.3	73
321	Neuroblastoma Killing Properties of VÎ´2 and VÎ´2-Negative Î³Î´T Cells Following Expansion by Artificial Antigen-Presenting Cells. Clinical Cancer Research, 2014, 20, 5720-5732.	3.2	99
322	Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations. Advances in Therapy, 2014, 31, 945-960.	1.3	35
323	Translational research in oncologyâ€”10 years of progress and future prospects. Nature Reviews Clinical Oncology, 2014, 11, 649-662.	12.5	65
324	Melanoma: immune checkpoint blockade story gets better. Lancet, The, 2014, 384, 1078-1079.	6.3	10
325	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. Journal of Clinical Oncology, 2014, 32, 1020-1030.	0.8	2,015
326	VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy. Cancer Immunology Research, 2014, 2, 510-517.	1.6	187
327	Lambrolizumab induced central nervous system (CNS) toxicity. Journal of the Neurological Sciences, 2014, 344, 229-231.	0.3	62
328	Melanomaâ€”the run of success continues. Nature Reviews Clinical Oncology, 2014, 11, 75-76.	12.5	74
329	Personalized treatments of cancer patients: A reality in daily practice, a costly dream or a shared vision of the future from the oncology community?. Cancer Treatment Reviews, 2014, 40, 1192-1198.	3.4	51
330	Cyclinâ€dependent kinases as therapeutic targets in melanoma. Pigment Cell and Melanoma Research, 2014, 27, 351-365.	1.5	21
331	In VitroCharacterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, andIn VivoToxicology in Non-Human Primates. Cancer Immunology Research, 2014, 2, 846-856.	1.6	514
332	Pathology in drug discovery and development. Journal of Pathology, 2014, 232, 99-102.	2.1	12
333	Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer, 2014, 85, 101-109.	0.9	106
334	Commentary: Molecular testing in melanoma. Journal of the American Academy of Dermatology, 2014, 70, 863-870.	0.6	4
335	Combinations of Radiation Therapy and Immunotherapy for Melanoma: A Review of Clinical Outcomes. International Journal of Radiation Oncology Biology Physics, 2014, 88, 986-997.	0.4	142

#	Article	IF	Citations
336	The State of the Art in Nonâ€“Small Cell Lung Cancer Immunotherapy. Seminars in Thoracic and Cardiovascular Surgery, 2014, 26, 26-35.	0.4	11
337	Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treatment Reviews, 2014, 40, 513-522.	3.4	141
338	Immunomodulatory Effects of Sex Hormones: Requirements for Pregnancy and Relevance in Melanoma. Mayo Clinic Proceedings, 2014, 89, 520-535.	1.4	53
339	Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends in Immunology, 2014, 35, 290-298.	2.9	96
340	Microtubule-Depolymerizing Agents Used in Antibodyâ€“Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells. Cancer Immunology Research, 2014, 2, 741-755.	1.6	134
341	Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions. Hepatology, 2014, 60, 1776-1782.	3.6	210
342	Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma. Clinical Cancer Research, 2014, 20, 3446-3457.	3.2	294
343	Vaccines for the 21st century. EMBO Molecular Medicine, 2014, 6, 708-720.	3.3	342
344	Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2014, 32, 129-160.	0.8	74
345	Programmed Deathâ€1: Therapeutic Success after More than 100â€...Years of Cancer Immunotherapy. Angewandte Chemie - International Edition, 2014, 53, 2286-2288.	7.2	62
346	The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. Cancer Immunology, Immunotherapy, 2014, 63, 925-938.	2.0	60
347	Brainstem melanomas presenting as a cavernous malformation. Neurochirurgie, 2014, 60, 184-187.	0.6	6
348	A Review of Novel Therapies for Melanoma. American Journal of Clinical Dermatology, 2014, 15, 323-337.	3.3	55
349	Surgical Management of Melanoma. Hematology/Oncology Clinics of North America, 2014, 28, 455-470.	0.9	14
350	Understanding the Biology of Melanoma and Therapeutic Implications. Hematology/Oncology Clinics of North America, 2014, 28, 437-453.	0.9	33
351	Clinical use of dendritic cells for cancer therapy. Lancet Oncology, The, 2014, 15, e257-e267.	5.1	565
352	Immune Checkpoint Blockade. Hematology/Oncology Clinics of North America, 2014, 28, 585-600.	0.9	70
353	Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma. Mayo Clinic Proceedings, 2014, 89, 504-519.	1.4	77

#	Article	IF	Citations
354	Towards combinatorial targeted therapy in melanoma: From pre-clinical evidence to clinical application (Review). International Journal of Oncology, 2014, 45, 929-949.	1.4	34
355	PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy. Cancer Control, 2014, 21, 231-237.	0.7	127
356	Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review). Oncology Reports, 2014, 32, 875-886.	1.2	37
357	Advances in targeted therapy for melanoma: a focus on MEK inhibition. Clinical Investigation, 2014, 4, 903-913.	0.0	0
358	MDSCs: the final frontier of the microenvironment in CLL?. Blood, 2014, 124, 666-668.	0.6	6
359	Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. Molecular Therapy - Oncolytics, 2014, 1, 14004.	2.0	33
360	Inhibition of mitogenâ€activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without <scp>PD</scp>â€L1â€upregulation in contrast to interferonâ€Î³ treatment. Cancer Science, 2014, 105, 1236-1244.	1.7	24
361	Update on Immune Checkpoint Inhibitors in Lung Cancer. Cancer Control, 2014, 21, 80-89.	0.7	76
362	Cancer Immunology, Success Without Sequencing. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 443-445.	2.3	0
363	BRAFV600E-Mutant Melanoma Presenting With Cardiac Involvement. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 611-615.	2.3	2
364	Agents Make â€œPreferred Listâ€•in Metastatic Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 785-787.	2.3	0
366	Combination therapies in advanced melanoma. Melanoma Management, 2014, 1, 47-56.	0.1	2
367	How anti-PD1 treatments are changing the management of melanoma. Melanoma Management, 2014, 1, 165-172.	0.1	5
368	Income-associated discrepancies in melanoma survival. Cancer Treatment Communications, 2015, 4, 143-147.	0.4	4
369	Targeting immune checkpoints in melanoma: an update. Melanoma Management, 2015, 2, 339-352.	0.1	2
370	Nanomedicines Targeting the Tumor Microenvironment. Cancer Journal (Sudbury, Mass), 2015, 21, 314-321.	1.0	64
371	2015 Guidance on cancer immunotherapy development in earlyâ€phase clinical studies. Cancer Science, 2015, 106, 1761-1771.	1.7	16
372	A phase <scp>2</scp>, multicenter, openâ€label study of sepantronium bromide (<scp>YM</scp>155) plus docetaxel in patients with stage <scp>III</scp> (unresectable) or stage <scp>IV</scp> melanoma. Cancer Medicine, 2015, 4, 643-650.	1.3	36

#	Article	IF	Citations
373	Singleâ€fraction radiation therapy in patients with metastatic Merkel cell carcinoma. Cancer Medicine, 2015, 4, 1161-1170.	1.3	59
374	The relationship between blood <scp>IL</scp>â€12p40 level and melanoma progression. International Journal of Cancer, 2015, 136, 1874-1880.	2.3	5
375	New clinical advances in immunotherapy for the treatment of solid tumours. Immunology, 2015, 145, 182-201.	2.0	35
376	Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 504-507.	0.7	12
377	Noncoding RNAs and chronic inflammation: Microâ€managing the fire within. BioEssays, 2015, 37, 1005-1015.	1.2	33
378	Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Science, 2015, 106, 945-950.	1.7	78
379	The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cellâ€“based immunotherapy. Blood, 2015, 126, 1203-1213.	0.6	103
380	Immune Checkpoint Blockade in Hepatocellular Carcinoma. Liver Cancer, 2015, 4, 201-207.	4.2	40
381	Microsatellite Instability. , 2015, , 2842-2845.		0
383	Understanding Immune Checkpoint Inhibitors for Effective Patient Care. Clinical Journal of Oncology Nursing, 2015, 19, 709-717.	0.3	17
384	Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. Biomarkers in Cancer, 2015, 7s2, BIC.S29325.	3.6	51
385	è§£æ˜Žã€Œé²ã‚€ã€Œå‘…ç–«ç™‚æ³•. Nature Digest, 2015, 12, 30-32.	0.0	0
386	Novel melanoma therapy. Experimental Hematology and Oncology, 2015, 5, 23.	2.0	8
387	Combining radiotherapy and immunotherapy for prostate cancer: two decades of research from preclinical to clinical trials. Journal of Radiation Oncology, 2015, 4, 365-375.	0.7	1
388	Principles of immunology and its nuances in the central nervous system: Fig. 1.. Neuro-Oncology, 2015, 17, vii3-vii8.	0.6	28
389	Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma. Melanoma Research, 2015, 25, 239-245.	0.6	23
390	Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Research, 2015, 17, 124.	2.2	210
391	MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603. Clinical Epigenetics, 2015, 7, 58.	1.8	19

#	Article	IF	Citations
392	Increased CTLA-4+ T cells and an increased ratio of monocytes with loss of class II (CD14+â€‰HLA-DRlo/neg) found in aggressive pediatric sarcoma patients. , 2015, 3, 35.		45
393	Ovarian Cancer Immunotherapy Using PDâ€Ł1 siRNA Targeted Delivery from Folic Acidâ€Functionalized Polyethylenimine: Strategies to Enhance T Cell Killing. Advanced Healthcare Materials, 2015, 4, 1180-1189.	3.9	140
394	Acute skin reaction suggestive of pembrolizumab-induced radiosensitization. Melanoma Research, 2015, 25, 555-558.	0.6	35
395	Inhibitory receptors as targets for cancer immunotherapy. European Journal of Immunology, 2015, 45, 1892-1905.	1.6	116
396	Treatment for metastatic melanoma: a new and evolving era. International Journal of Clinical Practice, 2015, 69, 273-280.	0.8	2
397	Ultrasound-guided core needle biopsy of superficial lymph nodes. Melanoma Research, 2015, 25, 519-527.	0.6	19
398	Pembrolizumab in the management of metastatic melanoma. Melanoma Management, 2015, 2, 315-325.	0.1	4
399	<scp>RAC</scp>1 P29S regulates <scp>PD</scp>â€Ł1 expression in melanoma. Pigment Cell and Melanoma Research, 2015, 28, 590-598.	1.5	69
400	Systemic therapy of metastatic melanoma. JDDG - Journal of the German Society of Dermatology, 2015, 13, 1223-1237.	0.4	12
401	Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities. Internal Medicine Journal, 2015, 45, 696-701.	0.5	28
402	FcÎ³R requirements leading to successful immunotherapy. Immunological Reviews, 2015, 268, 104-122.	2.8	41
403	Human IgG4: a structural perspective. Immunological Reviews, 2015, 268, 139-159.	2.8	119
404	Systemtherapie des metastasierten malignen Melanoms. JDDG - Journal of the German Society of Dermatology, 2015, 13, 1223-1238.	0.4	7
405	Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. Current Opinion in Oncology, 2015, 27, 384-391.	1.1	18
406	Comparative healthcare costs in patients with metastatic melanoma in the USA. Melanoma Research, 2015, 25, 312-320.	0.6	22
407	Pancreatitis Secondary to Antiâ€“Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT. Clinical Nuclear Medicine, 2015, 40, e528-e529.	0.7	62
408	Tumorâ€targeted and immuneâ€targeted monoclonal antibodies: Going from passive to active immunotherapy. Pediatric Blood and Cancer, 2015, 62, 1317-1325.	0.8	13
409	Perspectives From Masters in Rheumatology and Autoimmunity: Can We Get Closer to a Cure for Rheumatoid Arthritis?. Arthritis and Rheumatology, 2015, 67, 2283-2291.	2.9	49

#	Article	IF	Citations
410	Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. Pharmacotherapy, 2015, 35, 963-976.	1.2	183
411	Will modern immunotherapies become the standard of care for advanced synchronous or metachronous cancers?. Future Oncology, 2015, 11, 3053-3055.	1.1	2
412	Recent developments and future challenges in immune checkpoint inhibitory cancer treatment. Current Opinion in Oncology, 2015, 27, 482-488.	1.1	31
413	A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Research, 2015, 25, 265-268.	0.6	116
414	Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. Melanoma Research, 2015, 25, 503-509.	0.6	59
415	Emerging Immunotherapies in the Treatment of Nonâ€“small Cell Lung Cancer (NSCLC). American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 422-430.	0.6	64
416	Immunotherapies for bladder cancer. Current Opinion in Urology, 2015, 25, 586-596.	0.9	17
417	Myeloid Cells as Targets for Therapy in Solid Tumors. Cancer Journal (Sudbury, Mass), 2015, 21, 343-350.	1.0	32
418	Reversal of T-cell exhaustion as a strategy to improve immune control of HIV-1. Aids, 2015, 29, 1911-1915.	1.0	14
419	Immune Checkpoint Inhibitors: New Drugs on the Horizon. Journal of Leukemia (Los Angeles, Calif), 2015, s1, .	0.1	0
420	Increased Treatment-Related Toxicity Subsequent to an Antiâ€“PD-1 Agent. Current Oncology, 2015, 22, 320-322.	0.9	6
421	Antiâ€“PD-1/PD-L1 therapy of human cancer: past, present, and future. Journal of Clinical Investigation, 2015, 125, 3384-3391.	3.9	1,112
422	Immune Checkpoints Inhibitors: A Single Antiviral and Anticancer Magic Bullet. Journal of Pharmaceutical Care & Health Systems, 2015, 02, .	0.1	0
423	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 2015, 6, 42008-42018.	0.8	278
424	Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds?. Cancer Management and Research, 2015, 7, 93.	0.9	10
425	Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells. Immune Network, 2015, 15, 58.	1.6	11
426	Possible therapeutic implication of PD-L1/PD-1 axis in endometrial cancer. Journal of Solid Tumors, 2015, 5, .	0.1	1
427	Immunotherapy and Radiation â€“ A New Combined Treatment Approach for Bladder Cancer?. Bladder Cancer, 2015, 1, 15-27.	0.2	19

#	Article	IF	Citations
428	Biomarkers of Response to Immune Modulatory Therapies in Cancer. Journal of Clinical & Cellular Immunology, 2015, 06, .	1.5	1
429	New developments in the management of advanced melanoma – role of pembrolizumab. OncoTargets and Therapy, 2015, 8, 2535.	1.0	16
430	From dismal prognosis to rising star: melanoma leads the way with new generation cancer therapies. Medical Journal of Australia, 2015, 202, 115-116.	0.8	2
431	Immunotherapeutic Approaches in Prostate Cancer: Combinations and Clinical Integration. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e275-e283.	1.8	2
432	Neoadjuvant Therapy for Melanoma: A Promising Therapeutic Approach and an Ideal Platform in Drug Development. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e535-e542.	1.8	8
433	Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages. Vaccines, 2015, 3, 448-466.	2.1	19
434	Dendritic Cell-Based Adjuvant Vaccination Targeting Wilmsâ€™ Tumor 1 in Patients with Advanced Colorectal Cancer. Vaccines, 2015, 3, 1004-1018.	2.1	34
435	Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing. Sensors, 2015, 15, 16281-16313.	2.1	140
436	Establishing the pig as a large animal model for vaccine development against human cancer. Frontiers in Genetics, 2015, 6, 286.	1.1	24
437	Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. Frontiers in Immunology, 2015, 6, 271.	2.2	36
438	Inhibitory Receptors Beyond T Cell Exhaustion. Frontiers in Immunology, 2015, 6, 310.	2.2	188
439	Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics. Frontiers in Immunology, 2015, 6, 424.	2.2	12
440	Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses â€“ Pre-Clinical Evidence and Ongoing Clinical Applications. Frontiers in Immunology, 2015, 6, 505.	2.2	86
441	The Role of Chemokines in Shaping the Balance Between CD4+ T Cell Subsets and Its Therapeutic Implications in Autoimmune and Cancer Diseases. Frontiers in Immunology, 2015, 6, 609.	2.2	46
442	Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy. Frontiers in Oncology, 2015, 5, 152.	1.3	26
443	Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. OncoTargets and Therapy, 2015, 8, 929.	1.0	27
444	Update on use of aldesleukin for treatment of high-risk metastatic melanoma. ImmunoTargets and Therapy, 2015, 4, 79.	2.7	21
445	TIGIT and PD-1 impair tumor antigenâ€“specific CD8+ T cells in melanoma patients. Journal of Clinical Investigation, 2015, 125, 2046-2058.	3.9	603

#	Article	IF	Citations
446	Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. Forum on Immunopathological Diseases and Therapeutics, 2015, 6, 7-17.	0.1	82
447	Inhibitor of DNA Binding 4 (ID4) Is Highly Expressed in Human Melanoma Tissues and May Function to Restrict Normal Differentiation of Melanoma Cells. PLoS ONE, 2015, 10, e0116839.	1.1	9
448	Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-NaÃ¯ve Patients with Metastatic Uveal Melanoma. PLoS ONE, 2015, 10, e0118564.	1.1	197
449	Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-ÎºB. PLoS ONE, 2015, 10, e0123410.	1.1	181
450	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS ONE, 2015, 10, e0130142.	1.1	390
451	PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV. Case Reports in Oncological Medicine, 2015, 2015, 1-5.	0.2	74
452	Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. BioMed Research International, 2015, 2015, 1-16.	0.9	111
453	Analysis of the Intratumoral Adaptive Immune Response in Well Differentiated and Dedifferentiated Retroperitoneal Liposarcoma. Sarcoma, 2015, 2015, 1-9.	0.7	48
454	The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies. BioMed Research International, 2015, 2015, 1-12.	0.9	25
455	Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors. Journal of Immunology Research, 2015, 2015, 1-7.	0.9	49
456	Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma. BioMed Research International, 2015, 2015, 1-5.	0.9	6
457	Clinical Development of Immune Checkpoint Inhibitors. BioMed Research International, 2015, 2015, 1-12.	0.9	51
458	Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?. BioMed Research International, 2015, 2015, 1-9.	0.9	19
459	Immunotherapy in Tumors. Deutsches Ärzteblatt International, 2015, 112, 809-15.	0.6	31
460	From mice to humans: developments in cancer immunoediting. Journal of Clinical Investigation, 2015, 125, 3338-3346.	3.9	271
461	Patient-Specific Therapeutic Vaccines for Metastatic Melanoma. Oncology Issues, 2015, 30, 48-57.	0.0	3
462	Recent Clinical Advances in the Treatment of Cutaneous Melanoma. Clinical Cancer Drugs, 2015, 2, 16-28.	0.3	0
463	Managing Immune Checkpoint-Blocking Antibody Side Effects. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 76-83.	1.8	344

#	Article	IF	Citations
464	Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach. Oncotarget, 2015, 6, 2496-2508.	0.8	16
465	Current Therapeutic Leads for the Treatment of Melanoma: Targeted Immunotherapy in the Post-genomic Era. Current Molecular Pharmacology, 2015, 7, 33-43.	0.7	3
466	WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results. Ecancermedicalscience, 2015, 9, 604.	0.6	11
467	Challenges of Patient Selection for Phase I Oncology Trials. , 0, , .		2
468	New Insights in Cutaneous Melanoma Immune-Therapy â€" Tackling Immune-Suppression and Specific Anti-Tumoral Response. , 0, , .		2
469	T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?. Photochemical and Photobiological Sciences, 2015, 14, 1492-1509.	1.6	76
470	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine, 2015, 372, 2509-2520.	13.9	7,696
471	Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nature Reviews Drug Discovery, 2015, 14, 487-498.	21.5	203
472	Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma. Future Oncology, 2015, 11, 997-1009.	1.1	2
473	Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology. Annals of Pharmacotherapy, 2015, 49, 907-937.	0.9	155
474	Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers. Molecular Therapy - Nucleic Acids, 2015, 4, e237.	2.3	106
475	Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nature Reviews Clinical Oncology, 2015, 12, 408-424.	12.5	456
476	Programmed death-1 checkpoint blockade in acute myeloid leukemia. Expert Opinion on Biological Therapy, 2015, 15, 1191-1203.	1.4	75
477	PD-1/PD-L1 inhibitors. Current Opinion in Pharmacology, 2015, 23, 32-38.	1.7	483
478	Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. Therapeutic Advances in Medical Oncology, 2015, 7, 107-121.	1.4	8
479	The role of active vaccination in cancer immunotherapy: lessons from clinical trials. Current Opinion in Immunology, 2015, 35, 15-22.	2.4	33
480	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 2015, 373, 23-34.	13.9	6,773
481	The path forward. Vaccine, 2015, 33, B60-B63.	1.7	14

#	Article	IF	Citations
482	Immunology and Immunotherapy of Breast Cancer. , 2015, , 457-470.		0
483	Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era. Journal of Neuro-Oncology, 2015, 123, 75-84.	1.4	8
484	Dendritic cell immunotherapy for brain tumors. Journal of Neuro-Oncology, 2015, 123, 425-432.	1.4	10
485	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clinical Therapeutics, 2015, 37, 764-782.	1.1	469
486	Human PD-1 binds differently to its human ligands: A comprehensive modeling study. Journal of Molecular Graphics and Modelling, 2015, 57, 131-142.	1.3	45
487	Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. Lung Cancer, 2015, 88, 117-123.	0.9	49
488	Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. Future Oncology, 2015, 11, 133-140.	1.1	9
489	Antibody Positron Emission Tomography Imaging in Anticancer Drug Development. Journal of Clinical Oncology, 2015, 33, 1491-1504.	0.8	93
490	C-Reactive Protein As a Marker of Melanoma Progression. Journal of Clinical Oncology, 2015, 33, 1389-1396.	0.8	71
491	Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Antiâ€“PD-L1 Antibodies. Cancer Research, 2015, 75, 2928-2936.	0.4	193
492	Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study. Clinical Cancer Research, 2015, 21, 749-755.	3.2	223
493	Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma. Clinical Cancer Research, 2015, 21, 712-720.	3.2	225
494	PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunology Research, 2015, 3, 620-630.	1.6	84
495	Association BetweenNRASandBRAFMutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. JAMA Oncology, 2015, 1, 359.	3.4	164
496	Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers. Journal of Clinical Oncology, 2015, 33, 1993-1994.	0.8	20
497	Increased CCL17 serum levels are associated with improved survival in advanced melanoma. Cancer Immunology, Immunotherapy, 2015, 64, 1075-1082.	2.0	16
498	Transcriptional repression of IFNÎ²1 by ATF2 confers melanoma resistance to therapy. Oncogene, 2015, 34, 5739-5748.	2.6	23
499	Beyond adjuvants: Immunomodulation strategies to enhance T cell immunity. Vaccine, 2015, 33, B21-B28.	1.7	28

#	Article	IF	Citations
500	Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model. Cancer Immunology, Immunotherapy, 2015, 64, 1095-1108.	2.0	19
501	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Antiâ€“PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunology Research, 2015, 3, 1148-1157.	1.6	391
502	Stereotactic radiosurgery and immunotherapy for metastatic spinal melanoma. Neurosurgical Focus, 2015, 38, E6.	1.0	20
503	CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Frontiers in Oncology, 2014, 4, 385.	1.3	175
504	New Strategies in Melanoma: Entering the Era of Combinatorial Therapy. Clinical Cancer Research, 2015, 21, 2424-2435.	3.2	29
505	Is chemotherapy still an option in the treatment of melanoma?. Annals of Oncology, 2015, 26, 2203-2204.	0.6	1
506	Pseudoprogression and Immune-Related Response in Solid Tumors. Journal of Clinical Oncology, 2015, 33, 3541-3543.	0.8	720
507	Immunotherapy of Melanoma. Progress in Tumor Research, 2015, 42, 22-29.	0.1	14
508	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunology Research, 2015, 3, 1308-1315.	1.6	114
509	Beating Cancer with a Gut Feeling. Cell Host and Microbe, 2015, 18, 646-648.	5.1	4
510	Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies. Cancer Immunology Research, 2015, 3, 1292-1298.	1.6	38
512	Insights on Peptide Vaccines in Cancer Immunotherapy. Cancer Drug Discovery and Development, 2015, , 1-27.	0.2	2
513	Phase I Study of Pembrolizumab (MK-3475; Antiâ€“PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 4286-4293.	3.2	627
514	Ipilimumab-Induced Encephalopathy with a Reversible Splenial Lesion. Cancer Immunology Research, 2015, 3, 598-601.	1.6	57
515	Erfolge und Grenzen zielgerichteter Krebstherapien beim Melanom. Karger Kompass Dermatologie, 2015, 3, 65-72.	0.0	0
516	The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance. Cell Reports, 2015, 12, 2072-2085.	2.9	47
517	Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Therapeutic Advances in Medical Oncology, 2015, 7, 181-191.	1.4	20
518	TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization. Haematologica, 2015, 100, 1415-1425.	1.7	73

#	Article	IF	Citations
519	Novel insights into the pathophysiology and treatment of malignant pleural mesothelioma. Lung Cancer Management, 2015, 4, 249-259.	1.5	0
520	A longitudinal study of CEACAM1 expression in melanoma disease progression. Oncology Reports, 2015, 33, 1314-1318.	1.2	11
522	Developing biomarker-specific end points in lung cancer clinical trials. Nature Reviews Clinical Oncology, 2015, 12, 135-146.	12.5	43
523	PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunology Research, 2015, 3, 326-332.	1.6	310
524	Checkpoint inhibitors in immunotherapy of ovarian cancer. Tumor Biology, 2015, 36, 33-39.	0.8	19
525	Circulating Biomarkers in Malignant Melanoma. Advances in Clinical Chemistry, 2015, 69, 47-89.	1.8	34
526	Immune Checkpoint Inhibitors in Melanoma Provide the Cornerstones for Curative Therapies. Seminars in Oncology, 2015, 42, 429-435.	0.8	68
527	Dabrafenib in combination with trametinib for the treatment of metastatic melanoma. Expert Review of Clinical Pharmacology, 2015, 8, 25-33.	1.3	8
528	The role of CD95 and CD95 ligand in cancer. Cell Death and Differentiation, 2015, 22, 549-559.	5.0	243
529	Glioblastoma stem cells and stem cell-targeting immunotherapies. Journal of Neuro-Oncology, 2015, 123, 449-457.	1.4	25
531	Checkpoint Blockade Immunotherapy Relies on T-bet but Not Eomes to Induce Effector Function in Tumor-Infiltrating CD8+ T Cells. Cancer Immunology Research, 2015, 3, 116-124.	1.6	32
532	Immunomodulation of Selective Naive T Cell Functions by p110Î´ Inactivation Improves the Outcome of Mismatched Cell Transplantation. Cell Reports, 2015, 10, 702-710.	2.9	12
533	Lymphangiogenesis: Implications for Diagnosis, Treatment, and Prognosis in Patients With Melanoma. Actas Dermo-sifiliogrÃ¡ficas, 2015, 106, 7-16.	0.2	1
534	Immune Checkpoint Blockade and Interferon-Î± in Melanoma. Seminars in Oncology, 2015, 42, 436-447.	0.8	34
536	<scp>CTLA</scp>â€4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Cancer Medicine, 2015, 4, 661-672.	1.3	100
537	The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. Current Opinion in Immunology, 2015, 33, 23-35.	2.4	298
538	Immune Escape Mechanisms as a Guide for Cancer Immunotherapy. Clinical Cancer Research, 2015, 21, 687-692.	3.2	801
539	Radiation meets immunotherapy â€“ a perfect match in the era of combination therapy?. International Journal of Radiation Biology, 2015, 91, 299-305.	1.0	20

#	Article	IF	Citations
540	VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. Journal of Experimental Medicine, 2015, 212, 139-148.	4.2	836
541	Immune Checkpoint Blockade in Cancer Therapy. Journal of Clinical Oncology, 2015, 33, 1974-1982.	0.8	2,220
542	Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma. Journal of Medical Genetics, 2015, 52, 231-239.	1.5	17
543	Recurrence of Melanoma Following T Cell Treatment: Continued Antigen Expression in a Tumor That Evades T Cell Recruitment. Molecular Therapy, 2015, 23, 396-406.	3.7	22
544	Immune checkpoint modulation: Rational design of combination strategies. , 2015, 150, 23-32.		76
545	Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Antiâ€“PD-1 Therapy. Cancer Immunology Research, 2015, 3, 18-22.	1.6	100
546	Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2015, 7, 12-21.	1.4	22
547	Cutaneous adverse effects of targeted therapies. Journal of the American Academy of Dermatology, 2015, 72, 221-236.	0.6	150
548	Expression of the Novel Costimulatory Molecule B7-H5 in Pancreatic Cancer. Annals of Surgical Oncology, 2015, 22, 1574-1579.	0.7	29
549	Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons. European Journal of Cancer, 2015, 51, 327-339.	1.3	63
550	Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor TÂcells specific for tumor antigen GD2. Cytotherapy, 2015, 17, 487-495.	0.3	90
551	Combination Therapy with Antiâ€“CTLA-4 and Antiâ€“PD-1 Leads to Distinct Immunologic Changes In Vivo. Journal of Immunology, 2015, 194, 950-959.	0.4	362
552	Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour. Current Topics in Microbiology and Immunology, 2015, 405, 79-97.	0.7	8
553	Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E966-72.	3.3	369
554	Multiple checkpoints on the long road towards cancer immunotherapy. Immunology and Cell Biology, 2015, 93, 323-325.	1.0	9
556	IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. Cancer Research, 2015, 75, 1635-1644.	0.4	145
557	Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies. Cancer Immunology Research, 2015, 3, 288-295.	1.6	145
558	Requirement for Innate Immunity and CD90+ NK1.1â˜’ Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy. Cancer Immunology Research, 2015, 3, 296-304.	1.6	25

#	Article	IF	Citations
559	PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Molecular Cancer Therapeutics, 2015, 14, 847-856.	1.9	1,787
560	Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?. Cancer and Metastasis Reviews, 2015, 34, 129-144.	2.7	11
561	PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. Journal of Translational Medicine, 2015, 13, 5.	1.8	73
562	Biomarkers for glioma immunotherapy: the next generation. Journal of Neuro-Oncology, 2015, 123, 359-372.	1.4	23
563	Nivolumab in NSCLC: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2015, 7, 85-96.	1.4	196
564	Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2015, 33, 773-781.	0.8	501
565	Nivolumab in melanoma: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2015, 7, 97-106.	1.4	124
566	The immune response in cancer: from immunology to pathology to immunotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 127-135.	1.4	51
567	Genomic Classification of Cutaneous Melanoma. Cell, 2015, 161, 1681-1696.	13.5	2,562
568	Immune Checkpoints: The Search for a Single Antiviral-Anticancer Magic Bullet. Journal of Pharmaceutical Care & Health Systems, 2015, 02, .	0.1	1
569	Evolving Concepts: Immunity in Oncology from Targets to Treatments. Journal of Oncology, 2015, 2015, 1-15.	0.6	23
570	Numbers of CD8+PD-1+ and CD4+PD-1+ Cells in Peripheral Blood of Patients with Chronic Lymphocytic Leukemia Are Independent of Binet Stage and Are Significantly Higher Compared to Healthy Volunteers. Acta Haematologica, 2015, 134, 208-214.	0.7	18
571	A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Research, 2015, 75, 3800-3811.	0.4	201
572	New molecular therapies for hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, S80-S85.	0.7	30
573	¹⁸F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis. American Journal of Roentgenology, 2015, 205, 259-270.	1.0	57
574	Combination cancer immunotherapy and new immunomodulatory targets. Nature Reviews Drug Discovery, 2015, 14, 561-584.	21.5	1,058
575	Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. Cancer Immunology Research, 2015, 3, 464-469.	1.6	91
576	ErbB3â€“ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. Cancer Research, 2015, 75, 3554-3567.	0.4	18

#	Article	IF	Citations
577	Immune Checkpoint Inhibition in Renal Cell Carcinoma. , 2015, , 259-279.		0
578	PD-1/PD-L1 in Renal Cell Carcinoma: Projecting the Way Forward. Clinical Genitourinary Cancer, 2015, 13, 257-260.	0.9	2
579	Targeted Therapies in Melanoma: Translational Research at Its Finest. Journal of Investigative Dermatology, 2015, 135, 1929-1933.	0.3	12
580	Combination Immunotherapy for Melanoma. JAMA Oncology, 2015, 1, 387.	3.4	3
582	Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatology, 2015, 151, 1206.	2.0	385
583	Therapeutic Advances and Treatment Options in Metastatic Melanoma. JAMA Oncology, 2015, 1, 380.	3.4	66
584	Tumor Microenvironment Remodeling by 4-Methylumbelliferone Boosts the Antitumor Effect of Combined Immunotherapy in Murine Colorectal Carcinoma. Molecular Therapy, 2015, 23, 1444-1455.	3.7	18
585	Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2â^'/â^'IL2Rî³null Immunodeficient Mice. Cancer Research, 2015, 75, 3466-3478.	0.4	137
586	Novel drugs in clinical development for hepatocellular carcinoma. Expert Opinion on Investigational Drugs, 2015, 24, 1075-1082.	1.9	34
587	Pembrolizumab for the treatment of melanoma. Expert Review of Clinical Pharmacology, 2015, 8, 515-527.	1.3	2
589	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. OncoImmunology, 2015, 4, e1008814.	2.1	102
590	BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. OncoTargets and Therapy, 2015, 8, 157.	1.0	134
591	Adoptive T-cell therapy: a need for standard immune monitoring. Immunotherapy, 2015, 7, 513-533.	1.0	17
592	New immunotherapies targeting the PD-1 pathway. Trends in Pharmacological Sciences, 2015, 36, 587-595.	4.0	158
593	Blinatumomab and Pembrolizumab. Hospital Pharmacy, 2015, 50, 269-273.	0.4	4
594	Inflammation and Lung Cancer. , 2015, , .		2
595	T-cell exhaustion in the tumor microenvironment. Cell Death and Disease, 2015, 6, e1792-e1792.	2.7	743
596	The evolving locally-advanced non-small cell lung cancer landscape: Building on past evidence and experience. Critical Reviews in Oncology/Hematology, 2015, 96, 319-327.	2.0	25

#	Article	IF	Citations
597	Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein. Clinical and Translational Immunology, 2015, 4, e30.	1.7	39
598	Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Scientific Reports, 2015, 5, 11198.	1.6	150
599	Successes and setbacks of early investigational drugs for melanoma. Expert Opinion on Investigational Drugs, 2015, 24, 993-997.	1.9	4
600	Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some. Frontiers in Immunology, 2015, 6, 127.	2.2	51
601	Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. Journal of Investigative Dermatology, 2015, 135, 2266-2272.	0.3	7
602	Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors. Journal of the National Cancer Institute, 2015, 107, djv156.	3.0	62
603	Targeted Therapies for Melanoma. , 2015, , 1529-1541.		0
604	Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. Drug Discovery Today, 2015, 20, 1127-1134.	3.2	27
605	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clinical Cancer Research, 2015, 21, 4607-4618.	3.2	271
606	Lentivirus-induced â€˜Smartâ€™ dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma. Gene Therapy, 2015, 22, 707-720.	2.3	37
607	Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy, 2015, 7, 611-619.	1.0	141
609	Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nature Reviews Cancer, 2015, 15, 457-472.	12.8	576
610	Cancer Immunotherapy with Vaccines and Checkpoint Blockade. , 2015, , 709-738.e8.		0
612	Engineered materials for cancer immunotherapy. Nano Today, 2015, 10, 511-531.	6.2	96
613	Immune Targeting of Tumor Epithelialâ€“Mesenchymal Transition via Brachyury-Based Vaccines. Advances in Cancer Research, 2015, 128, 69-93.	1.9	12
614	Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity. Cancer Research, 2015, 75, 3747-3759.	0.4	93
615	Metastatic Melanoma â€“ A Review of Current and Future Treatment Options. Acta Dermato-Venereologica, 2015, 95, 516-524.	0.6	186
616	Concepts of immunotherapy for glioma. Journal of Neuro-Oncology, 2015, 123, 323-330.	1.4	12

#	Article	IF	Citations
617	Biological Therapy of Cancer. , 2015, , 561-593.		0
618	Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends in Molecular Medicine, 2015, 21, 482-491.	3.5	146
619	PET/CT, MR, and PET/MR in Lymphoma and Melanoma. Seminars in Nuclear Medicine, 2015, 45, 322-331.	2.5	32
620	Primary malignant melanoma of the trachea: A case report. Oncology Letters, 2015, 9, 657-660.	0.8	6
621	Gaining momentum: New options and opportunities for the treatment of advanced melanoma. Cancer Treatment Reviews, 2015, 41, 660-670.	3.4	51
622	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology, The, 2015, 16, 908-918.	5.1	1,419
623	The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nature Medicine, 2015, 21, 688-697.	15.2	455
624	Novel therapeutic strategies for multiple myeloma. Experimental Hematology, 2015, 43, 732-741.	0.2	98
625	The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist, 2015, 20, 812-822.	1.9	198
626	Antagonists of PD-1 and PD-L1 in Cancer Treatment. Seminars in Oncology, 2015, 42, 587-600.	0.8	259
627	Are Macrophages in Tumors Good Targets for Novel Therapeutic Approaches?. Molecules and Cells, 2015, 38, 95-104.	1.0	9
628	Immuno-regulatory antibodies for the treatment of cancer. Expert Opinion on Biological Therapy, 2015, 15, 787-801.	1.4	40
629	Î³Î´ T Cell Immunotherapyâ€"A Review. Pharmaceuticals, 2015, 8, 40-61.	1.7	50
630	Toxicities of Immunotherapy for the Practitioner. Journal of Clinical Oncology, 2015, 33, 2092-2099.	0.8	521
631	Programmed cell death-1 inhibition in lymphoma. Lancet Oncology, The, 2015, 16, e234-e245.	5.1	56
632	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitorâ€"Treated Melanoma Patients. Clinical Cancer Research, 2015, 21, 3140-3148.	3.2	120
633	The future of immune checkpoint therapy. Science, 2015, 348, 56-61.	6.0	3,735
634	Pembrolizumab for the Treatment of Nonâ€"Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 372, 2018-2028.	13.9	5,183

#	Article	IF	Citations
636	Broadening the repertoire of melanoma-associated T-cell epitopes. Cancer Immunology, Immunotherapy, 2015, 64, 609-620.	2.0	8
637	AERIO news in brief. Oncologie, 2015, 17, 135-138.	0.2	1
638	The role of checkpoints in the treatment of GBM. Journal of Neuro-Oncology, 2015, 123, 413-423.	1.4	15
639	Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. Journal of Neuro-Oncology, 2015, 123, 339-346.	1.4	10
640	The TLR2 agonist in polysaccharide-K is a structurally distinct lipid which acts synergistically with the protein-bound Î²-glucan. Journal of Natural Medicines, 2015, 69, 198-208.	1.1	13
641	Treatment of NRAS-Mutant Melanoma. Current Treatment Options in Oncology, 2015, 16, 15.	1.3	110
642	Immunotherapy in Prostate Cancer. Current Urology Reports, 2015, 16, 34.	1.0	8
643	Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations. Clinical Investigation, 2015, 5, 75-87.	0.0	1
644	Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2015, 372, 2521-2532.	13.9	4,838
645	Targeting cancer-specific mutations by T cell receptor gene therapy. Current Opinion in Immunology, 2015, 33, 112-119.	2.4	82
646	Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. New England Journal of Medicine, 2015, 372, 2006-2017.	13.9	2,489
647	The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis. European Journal of Surgical Oncology, 2015, 41, 450-456.	0.5	228
648	The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. Drugs, 2015, 75, 563-575.	4.9	18
649	Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunology Research, 2015, 3, 399-411.	1.6	387
650	Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Research, 2015, 75, 2139-2145.	0.4	1,167
652	Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). Annals of Oncology, 2015, 26, 1677-1684.	0.6	68
653	Immunotherapeutic Approaches to Sarcoma. Current Treatment Options in Oncology, 2015, 16, 26.	1.3	48
654	Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. , 2015, 3, 11.		274

#	Article	IF	Citations
655	Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives. Cancer Chemotherapy and Pharmacology, 2015, 76, 219-233.	1.1	30
656	Beyond the Vascular Endothelial Growth Factor Axis: Update on Role of Imaging in Nonantiangiogenic Molecular Targeted Therapies in Oncology. American Journal of Roentgenology, 2015, 204, 919-932.	1.0	10
657	Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF ^{V600E} melanoma. Science Translational Medicine, 2015, 7, 279ra41.	5.8	470
658	Overcoming T cell exhaustion in infection and cancer. Trends in Immunology, 2015, 36, 265-276.	2.9	856
660	Awakening the immune system with radiation: Optimal dose and fractionation. Cancer Letters, 2015, 368, 185-190.	3.2	91
661	Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8+ T-cell Response and Protects Mice from Melanoma. Cancer Immunology Research, 2015, 3, 536-546.	1.6	51
662	<scp>PD</scp>â€Ł1 expression in melanoma shows marked heterogeneity within and between patients: implications for antiâ€<scp>PD</scp>â€1/<scp>PD</scp>â€<scp>L</scp>1 clinical trials. Pigment Cell and Melanoma Research, 2015, 28, 245-253.	1.5	356
663	A Stressful Microenvironment: Opposing Effects of the Endoplasmic Reticulum Stress Response in the Suppression and Enhancement of Adaptive Tumor Immunity. International Reviews of Immunology, 2015, 34, 104-122.	1.5	16
664	On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Science Translational Medicine, 2015, 7, 280sr1.	5.8	134
665	The interplay of effector and regulatory T cells in cancer. Current Opinion in Immunology, 2015, 33, 101-111.	2.4	114
666	Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature, 2015, 520, 373-377.	13.7	1,955
667	Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clinical Cancer Research, 2015, 21, 3052-3060.	3.2	198
668	Role for Radiation Therapy in Melanoma. Surgical Oncology Clinics of North America, 2015, 24, 323-335.	0.6	13
669	Metastasectomy for Stage IV Melanoma. Surgical Oncology Clinics of North America, 2015, 24, 279-298.	0.6	23
670	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2015, 16, 375-384.	5.1	2,353
671	Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Molecular Immunology, 2015, 67, 4-17.	1.0	180
672	Modular Three-component Delivery System Facilitates HLA Class I Antigen Presentation and CD8 + T-cell Activation Against Tumors. Molecular Therapy, 2015, 23, 1092-1102.	3.7	6
673	IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma. Clinical Cancer Research, 2015, 21, 2167-2176.	3.2	16

#	Article	IF	Citations
674	American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment. Journal of Clinical Oncology, 2015, 33, 278-284.	0.8	102
675	Targeting precision medicine toxicity: recent developments. Therapeutic Advances in Drug Safety, 2015, 6, 4-14.	1.0	4
676	Immunosurveillance and therapy of multiple myeloma are CD226 dependent. Journal of Clinical Investigation, 2015, 125, 2077-2089.	3.9	111
677	Novel therapeutic targets and predictive markers for hepatocellular carcinoma. Expert Opinion on Therapeutic Targets, 2015, 19, 973-983.	1.5	9
678	Strategies to relieve immunosuppression in pancreatic cancer. Immunotherapy, 2015, 7, 363-376.	1.0	30
679	Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma. Clinical Cancer Research, 2015, 21, 2892-2897.	3.2	31
680	The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. , 2015, 3, 15.		57
681	Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. Molecular Therapy, 2015, 23, 1380-1390.	3.7	88
682	The Expanding Role of Therapeutic Antibodies. International Reviews of Immunology, 2015, 34, 202-264.	1.5	22
683	Safety of pembrolizumab for the treatment of melanoma. Expert Opinion on Drug Safety, 2015, 14, 957-964.	1.0	27
684	Identification and Characterization of MEDI4736, an Antagonistic Antiâ€“PD-L1 Monoclonal Antibody. Cancer Immunology Research, 2015, 3, 1052-1062.	1.6	314
685	Melanoma. Nature Reviews Disease Primers, 2015, 1, 15003.	18.1	417
686	PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors. Journal of Immunotherapy, 2015, 38, 1-11.	1.2	333
687	Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma. Melanoma Research, 2015, 25, 178-179.	0.6	15
688	Diffuse High Intensity PDâ€“L1 Staining in Thymic Epithelial Tumors. Journal of Thoracic Oncology, 2015, 10, 500-508.	0.5	129
689	Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma. Journal of Immunotherapy, 2015, 38, 37-39.	1.2	112
690	Antiâ€“PD-1 Therapy in Melanoma. Seminars in Oncology, 2015, 42, 466-473.	0.8	41
691	Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. British Journal of Cancer, 2015, 112, 1421-1427.	2.9	215

#	Article	IF	Citations
692	Toxicity Patterns With Immunomodulating Antibodies and Their Combinations. Seminars in Oncology, 2015, 42, 423-428.	0.8	55
693	Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. European Journal of Radiology, 2015, 84, 1259-1268.	1.2	105
694	Immune-mediated mechanisms influencing the efficacy of anticancer therapies. Trends in Immunology, 2015, 36, 198-216.	2.9	121
695	Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell, 2015, 27, 450-461.	7.7	3,266
696	Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. Cell, 2015, 161, 205-214.	13.5	1,872
697	Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy. OncoImmunology, 2015, 4, e973808.	2.1	14
698	NF-Î²B Regulates PD-1 Expression in Macrophages. Journal of Immunology, 2015, 194, 4545-4554.	0.4	134
699	When are signal transduction targeted therapies acting as immunotherapy?. Cancer Biology and Therapy, 2015, 16, 645-647.	1.5	1
700	TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10. International Journal of Cancer, 2015, 137, 1386-1396.	2.3	25
701	Robust Antitumor Effects of Combined Antiâ€“CD4-Depleting Antibody and Antiâ€“PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice. Cancer Immunology Research, 2015, 3, 631-640.	1.6	67
702	Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. Bone Marrow Transplantation, 2015, 50, 770-780.	1.3	9
703	Merkel cell carcinoma showing regression after biopsy: Evaluation of programmed cell death 1â€positive cells. Journal of Dermatology, 2015, 42, 496-499.	0.6	6
704	TGFÎ² Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Research, 2015, 75, 2232-2242.	0.4	429
705	Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells. Cancer Immunology, Immunotherapy, 2015, 64, 1287-1293.	2.0	18
706	Cancer Vaccines: Can They Improve Survival?. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 147-151.	0.7	6
707	Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Expert Opinion on Drug Safety, 2015, 14, 1507-1518.	1.0	44
708	The role of immunotherapy in oncology. Future Oncology, 2015, 11, 2861-2864.	1.1	0
709	Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncology, The, 2015, 16, e498-e509.	5.1	660

#	Article	IF	Citations
710	Immunotherapeutic options on the horizon in breast cancer treatment. , 2015, 156, 90-101.		17
711	Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Modern Pathology, 2015, 28, 1535-1544.	2.9	76
712	Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of Oncology, 2015, 26, 2375-2391.	0.6	1,136
713	Nivolumab in combination with ipilimumab for the treatment of melanoma. Expert Review of Anticancer Therapy, 2015, 15, 1135-1141.	1.1	22
714	Anti-PD-1 therapiesâ€"a new first-line option in advanced melanoma. Nature Reviews Clinical Oncology, 2015, 12, 625-626.	12.5	38
715	Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. Cancer Immunology Research, 2015, 3, 1344-1355.	1.6	285
717	Predictors of clinical response to immunotherapy with or without radiotherapy. Journal of Radiation Oncology, 2015, 4, 339-345.	0.7	17
719	Immunosuppressive mechanisms in glioblastoma: Fig. 1.. Neuro-Oncology, 2015, 17, vii9-vii14.	0.6	275
720	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncology, The, 2015, 16, e534-e542.	5.1	582
721	Cancer immunotherapy via nucleic acid aptamers. International Immunopharmacology, 2015, 29, 926-936.	1.7	44
722	Cancer immunotherapy: Strategies for personalization and combinatorial approaches. Molecular Oncology, 2015, 9, 2043-2053.	2.1	87
723	Anti-TNF agents in patients with inflammatory bowel disease and malignant melanomaâ€"challenges in management. International Journal of Colorectal Disease, 2015, 30, 1595-1602.	1.0	5
724	Commensal Bifidobacterium promotes antitumor immunity and facilitates antiâ€"PD-L1 efficacy. Science, 2015, 350, 1084-1089.	6.0	2,782
725	Radiation triggering immune response and inflammation. Cancer Letters, 2015, 368, 156-163.	3.2	86
726	Immunogenicity of somatic mutations in human gastrointestinal cancers. Science, 2015, 350, 1387-1390.	6.0	639
727	Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. Structure, 2015, 23, 2341-2348.	1.6	399
728	Multiple Structural and Epigenetic Defects in the Human Leukocyte Antigen Class I Antigen Presentation Pathway in a Recurrent Metastatic Melanoma Following Immunotherapy. Journal of Biological Chemistry, 2015, 290, 26562-26575.	1.6	59
729	Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nature Reviews Neurology, 2015, 11, 504-514.	4.9	307

#	Article	IF	Citations
730	Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Expert Review of Anticancer Therapy, 2015, 15, 981-993.	1.1	59
731	Programmed death-1 & its ligands: promising targets for cancer immunotherapy. Immunotherapy, 2015, 7, 777-792.	1.0	18
732	Injectable cryogel-based whole-cell cancer vaccines. Nature Communications, 2015, 6, 7556.	5.8	312
733	The future of targeted therapies for brain metastases. Future Oncology, 2015, 11, 2315-2327.	1.1	6
734	Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?. Future Oncology, 2015, 11, 2299-2306.	1.1	20
735	Epigenetic and Immune Regulation of Colorectal Cancer Stem Cells. Current Colorectal Cancer Reports, 2015, 11, 414-421.	1.0	5
736	Targeting immune checkpoints: New opportunity for mesothelioma treatment?. Cancer Treatment Reviews, 2015, 41, 914-924.	3.4	41
737	Analogue peptides for the immunotherapy of human acute myeloid leukemia. Cancer Immunology, Immunotherapy, 2015, 64, 1357-1367.	2.0	11
738	Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance. Expert Opinion on Biological Therapy, 2015, 15, 1757-1771.	1.4	54
739	Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients. Drugs and Aging, 2015, 32, 821-834.	1.3	12
740	Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!. Clinical Cancer Research, 2015, 21, 4251-4253.	3.2	1
741	Genetic instability in the tumor microenvironment: a new look at an old neighbor. Molecular Cancer, 2015, 14, 145.	7.9	48
742	Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations. Immunotherapy, 2015, 7, 981-997.	1.0	5
743	Resimmune, an anti-CD3Â recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica, 2015, 100, 794-800.	1.7	46
744	Immune Response to Cancer Therapy: Mounting an Effective Antitumor Response and Mechanisms of Resistance. Trends in Cancer, 2015, 1, 66-75.	3.8	101
745	Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes. Bioconjugate Chemistry, 2015, 26, 2062-2069.	1.8	139
746	HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. Cancer Immunology Research, 2015, 3, 1375-1385.	1.6	342
747	Melanoma Risk and Survival among Organ Transplant Recipients. Journal of Investigative Dermatology, 2015, 135, 2657-2665.	0.3	108

#	Article	IF	Citations
748	Gauging the Long-Term Benefits of Ipilimumab in Melanoma. Journal of Clinical Oncology, 2015, 33, 1865-1866.	0.8	41
749	Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. OncoImmunology, 2015, 4, e1016700.	2.1	195
750	Heterogeneity of T Cell Responses to Pandemic pH1N1 Monovalent Vaccine in HIV-Infected Pregnant Women. AIDS Research and Human Retroviruses, 2015, 31, 1170-1177.	0.5	1
751	Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy. JAMA Oncology, 2015, 1, 1340.	3.4	63
752	Immune-mediated adverse events of anticytotoxic T lymphocyteâ€“associated antigen 4Âantibody therapy in metastatic melanoma. Translational Research, 2015, 166, 412-424.	2.2	65
753	Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. Seminars in Oncology, 2015, 42, 640-655.	0.8	179
754	Shifting paradigms in the treatment of chronic lymphocytic leukemia. Future Oncology, 2015, 11, 641-657.	1.1	3
755	Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncology, 2015, 11, 2471-2484.	1.1	70
756	Pembrolizumab. , 2015, 3, 36.		171
757	Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity. Connective Tissue Research, 2015, 56, 414-425.	1.1	123
758	Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell, 2015, 162, 1229-1241.	13.5	2,158
759	Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1738-1741.	1.8	114
760	Immunology and Immunotherapy of Head and Neck Cancer. Journal of Clinical Oncology, 2015, 33, 3293-3304.	0.8	566
761	Immune checkpoint inhibitors in melanoma. Melanoma Management, 2015, 2, 267-284.	0.1	6
762	Immune Checkpoint Inhibitors. Progress in Tumor Research, 2015, 42, 55-66.	0.1	151
763	Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell, 2015, 162, 1242-1256.	13.5	507
764	An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression. Cancer Gene Therapy, 2015, 22, 454-462.	2.2	62
765	FcÎ³Rs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. Cancer Cell, 2015, 28, 285-295.	7.7	291

#	Article	IF	Citations
766	Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma. Melanoma Management, 2015, 2, 41-50.	0.1	7
767	Emerging immune checkpoints for cancer therapy. Acta OncolÃ³gica, 2015, 54, 1706-1713.	0.8	40
768	Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies. Current Hematologic Malignancy Reports, 2015, 10, 395-404.	1.2	13
769	Immune Memory and Exhaustion: Clinically Relevant Lessons from the LCMV Model. Advances in Experimental Medicine and Biology, 2015, 850, 137-152.	0.8	49
771	Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. Seminars in Oncology, 2015, 42, 562-572.	0.8	30
772	Breast cancer and immunology: biomarker and therapeutic developments. Expert Review of Anticancer Therapy, 2015, 15, 1215-1222.	1.1	9
773	Engineering opportunities in cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14467-14472.	3.3	111
775	Turning Radiotherapy into an Effective Systemic Anti-cancer Treatment in Combination with Immunotherapy. Clinical Oncology, 2015, 27, 696-699.	0.6	11
776	Cell Death and Cancer Therapy: Don't Forget to Kill the Cancer Cell!. Clinical Cancer Research, 2015, 21, 5015-5020.	3.2	23
777	Trastuzumab emtansine (T-DM1) renders HER2 ⁺ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Science Translational Medicine, 2015, 7, 315ra188.	5.8	261
778	Malaria parasites target the hepatocyte receptor EphA2 for successful host infection. Science, 2015, 350, 1089-1092.	6.0	119
779	Overview of current immunotherapeutic strategies for glioma. Immunotherapy, 2015, 7, 1073-1104.	1.0	40
780	STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15408-15413.	3.3	404
781	Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy, 2015, 7, 1213-1227.	1.0	77
782	Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treatment Reviews, 2015, 41, 868-876.	3.4	358
783	Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Molecular Oncology, 2015, 9, 1936-1965.	2.1	64
784	Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-ÎºB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. Cancer Research, 2015, 75, 5034-5045.	0.4	439
785	Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6506-14.	3.3	299

#	Article	IF	Citations
786	The role of programmed cell deathâ€1 (PDâ€1) and its ligands in pediatric cancer. Pediatric Blood and Cancer, 2015, 62, 190-197.	0.8	24
787	New therapeutic options for advanced non-resectable malignant melanoma. Advances in Medical Sciences, 2015, 60, 83-88.	0.9	40
788	Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. Journal of Oncology Pharmacy Practice, 2015, 21, 451-467.	0.5	90
789	Future Directions and Targeted Therapies in Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 361-376.	0.9	22
790	Tumourâ€infiltrating lymphocytes and expression of programmed death ligand 1 (PDâ€L1) in melanoma brain metastases. Histopathology, 2015, 66, 289-299.	1.6	99
791	Novel immunotherapies for hematologic malignancies. Immunological Reviews, 2015, 263, 90-105.	2.8	44
792	Clinical blockade of PD1 and LAG3 â€" potential mechanisms of action. Nature Reviews Immunology, 2015, 15, 45-56.	10.6	524
793	Radiotherapy and Toll-Like Receptor Agonists. Seminars in Radiation Oncology, 2015, 25, 34-39.	1.0	24
794	The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience. , 2015, 148, 132-153.		50
795	Oral health in oncology: impact of immunotherapy. Supportive Care in Cancer, 2015, 23, 1-3.	1.0	39
796	Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans. Clinical Cancer Research, 2015, 21, 534-543.	3.2	47
797	Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends in Molecular Medicine, 2015, 21, 24-33.	3.5	628
798	Structural genomic alterations in primary mediastinal large B-cell lymphoma. Leukemia and Lymphoma, 2015, 56, 2239-2250.	0.6	18
799	Subunit Vaccine Delivery. Advances in Delivery Science and Technology, 2015, , .	0.4	9
800	Inflammation and tuberculosis: hostâ€directed therapies. Journal of Internal Medicine, 2015, 277, 373-387.	2.7	103
801	La linfangiogÃ©nesis. Sus implicaciones en el diagnÃ³stico, tratamiento y pronÃ³stico del melanoma. Actas Dermo-sifiliogrÃ¡ficas, 2015, 106, 7-16.	0.2	9
802	Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. International Immunology, 2015, 27, 39-46.	1.8	286
803	The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints. Cancer Discovery, 2015, 5, 43-51.	7.7	1,180

#	Article	IF	Citations
804	Comparison of gene expression patterns across 12 tumor types identifies a cancer supercluster characterized by TP53 mutations and cell cycle defects. Oncogene, 2015, 34, 2732-2740.	2.6	46
805	Therapeutic use of anti-CTLA-4 antibodies. International Immunology, 2015, 27, 3-10.	1.8	96
806	Immunotherapy in Melanoma. Journal of Pharmacy Practice, 2015, 28, 193-203.	0.5	8
807	Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy. Blood Reviews, 2015, 29, 25-32.	2.8	38
808	PD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy. JCI Insight, 2016, 1, .	2.3	60
809	19. Translating science into therapy of lymphoma. , 2016, , 379-402.		0
810	A case report and literature review of primary resistant Hodgkin lymphoma: a response to anti-PD-1 after failure of autologous stem cell transplantation and brentuximab vedotin. OncoTargets and Therapy, 2016, Volume 9, 5781-5789.	1.0	2
811	Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date. OncoTargets and Therapy, 2016, Volume 9, 5855-5866.	1.0	11
812	New advances in targeted gastric cancer treatment. World Journal of Gastroenterology, 2016, 22, 6776.	1.4	74
813	An update on Dendritic Cell-Based Cancer Immunotherapy. Immunome Research, 2016, 12, .	0.1	1
814	Tumor immune profiling predicts response to antiâ€“PD-1 therapy in human melanoma. Journal of Clinical Investigation, 2016, 126, 3447-3452.	3.9	439
815	Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy. Przeglad Dermatologiczny, 2016, 2, 127-138.	0.0	0
816	Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists. Oncotarget, 2016, 7, 42919-42942.	0.8	21
817	Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. OncoTargets and Therapy, 2016, 9, 3187.	1.0	11
818	Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2016, Volume 3, 31-36.	1.8	32
819	Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy. Immune Network, 2016, 16, 134.	1.6	8
820	T cell Bim levels reflect responses to antiâ€“PD-1 cancer therapy. JCI Insight, 2016, 1, .	2.3	68
821	Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e387-e398.	1.8	22

#	Article	IF	Citations
822	The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight, 2016, 1, e89829.	2.3	569
823	Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e175-e184.	1.8	13
824	The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 34-42.	1.8	85
825	PD-L1 expression in lung cancer. Journal of Thoracic Disease, 2016, 8, 3053-3055.	0.6	2
827	Genomic landscape of DNA repair genes in cancer. Oncotarget, 2016, 7, 23312-23321.	0.8	153
828	Brain Metastases from Melanoma. , 2016, , 65-83.		0
829	Beyond RAS and BRAF: a target rich disease that is ripe for picking. Journal of Gastrointestinal Oncology, 2016, 7, 705-712.	0.6	2
830	The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer. Oncotarget, 2016, 7, 37331-37346.	0.8	73
831	NUEVAS TERAPIAS SISTÃ‰MICAS PARA EL TRATAMIENTO DEL MELANOMA. Revista Chilena De Cirugia, 2016, 68, 81-86.	0.1	1
832	Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget, 2016, 7, 32318-32328.	0.8	141
833	Clinical pharmacologic aspects of immune checkpoint inhibitors in cancer therapy. Translational and Clinical Pharmacology, 2016, 24, 7.	0.3	3
834	Current Immunotherapies for Sarcoma: Clinical Trials and Rationale. Sarcoma, 2016, 2016, 1-6.	0.7	20
835	Nanodelivery of Anticancer Agents in Melanoma. , 2016, , 189-201.		2
836	PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight, 2016, 1, .	2.3	128
837	Enhanced Anti-Tumor Efficacy through a Combination of Integrin Î±vÎ²6-Targeted Photodynamic Therapy and Immune Checkpoint Inhibition. Theranostics, 2016, 6, 627-637.	4.6	92
839	Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. Journal of Gynecologic Oncology, 2016, 27, e51.	1.0	99
840	Epstein-Barr virus-positive gastric cancer: a distinct molecular subtype of the disease?. Revista Da Sociedade Brasileira De Medicina Tropical, 2016, 49, 150-157.	0.4	25
841	Versatile roles of extracellular vesicles in cancer. Journal of Clinical Investigation, 2016, 126, 1163-1172.	3.9	261

#	Article	IF	Citations
842	Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer. International Journal of Environmental Research and Public Health, 2016, 13, 892.	1.2	43
843	New Strategies for the Treatment of Solid Tumors with CAR-T Cells. International Journal of Biological Sciences, 2016, 12, 718-729.	2.6	67
844	The emerging role of immunotherapy in colorectal cancer. Annals of Translational Medicine, 2016, 4, 305-305.	0.7	63
845	Harnessing the immune system to improve cancer therapy. Annals of Translational Medicine, 2016, 4, 261-261.	0.7	225
846	Regulation of Natural Killer Cell Function by STAT3. Frontiers in Immunology, 2016, 7, 128.	2.2	64
847	Differential Expression of Immune Checkpoint Modulators on In Vitro Primed CD4+ and CD8+ T Cells. Frontiers in Immunology, 2016, 7, 221.	2.2	20
848	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Frontiers in Immunology, 2016, 7, 550.	2.2	409
849	Cancer Immunosurveillance: Immunoediting. , 2016, , 396-405.		3
850	Humanized Mice in Translational Immunology. , 2016, , 285-326.		11
851	Direct Lymph Node Vaccination of Lentivector/Prostate-Specific Antigen is Safe and Generates Tissue-Specific Responses in Rhesus Macaques. Biomedicines, 2016, 4, 6.	1.4	2
852	Updates in Therapy for Advanced Melanoma. Cancers, 2016, 8, 17.	1.7	37
853	A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab. Drug Target Insights, 2016, 10, DTI.S31565.	0.9	26
854	Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. PLoS ONE, 2016, 11, e0160221.	1.1	373
855	PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model. PLoS Pathogens, 2016, 12, e1005642.	2.1	87
856	Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors. Oncotarget, 2016, 7, 23282-23299.	0.8	81
857	PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets and Therapy, 2016, Volume 9, 5023-5039.	1.0	558
858	Sipuleucel-T â€“ A Model for Immunotherapy Trial Development. , 2016, , 523-531.		0
859	Immune checkpoint inhibitors: the new frontier in non–small cell lung cancer treatment. OncoTargets and Therapy, 2016, Volume 9, 5101-5116.	1.0	27

#	Article	IF	Citations
860	High-dose irradiation in combination with toll-like receptor 9 agonist CpG oligodeoxynucleotide 7909 downregulates PD-L1 expression via the NF-κB signaling pathway in non-small cell lung cancer cells. OncoTargets and Therapy, 2016, Volume 9, 6511-6518.	1.0	13
861	PD-L1promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncotarget, 2016, 7, 79943-79955.	0.8	73
862	Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget, 2016, 7, 17194-17211.	0.8	80
863	Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. BMJ Case Reports, 2016, 2016, bcr2016216228.	0.2	61
864	The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget, 2016, 7, 73068-73079.	0.8	76
865	Prognostic Factors for Survival in Melanoma Patients with Brain Metastases. , 2016, , 267-297.		11
866	Checkpoint Inhibition. Cancer Journal (Sudbury, Mass), 2016, 22, 17-22.	1.0	17
867	Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies. Cancer Journal (Sudbury,) Tj ETQq1 1 0.784314 rgBT /Ov	1.0	17
868	Immune Checkpoint Therapy in Melanoma. Cancer Journal (Sudbury, Mass), 2016, 22, 73-80.	1.0	10
869	Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma. Melanoma Research, 2016, 26, 1-11.	0.6	13
870	Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod. Melanoma Research, 2016, 26, 409-412.	0.6	20
871	Safety of immune checkpoint inhibitors in Chinese patients with melanoma. Melanoma Research, 2016, 26, 284-289.	0.6	21
872	Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer. Dermatologic Surgery, 2016, 42, S40-S48.	0.4	8
873	Pembrolizumab (Keytruda). Human Vaccines and Immunotherapeutics, 2016, 12, 2777-2789.	1.4	237
874	Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy, 2016, 8, 821-837.	1.0	139
875	Residual <scp>FDG</scp>â€<scp>PET</scp> metabolic activity in metastatic melanoma patients with prolonged response to antiâ€<scp>PD</scp>â€1 therapy. Pigment Cell and Melanoma Research, 2016, 29, 572-577.	1.5	81
876	The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Research, 2016, 26, 300-303.	0.6	90
877	Immune Checkpoint Therapy and the Search for Predictive Biomarkers. Cancer Journal (Sudbury, Mass) Tj ETQq1 1 0.784314 rgBT /Ov	1.0	31

#	Article	IF	Citations
878	Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. Cancer Immunology Research, 2016, 4, 569-573.	1.6	20
879	PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases. Melanoma Research, 2016, 26, 421-424.	0.6	40
880	Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Current Opinion in Oncology, 2016, 28, 254-263.	1.1	213
881	Immunotherapy advances in uro-genital malignancies. Critical Reviews in Oncology/Hematology, 2016, 105, 52-64.	2.0	19
882	Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?. Cancer Treatment Reviews, 2016, 48, 61-68.	3.4	102
883	BRAFV600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis. OncoImmunology, 2016, 5, e1185582.	2.1	46
884	Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle and Nerve, 2016, 54, 157-161.	1.0	87
885	Update on immune therapy in melanoma. Expert Opinion on Orphan Drugs, 2016, 4, 799-808.	0.5	0
886	Immune-mediated respiratory adverse events of checkpoint inhibitors. Current Opinion in Oncology, 2016, 28, 269-277.	1.1	39
887	Reversing T Cell Dysfunction for Tumor Immunotherapy. , 2016, , 109-128.		0
888	Novel Targets and Their Assessment for Cancer Treatment. , 2016, , 163-180.		0
889	Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab. Lung Cancer, 2016, 99, 123-126.	0.9	46
890	Immune checkpoint inhibitors side effects and management. Immunotherapy, 2016, 8, 799-807.	1.0	62
891	Programmed death ligandâ€1 expression is associated with poor disease free survival in salivary gland carcinomas. Journal of Surgical Oncology, 2016, 114, 36-43.	0.8	87
892	Ocular and orbital side-effects of checkpoint inhibitors: a review article. Current Opinion in Oncology, 2016, 28, 288-294.	1.1	117
893	Immuneâ€Related Adverse Events From Immune Checkpoint Inhibitors. Clinical Pharmacology and Therapeutics, 2016, 100, 242-251.	2.3	84
894	Autoimmune dermatologic toxicities from immune checkpoint blockade with antiâ€‹scp›PD‹/scp›â€1 antibody therapy: a report on bullous skin eruptions. Journal of Cutaneous Pathology, 2016, 43, 688-696.	0.7	126
895	Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. OncoImmunology, 2016, 5, e1186323.	2.1	2

#	Article	IF	Citations
896	Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease. ESMO Open, 2016, 1, e000084.	2.0	9
897	Explaining the Paucity of Intratumoral T Cells: A Construction Out of Known Entities. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 219-226.	2.0	6
898	Can T cells be too exhausted to fight back?. Science, 2016, 354, 1104-1105.	6.0	12
899	Responses to immune checkpoint inhibitors in nonagenarians. OncoImmunology, 2016, 5, e1234572.	2.1	24
900	PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. Breast Care, 2016, 11, 385-390.	0.8	20,872
901	Current treatments for advanced melanoma and introduction of a promising novel gene therapy for melanoma (Review). Oncology Reports, 2016, 36, 1779-1786.	1.2	14
902	Cancer immunotherapy trials: leading a paradigm shift in drug development. , 2016, 4, 42.		35
903	Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma. Oncology Nursing Forum, 2016, 43, 219-226.	0.5	18
904	Canine cancer immunotherapy studies: linking mouse and human. , 2016, 4, 97.		86
905	A New VISTA on combination therapy for negative checkpoint regulator blockade. , 2016, 4, 86.		36
906	Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy. Oncology Reports, 2016, 36, 2625-2632.	1.2	4
907	A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity. Signal Transduction and Targeted Therapy, 2016, 1, 16025.	7.1	35
908	Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib. Scientific Reports, 2016, 6, 39598.	1.6	6
909	Nivolumab-associated acute glomerulonephritis: a case report and literature review. BMC Nephrology, 2016, 17, 188.	0.8	91
910	Immune checkpoint inhibitors renal side effects and management. Immunotherapy, 2016, 8, 1417-1425.	1.0	13
911	Renal effects of immune checkpoint inhibitors. Nephrology Dialysis Transplantation, 2017, 32, gfw382.	0.4	67
912	Rapid remission of symptomatic brain metastases in melanoma by programmed-death-receptor-1 inhibition. Melanoma Research, 2016, 26, 528-531.	0.6	9
913	Myeloid Cell Leukemia Sequence 1. , 2016, , 2989-2989.		0

#	Article	IF	Citations
914	An In Vitro Model That Predicts the Therapeutic Efficacy of Immunomodulatory Antibodies. Journal of Immunotherapy, 2016, 39, 298-305.	1.2	4
915	A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Research, 2016, 26, 469-480.	0.6	30
916	Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition. American Journal of Dermatopathology, 2016, 38, e159-e162.	0.3	7
917	Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. , 2016, 4, 84.		94
919	Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients. Journal of Translational Medicine, 2016, 14, 232.	1.8	27
920	Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2016, 23, 2610-2617.	0.7	128
921	Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. OncoImmunology, 2016, 5, e1165377.	2.1	42
922	Adjuvant treatment for stage III melanoma in the era of targeted medicine and immunotherapy. Melanoma Management, 2016, 3, 137-147.	0.1	1
923	Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncology, The, 2016, 17, 956-965.	5.1	1,369
924	Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies. Annals of Medicine, 2016, 48, 428-439.	1.5	32
925	Intralesional treatment for advanced melanoma: what's on the horizon?. Melanoma Management, 2016, 3, 113-123.	0.1	0
926	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. Drugs, 2016, 76, 925-945.	4.9	123
927	Treatment of murine lupus with PD-Llg. Clinical Immunology, 2016, 162, 1-8.	1.4	16
928	Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. American Journal of Kidney Diseases, 2016, 68, 287-291.	2.1	253
929	Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2016, 34, 2389-2397.	0.8	293
930	Novel immunotherapies for the treatment of melanoma. Immunotherapy, 2016, 8, 613-632.	1.0	5
931	A fully human IgG1 antiâ€PDâ€L1 MAb in an in vitro assay enhances antigenâ€specific Tâ€cell responses. Clinical and Translational Immunology, 2016, 5, e83.	1.7	52
932	Emerging molecular classifications and therapeutic implications for gastric cancer. Chinese Journal of Cancer, 2016, 35, 49.	4.9	35

#	Article	IF	Citations
933	What Is New in Melanoma Genetics and Treatment?. Dermatology, 2016, 232, 259-264.	0.9	25
934	Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. Current Treatment Options in Oncology, 2016, 17, 31.	1.3	57
935	Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. Current Oncology Reports, 2016, 18, 42.	1.8	54
936	Malignant melanomaâ€"The cradle of anti-neoplastic immunotherapy. Critical Reviews in Oncology/Hematology, 2016, 106, 25-54.	2.0	33
937	PD-L1 Expression in Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 964-975.	0.5	329
939	Targeting T Cell Co-receptors for Cancer Therapy. Immunity, 2016, 44, 1069-1078.	6.6	418
940	Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study. Journal of the American Academy of Dermatology, 2016, 75, 516-524.	0.6	61
941	First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma. British Journal of Cancer, 2016, 114, 1199-1205.	2.9	30
942	Combinatorial Cancer Immunotherapies. Advances in Immunology, 2016, 130, 251-277.	1.1	107
943	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clinical Cancer Research, 2016, 22, 5487-5496.	3.2	480
944	Molecular Drivers of the Nonâ€"T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunology Research, 2016, 4, 563-568.	1.6	293
945	The Role of the Immune System and Immunoregulatory Mechanisms Relevant to Melanoma. , 2016, , 31-65.		0
946	Endocrinological side-effects of immune checkpoint inhibitors. Current Opinion in Oncology, 2016, 28, 278-287.	1.1	115
947	Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors. Molecular Cancer Therapeutics, 2016, 15, 1746-1756.	1.9	45
948	PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. Immunotherapy, 2016, 8, 733-746.	1.0	28
949	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Annals of Oncology, 2016, 27, 1492-1504.	0.6	460
950	Pembrolizumab for the treatment of advanced melanoma. Expert Opinion on Orphan Drugs, 2016, 4, 867-873.	0.5	10
951	Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma. OncoImmunology, 2016, 5, e1052212.	2.1	83

#	Article	IF	Citations
952	Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science, 2016, 352, 189-196.	6.0	3,421
953	Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma. Cancer Immunology Research, 2016, 4, 531-540.	1.6	20
954	PD-1 Blockade Boosts Radiofrequency Ablationâ€“Elicited Adaptive Immune Responses against Tumor. Clinical Cancer Research, 2016, 22, 1173-1184.	3.2	207
955	Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies. Leukemia and Lymphoma, 2016, 57, 1269-1280.	0.6	4
956	Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Annals of Oncology, 2016, 27, 1482-1492.	0.6	765
957	Ipilimumab-induced colitis: A new challenge for gastroenterologists. GastroenterologÃa Y HepatologÃa (English Edition), 2016, 39, 233-238.	0.0	1
958	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews Cancer, 2016, 16, 275-287.	12.8	2,133
959	Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers. Expert Opinion on Biological Therapy, 2016, 16, 989-1004.	1.4	10
960	MicroRNAs provide a novel pathway toward combinatorial immune checkpoint blockade. Neuro-Oncology, 2016, 18, 601-602.	0.6	2
961	The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. Clinical Cancer Research, 2016, 22, 1865-1874.	3.2	700
962	Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?. Current Opinion in Immunology, 2016, 40, vii-xiii.	2.4	20
963	Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. European Journal of Cancer, 2016, 60, 210-225.	1.3	490
964	Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. European Journal of Cancer, 2016, 60, 190-209.	1.3	546
965	The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma. Medicine (United States), 2016, 95, e3134.	0.4	13
966	Advances in immunotherapy for melanoma. BMC Medicine, 2016, 14, 20.	2.3	111
967	Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. European Journal of Cancer, 2016, 60, 12-25.	1.3	321
968	Harnessing the immune system for the treatment of melanoma: current status and future prospects. Expert Review of Clinical Immunology, 2016, 12, 879-893.	1.3	8
969	Biomarkers for PD-1/PD-L1 Blockade Therapy inÂNonâ€“Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?. Clinical Lung Cancer, 2016, 17, 350-361.	1.1	100

#	Article	IF	Citations
970	PD-1 Blockade in Melanoma. JAMA - Journal of the American Medical Association, 2016, 315, 1573.	3.8	5
971	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA - Journal of the American Medical Association, 2016, 315, 1600.	3.8	857
972	Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: Case report. Canadian Journal of Ophthalmology, 2016, 51, e4-e6.	0.4	51
973	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. New England Journal of Medicine, 2016, 374, 2542-2552.	13.9	1,048
974	Reversing T-cell Dysfunction and Exhaustion in Cancer. Clinical Cancer Research, 2016, 22, 1856-1864.	3.2	317
975	A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma. Investigational New Drugs, 2016, 34, 439-449.	1.2	86
976	Surgical Oncology Manual. , 2016, , .		1
977	Talimogene Laherparepvec for the Treatment of Advanced Melanoma. Clinical Cancer Research, 2016, 22, 3127-3131.	3.2	80
978	Suppression of Antitumor Immune Responses by Human Papillomavirus through Epigenetic Downregulation of CXCL14. MBio, 2016, 7, .	1.8	88
979	Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab. Immunotherapy, 2016, 8, 687-692.	1.0	7
980	Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. British Journal of Cancer, 2016, 114, 1084-1089.	2.9	113
981	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature Reviews Clinical Oncology, 2016, 13, 473-486.	12.5	831
982	A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors. Immunotherapy, 2016, 8, 665-674.	1.0	39
983	Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. Cancer Discovery, 2016, 6, 703-713.	7.7	92
985	Roles of regulatory T cells in cancer immunity. International Immunology, 2016, 28, 401-409.	1.8	412
986	The integration of radiation therapy and immunotherapy in melanoma management. Journal of Radiation Oncology, 2016, 5, 131-142.	0.7	2
987	Genetics of Melanoma. , 2016, , .		3
988	Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. OncoImmunology, 2016, 5, e1151595.	2.1	57

#	Article	IF	Citations
989	Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2863-2873.	1.8	137
990	Biology and treatment of BRAF mutant metastatic melanoma. Melanoma Management, 2016, 3, 33-45.	0.1	28
991	Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. Cancer Immunology Research, 2016, 4, 845-857.	1.6	110
992	Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma. Future Oncology, 2016, 12, 2683-2688.	1.1	17
993	Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion. Journal of Virology, 2016, 90, 8934-8946.	1.5	69
994	The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nature Immunology, 2016, 17, 1273-1281.	7.0	277
995	Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. European Journal of Cancer, 2016, 67, 46-54.	1.3	77
996	Review on the immunotherapy strategies against metastatic colorectal carcinoma. Immunotherapy, 2016, 8, 1245-1261.	1.0	8
997	Current Flow Cytometry Methods for the Clinical Development of Immunomodulatory Biologics. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 141-151.	0.2	2
998	Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics. Current Opinion in Pharmacology, 2016, 30, 93-105.	1.7	25
999	Progress and opportunities for immune therapeutics in osteosarcoma. Immunotherapy, 2016, 8, 1233-1244.	1.0	54
1000	Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential. Immunotherapy, 2016, 8, 1219-1232.	1.0	22
1001	Genetics of triple-negative breast cancer: Implications for patient care. Current Problems in Cancer, 2016, 40, 130-140.	1.0	24
1002	CD200R, a co-inhibitory receptor on immune cells, predicts the prognosis of human hepatocellular carcinoma. Immunology Letters, 2016, 178, 105-113.	1.1	10
1004	Advances in PET Detection of the Antitumor T Cell Response. Advances in Immunology, 2016, 131, 187-231.	1.1	39
1005	Inmunoterapia del melanoma. Piel, 2016, 31, 649-656.	0.0	0
1006	Immunotherapy for malignant mesothelioma: reality check. Expert Review of Anticancer Therapy, 2016, 16, 1167-1176.	1.1	10
1007	Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. Journal of Clinical Oncology, 2016, 34, 3838-3845.	0.8	715

#	Article	IF	Citations
1008	Immunotherapy of Melanoma. Oncology Research and Treatment, 2016, 39, 369-376.	0.8	14
1009	The full blood count as a biomarker of outcome and toxicity in ipilimumabâ€treated cutaneous metastatic melanoma. Cancer Medicine, 2016, 5, 2792-2799.	1.3	72
1010	A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma. Pharmacotherapy, 2016, 36, e183-e188.	1.2	49
1011	Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?. Haematologica, 2016, 101, 1144-1158.	1.7	6
1012	Immunotherapy for Lung Cancer: No Longer an Abstract Concept. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 771-782.	0.8	12
1013	Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. British Journal of Cancer, 2016, 115, 1186-1192.	2.9	50
1014	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy, 2016, 65, 1533-1544.	2.0	89
1015	Programmed Death-Ligand 1 Expression and Response to the Antiâ€"Programmed Death 1 Antibody Pembrolizumab in Melanoma. Journal of Clinical Oncology, 2016, 34, 4102-4109.	0.8	528
1016	Rapid and objective CT scan prognostic scoring identifiesÂmetastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy. European Journal of Cancer, 2016, 65, 33-42.	1.3	58
1017	Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1247-1253.	1.5	50
1018	Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and metaâ€analysis of antiâ€CTLAâ€4 and antiâ€PDâ€1 agents trials. Cancer Medicine, 2016, 5, 1481-1491.	1.3	86
1019	Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of antiâ€cancer antibodies: IUPHAR Review 18. British Journal of Pharmacology, 2016, 173, 1407-1424.	2.7	56
1020	Pembrolizumab in classical Hodgkin's lymphoma. European Journal of Haematology, 2016, 97, 219-227.	1.1	22
1021	Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. Cancer Science, 2016, 107, 107-115.	1.7	28
1022	Negative influence of programmed deathâ€1â€ligands on the survival of esophageal cancer patients treated with chemotherapy. Cancer Science, 2016, 107, 726-733.	1.7	43
1023	Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome. Cancer Research, 2016, 76, 4602-4607.	0.4	92
1024	The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Antiâ€"PD-1 Response in Patients with Renal Cell Carcinoma. Cancer Immunology Research, 2016, 4, 726-733.	1.6	133
1025	Lymphocyteâ€activation geneâ€3, an important immune checkpoint in cancer. Cancer Science, 2016, 107, 1193-1197.	1.7	168

#	Article	IF	Citations
1026	Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. , 2016, 4, 50.		413
1027	Pancreatic Cancer. Gastroenterology Clinics of North America, 2016, 45, 429-445.	1.0	73
1028	A Prospective Clinical Trial Combining RadiationÂTherapy With Systemic Immunotherapy inÂMetastatic Melanoma. International Journal of Radiation Oncology Biology Physics, 2016, 96, 578-588.	0.4	190
1029	Development of a Companion Diagnostic for Pembrolizumab in Nonâ€“Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1. Archives of Pathology and Laboratory Medicine, 2016, 140, 1243-1249.	1.2	100
1030	Translating Molecular Biomarkers into Clinical Assays. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , .	0.2	0
1031	PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors?. Annals of Oncology, 2016, 27, 1658-1659.	0.6	3
1032	Clinical outcomes in metastatic uveal melanoma treated with PDâ€1 and PDâ€L1 antibodies. Cancer, 2016, 122, 3344-3353.	2.0	288
1033	The efficacy of antiâ€PDâ€1 agents in acral and mucosal melanoma. Cancer, 2016, 122, 3354-3362.	2.0	236
1034	PD-1 Inhibitorâ€“Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clinical Cancer Research, 2016, 22, 6051-6060.	3.2	393
1035	Incidence of Programmed Cell Death 1 Inhibitorâ€“Related Pneumonitis in Patients With Advanced Cancer. JAMA Oncology, 2016, 2, 1607.	3.4	600
1036	PDâ€1 expression on the surface of peripheral blood CD4 + T cell and its association with the prognosis of patients with diffuse large Bâ€cell lymphoma. Cancer Medicine, 2016, 5, 3077-3084.	1.3	26
1037	Does clinical trial participation improve outcomes in patients with ovarian cancer?. ESMO Open, 2016, 1, e000057.	2.0	9
1038	Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cellâ€“Rich Tumor. Cancer Research, 2016, 76, 6266-6277.	0.4	74
1039	PD-1 blockade in Hodgkinâ€™s lymphoma: learning new tricks from an old teacher. Expert Review of Hematology, 2016, 9, 939-949.	1.0	13
1040	Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. OncoImmunology, 2016, 5, e1214788.	2.1	123
1042	Harnessing the potential of noninvasive in vivo preclinical imaging of the immune system: challenges and prospects. Nanomedicine, 2016, 11, 2711-2722.	1.7	6
1043	Intralesional and systemic immunotherapy for metastatic melanoma. Expert Opinion on Biological Therapy, 2016, 16, 1491-1499.	1.4	15
1044	PD-L1 expression is associated with advanced non-small cell lung cancer. Oncology Letters, 2016, 12, 921-927.	0.8	18

#	Article	IF	Citations
1045	Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer. Oncology Letters, 2016, 12, 944-950.	0.8	75
1046	Advances in immunotherapy for melanoma management. Human Vaccines and Immunotherapeutics, 2016, 12, 2501-2511.	1.4	15
1047	MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair. Human Mutation, 2016, 37, 1004-1012.	1.1	6
1048	Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. Immunotherapy, 2016, 8, 775-784.	1.0	24
1049	Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Modern Pathology, 2016, 29, 1433-1442.	2.9	144
1050	Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1. Cancer Immunology Research, 2016, 4, 779-788.	1.6	80
1051	Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. New England Journal of Medicine, 2016, 375, 819-829.	13.9	2,430
1052	Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab. Oral Oncology, 2016, 63, e1-e3.	0.8	11
1053	Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. BioDrugs, 2016, 30, 571-584.	2.2	93
1054	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nature Communications, 2016, 7, 10582.	5.8	412
1055	Magneto-nanosensor platform for probing low-affinity proteinâ€“protein interactions and identification of a low-affinity PD-L1/PD-L2 interaction. Nature Communications, 2016, 7, 12220.	5.8	29
1056	BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma. Immunotherapy, 2016, 8, 1351-1353.	1.0	6
1057	Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death. Cell Reports, 2016, 17, 957-965.	2.9	22
1058	Emerging role of immunotherapy in urothelial carcinomaâ€”Immunobiology/biomarkers. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 556-565.	0.8	23
1059	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science Translational Medicine, 2016, 8, 328rv4.	5.8	1,844
1060	Interdependent IL-7 and IFN-Î³ signalling in T-cell controls tumour eradication by combined Î±-CTLA-4+Î±-PD-1 therapy. Nature Communications, 2016, 7, 12335.	5.8	93
1061	The tumor microenvironment disarms CD8⁺ T lymphocyte function via a miR-26a-EZH2 axis. OncoImmunology, 2016, 5, e1245267.	2.1	15
1062	Recent Trends in the Management of Hepatocellular Carcinoma with Special Emphasis on Treatment with Regorafenib and Immune Checkpoint Inhibitors. Digestive Diseases, 2016, 34, 714-730.	0.8	7

#	Article	IF	Citations
1063	Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nature Communications, 2016, 7, 13354.	5.8	224
1064	Approaches to modernize the combination drug development paradigm. Genome Medicine, 2016, 8, 115.	3.6	64
1065	Immune checkpoint therapy and type 1 diabetes. Diabetology International, 2016, 7, 221-227.	0.7	12
1066	THE APPLICATION FOR CANCER IMMUNOTHERAPY USING in vivo OR in vitro ACTIVATED Î³Î´ T CELL. Japanese Journal of Transfusion and Cell Therapy, 2016, 62, 3-12.	0.1	0
1068	Acute visual loss after ipilimumab treatment for metastatic melanoma. , 2016, 4, 66.		59
1069	Current Status of Immunotherapy Treatments for Pancreatic Cancer. Journal of Clinical Gastroenterology, 2016, 50, 836-848.	1.1	11
1070	Innovation in Bladder Cancer Immunotherapy. Journal of Immunotherapy, 2016, 39, 291-297.	1.2	4
1072	Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck. Head and Neck, 2016, 38, 1008-1016.	0.9	14
1073	Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma. Journal of Cutaneous Pathology, 2016, 43, 787-791.	0.7	63
1074	Checkpoint inhibition in meningiomas. Immunotherapy, 2016, 8, 721-731.	1.0	22
1075	Progress in Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2016, , .	0.8	6
1076	Harnessing the immune system in acute myeloid leukaemia. Critical Reviews in Oncology/Hematology, 2016, 103, 62-77.	2.0	90
1077	Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition. Journal of Translational Medicine, 2016, 14, 88.	1.8	10
1078	Phase I study with ONCOS-102 for the treatment of solid tumors â€“ an evaluation of clinical response and exploratory analyses of immune markers. , 2016, 4, 17.		155
1079	Multiple Inhibitory Pathways Contribute to Lung CD8+ T Cell Impairment and Protect against Immunopathology during Acute Viral Respiratory Infection. Journal of Immunology, 2016, 197, 233-243.	0.4	26
1080	Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy. Japanese Journal of Clinical Oncology, 2016, 46, 775-780.	0.6	9
1081	Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. Oncologist, 2016, 21, 804-816.	1.9	208
1082	Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). Medical Oncology, 2016, 33, 80.	1.2	32

#	Article	IF	Citations
1083	Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity, 2016, 44, 1255-1269.	6.6	797
1084	Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis. Clinical Oncology, 2016, 28, e127-e138.	0.6	35
1085	Radiotherapy and immune checkpoints inhibitors for advanced melanoma. Radiotherapy and Oncology, 2016, 120, 1-12.	0.3	44
1086	Mouse Models of Tumor Immunotherapy. Advances in Immunology, 2016, 130, 1-24.	1.1	30
1087	Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma. Melanoma Research, 2016, 26, 125-137.	0.6	18
1088	Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines. Cancer Research, 2016, 76, 4332-4346.	0.4	93
1089	Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC. Journal of Thoracic Oncology, 2016, 11, 1819-1836.	0.5	31
1090	Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer. Oncology and Therapy, 2016, 4, 17-33.	1.0	19
1091	Prognostic Significance of PD-L1 in Patients with Nonâ€“Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases. Journal of Thoracic Oncology, 2016, 11, 1003-1011.	0.5	130
1093	Adoptive Cellular Therapy (ACT) for Cancer Treatment. Advances in Experimental Medicine and Biology, 2016, 909, 169-239.	0.8	14
1094	Personalized immunotherapy in colorectal cancer. Expert Review of Precision Medicine and Drug Development, 2016, 1, 267-277.	0.4	2
1095	Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. Breast Cancer Research, 2016, 18, 50.	2.2	56
1096	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. , 2016, 4, 15.		67
1097	Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid. , 2016, 4, 20.		32
1098	Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies. , 2016, , 1-39.		0
1099	Biologics and Their Interactions with Radiation. , 2016, , 80-92.e4.		0
1100	Modified breast cancer model for preclinical immunotherapy studies. Journal of Surgical Research, 2016, 204, 467-474.	0.8	22
1101	Molecular and genetic inflammation networks in major human diseases. Molecular BioSystems, 2016, 12, 2318-2341.	2.9	49

#	Article	IF	Citations
1102	Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer, 2016, 19, 42-52.	2.7	230
1103	Unknown primary tumors: is there a future therapeutic role for immune checkpoint inhibitors?. Future Oncology, 2016, 12, 429-431.	1.1	3
1104	Overall Survival and Durable Responses in Patients With BRAF V600â€“Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. Journal of Clinical Oncology, 2016, 34, 871-878.	0.8	266
1105	Immune-related adverse events with immune checkpoint blockade: a comprehensive review. European Journal of Cancer, 2016, 54, 139-148.	1.3	1,687
1106	Treatment of Melanoma CNS Metastases. Cancer Treatment and Research, 2016, 167, 263-279.	0.2	6
1107	The PD-1 Axis Enforces an Anatomical Segregation of CTL Activity that Creates Tumor Niches after Allogeneic Hematopoietic Stem Cell Transplantation. Immunity, 2016, 44, 143-154.	6.6	76
1108	Molecular basis of antibody binding to mucin glycopeptides in lung cancer. International Journal of Oncology, 2016, 48, 587-594.	1.4	13
1109	Clinical trials exploring the benefit of immunotherapy and radiation in cancer treatment: A review of the past and a look into the future. Current Problems in Cancer, 2016, 40, 38-67.	1.0	9
1110	Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. Journal of the American Academy of Dermatology, 2016, 74, 455-461.e1.	0.6	247
1111	Synthetic RORÎ³t Agonists Enhance Protective Immunity. ACS Chemical Biology, 2016, 11, 1012-1018.	1.6	48
1112	Strategies and developments of immunotherapies in osteosarcoma. Oncology Letters, 2016, 11, 511-520.	0.8	43
1113	A panoply of errors: polymerase proofreading domain mutations in cancer. Nature Reviews Cancer, 2016, 16, 71-81.	12.8	292
1114	Current status of immunotherapy. Japanese Journal of Clinical Oncology, 2016, 46, 191-203.	0.6	52
1115	Recurrence and Survival Outcomes After Percutaneous Thermal Ablation of Oligometastatic Melanoma. Mayo Clinic Proceedings, 2016, 91, 288-296.	1.4	17
1116	Synergistic COX2 Induction by IFNÎ³ and TNFÎ± Self-Limits Type-1 Immunity in the Human Tumor Microenvironment. Cancer Immunology Research, 2016, 4, 303-311.	1.6	53
1117	Modulation of tumor immunity: a patent evaluation of WO2015026684A1. Expert Opinion on Therapeutic Patents, 2016, 26, 417-425.	2.4	8
1118	New insights into the anti-PD-L1 and anti-PD-1 reagents in cancer therapy. European Journal of Inflammation, 2016, 14, 61-65.	0.2	0
1119	Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-ÎºB, NFAT and AP-1. Journal of Immunological Methods, 2016, 430, 10-20.	0.6	140

#	Article	IF	Citations
1120	Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. Cancer Discovery, 2016, 6, 446-459.	7.7	198
1121	PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunology Research, 2016, 4, 194-203.	1.6	321
1122	Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. Future Oncology, 2016, 12, 413-425.	1.1	115
1123	Pembrolizumab for the treatment of non-small cell lung cancer. Expert Opinion on Biological Therapy, 2016, 16, 397-406.	1.4	56
1124	Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Nonâ€“Small-Cell Lung Cancer. JAMA Oncology, 2016, 2, 46.	3.4	693
1125	New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 57-75.	1.5	46
1126	Checkpoint Blockade for the Treatment of Advanced Melanoma. Cancer Treatment and Research, 2016, 167, 231-250.	0.2	36
1127	Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma. Oncologist, 2016, 21, 84-94.	1.9	20
1128	Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. OncoImmunology, 2016, 5, e1100789.	2.1	45
1129	Tumor vaccines with dsRNA adjuvant ARNAX induces antigen-specific tumor shrinkage without cytokinemia. OncoImmunology, 2016, 5, e1043506.	2.1	12
1130	Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell, 2016, 165, 35-44.	13.5	2,437
1131	Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice. Cancer Immunology, Immunotherapy, 2016, 65, 601-611.	2.0	13
1132	Principles of immunotherapy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 163-181.	1.0	12
1133	Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecologic Oncology, 2016, 141, 86-94.	0.6	26
1134	Immunotherapy for head and neck cancer: latest developments and clinical potential. Therapeutic Advances in Medical Oncology, 2016, 8, 168-175.	1.4	18
1135	New Translational Research in the Medical Management of Orbital Melanoma. Seminars in Ophthalmology, 2016, 31, 53-58.	0.8	4
1136	Immuntherapie des Melanoms: Wirksamkeit und Wirkungsmechanismen. JDDG - Journal of the German Society of Dermatology, 2016, 14, 28-37.	0.4	4
1137	Immunotherapy of melanoma: efficacy and mode of action. JDDG - Journal of the German Society of Dermatology, 2016, 14, 28-36.	0.4	16

#	Article	IF	Citations
1138	Checkpoint inhibitors in <scp>H</scp>odgkin's lymphoma. European Journal of Haematology, 2016, 96, 335-343.	1.1	14
1139	A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage. OncoImmunology, 2016, 5, e1091146.	2.1	66
1140	Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma. Cancer Immunology Research, 2016, 4, 175-178.	1.6	89
1141	Combination Therapies for Melanoma: A New Standard of Care?. American Journal of Clinical Dermatology, 2016, 17, 99-105.	3.3	23
1142	Enhancement of CD3AK cell proliferation and killing ability by Î±-Thujone. International Immunopharmacology, 2016, 30, 57-61.	1.7	13
1143	Noncutaneous Melanomas: A Single-Center Analysis. Dermatology, 2016, 232, 22-29.	0.9	14
1144	Immune checkpoint therapy for non-small-cell lung cancer: an update. Immunotherapy, 2016, 8, 279-298.	1.0	56
1145	Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?. Seminars in Immunology, 2016, 28, 73-80.	2.7	56
1146	Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment. Seminars in Immunology, 2016, 28, 54-63.	2.7	47
1147	Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data. European Journal of Cancer, 2016, 55, 147-157.	1.3	28
1148	Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunology Research, 2016, 4, 345-353.	1.6	214
1149	Angiogenesis in melanoma: an update with a focus on current targeted therapies. Journal of Clinical Pathology, 2016, 69, 472-483.	1.0	55
1150	Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. Targeted Oncology, 2016, 11, 469-477.	1.7	34
1151	Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer. Molecular Diagnosis and Therapy, 2016, 20, 175-181.	1.6	30
1152	A phase I/IIa clinical trial in stage IV melanoma of an autologous tumorâ€“dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2. Cancer Immunology, Immunotherapy, 2016, 65, 383-392.	2.0	28
1153	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nature Medicine, 2016, 22, 433-438.	15.2	721
1154	Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis. OncoImmunology, 2016, 5, e1128611.	2.1	64
1155	Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. Human Vaccines and Immunotherapeutics, 2016, 12, 1092-1101.	1.4	37

#	Article	IF	Citations
1156	Prioritization schema for immunotherapy clinical trials in glioblastoma. OncoImmunology, 2016, 5, e1145332.	2.1	13
1157	Pembrolizumab: A Review in Advanced Melanoma. Drugs, 2016, 76, 375-386.	4.9	39
1158	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. OncoImmunology, 2016, 5, e1136044.	2.1	55
1159	Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. Clinical Cancer Research, 2016, 22, 2261-2270.	3.2	217
1160	Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report. Targeted Oncology, 2016, 11, 557-563.	1.7	16
1161	Breast cancer stem cells phenotype and plasma cell-predominant breast cancer independently indicate poor survival. Pathology Research and Practice, 2016, 212, 294-301.	1.0	20
1162	Rare cancers: a sea of opportunity. Lancet Oncology, The, 2016, 17, e52-e61.	5.1	76
1163	Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma. American Journal of Health-System Pharmacy, 2016, 73, 193-201.	0.5	75
1164	The impact of sequencing on diagnosis and treatment of malignant melanoma. Expert Review of Molecular Diagnostics, 2016, 16, 423-433.	1.5	4
1165	Surgical Management of Melanoma. Cancer Treatment and Research, 2016, 167, 149-179.	0.2	14
1166	Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. OncoImmunology, 2016, 5, e1074374.	2.1	147
1167	Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma. Clinical Cancer Research, 2016, 22, 3849-3859.	3.2	109
1168	PD-1/PD-L1 blockage in cancer treatmentâ€"from basic research to clinical application. International Journal of Clinical Oncology, 2016, 21, 447-447.	1.0	10
1169	High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy. Cancer Immunology, Immunotherapy, 2016, 65, 813-819.	2.0	53
1170	Coinhibitory Pathways in Immunotherapy for Cancer. Annual Review of Immunology, 2016, 34, 539-573.	9.5	718
1171	Immunotherapy of Cancer. , 2016, , .		3
1172	Monoclonal antibodies for treating gastric cancer: promises and pitfalls. Expert Opinion on Biological Therapy, 2016, 16, 759-769.	1.4	6
1173	Cutting Edge: Engineering Active IKKÎ² in T Cells Drives Tumor Rejection. Journal of Immunology, 2016, 196, 2933-2938.	0.4	18

#	Article	IF	Citations
1174	Anti-PD-1 and Anti-PD-L1 mAbs. , 2016, , 283-294.		1
1175	Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Antiâ€“PD-L1 Immune Checkpoint Inhibitor. Cancer Immunology Research, 2016, 4, 452-462.	1.6	76
1176	Targeting Oral Cancer. , 2016, , .		0
1177	Requirement of interleukin 7 signaling for anti-tumor immune response under lymphopenic conditions in a murine lung carcinoma model. Cancer Immunology, Immunotherapy, 2016, 65, 341-354.	2.0	9
1178	Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma. European Urology Focus, 2016, 1, 265-268.	1.6	45
1179	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, The, 2016, 387, 1909-1920.	6.3	3,077
1180	Role for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma. Lancet, The, 2016, 387, 1881-1882.	6.3	8
1181	Genetic and Epigenetic Regulation of PD-1 Expression. Journal of Immunology, 2016, 196, 2431-2437.	0.4	181
1182	Immunotherapy in Head and Neck Cancers. , 2016, , 211-224.		0
1183	Nivolumab-induced organizing pneumonia in a melanoma patient. Japanese Journal of Clinical Oncology, 2016, 46, 270-272.	0.6	45
1184	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. Journal of Clinical Oncology, 2016, 34, 1510-1517.	0.8	627
1185	Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials. Critical Reviews in Oncology/Hematology, 2016, 98, 122-136.	2.0	24
1186	Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine, 2016, 6, 50-58.	2.7	113
1187	Development of immuno-oncology drugs â€" from CTLA4 to PD1 to the next generations. Nature Reviews Drug Discovery, 2016, 15, 235-247.	21.5	503
1188	Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Therapeutic Advances in Respiratory Disease, 2016, 10, 183-193.	1.0	112
1189	PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations. Cancer Biology and Therapy, 2016, 17, 407-413.	1.5	113
1190	Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy. Clinical Cancer Research, 2016, 22, 4023-4029.	3.2	160
1191	Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Antiâ€“PD-1 Therapy. Cancer Immunology Research, 2016, 4, 474-480.	1.6	17

#	Article	IF	Citations
1192	Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application. International Journal of Clinical Oncology, 2016, 21, 456-461.	1.0	29
1193	Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy. Clinical Cancer Research, 2016, 22, 1048-1054.	3.2	226
1194	Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2016, 8, 4-31.	1.4	40
1196	Predictors of tumor-infiltrating lymphocyte efficacy in melanoma. Immunotherapy, 2016, 8, 35-43.	1.0	21
1197	Personalized Preclinical Trials in BRAF Inhibitorâ€“Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clinical Cancer Research, 2016, 22, 1592-1602.	3.2	108
1198	Biomaterials and emerging anticancer therapeutics: engineering the microenvironment. Nature Reviews Cancer, 2016, 16, 56-66.	12.8	341
1199	Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma. Current Oncology Reports, 2016, 18, 6.	1.8	26
1200	Whom to blame for metastasis, the epithelialâ€“mesenchymal transition or the tumor microenvironment?. Cancer Letters, 2016, 380, 359-368.	3.2	54
1201	Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Annals of Oncology, 2016, 27, 559-574.	0.6	749
1202	Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment. Journal of the National Cancer Institute, 2016, 108, djv406.	3.0	61
1203	Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. Current Opinion in Immunology, 2016, 39, 30-38.	2.4	23
1204	The Role of Anti-Drug Antibodies in the Pharmacokinetics, Disposition, Target Engagement, and Efficacy of a GITR Agonist Monoclonal Antibody in Mice. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 574-586.	1.3	15
1205	Cancer immunology and canine malignant melanoma: A comparative review. Veterinary Immunology and Immunopathology, 2016, 169, 15-26.	0.5	62
1206	Current progress in immunotherapy for pancreatic cancer. Cancer Letters, 2016, 381, 244-251.	3.2	149
1207	Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. Nucleic Acids Research, 2016, 44, e30-e30.	6.5	109
1208	The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. Trends in Immunology, 2016, 37, 141-153.	2.9	24
1209	Identification of an Immunogenic Subset of Metastatic Uveal Melanoma. Clinical Cancer Research, 2016, 22, 2237-2249.	3.2	71
1211	Reprogramming away from the exhausted T cell state. Seminars in Immunology, 2016, 28, 35-44.	2.7	25

#	Article	IF	Citations
1212	Mucosal Melanoma: Epidemiology, Biology and Treatment. Cancer Treatment and Research, 2016, 167, 295-320.	0.2	89
1213	Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases. Annals of Surgical Oncology, 2016, 23, 1309-1319.	0.7	117
1214	Metastatic melanoma treatment: Combining old and new therapies. Critical Reviews in Oncology/Hematology, 2016, 98, 242-253.	2.0	64
1215	Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines. Pediatric Research, 2016, 79, 371-377.	1.1	12
1216	PD-1 expression conditions T cell avidity within an antigen-specific repertoire. OncoImmunology, 2016, 5, e1104448.	2.1	47
1217	Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute. Journal of the National Cancer Institute, 2016, 108, .	3.0	7
1218	Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab. Expert Review of Anticancer Therapy, 2016, 16, 5-12.	1.1	13
1219	Treatment of HIV/AIDS associated cancers with immunotherapy targeting PD-1/PD-L1 instead of chemotherapy. Medical Hypotheses, 2016, 86, 129-131.	0.8	2
1220	Combination cancer immunotherapies tailored to the tumour microenvironment. Nature Reviews Clinical Oncology, 2016, 13, 143-158.	12.5	753
1221	Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Annals of Oncology, 2016, 27, 214-224.	0.6	86
1222	Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. European Journal of Cancer, 2016, 52, 1-9.	1.3	115
1223	The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities. Neuro-Oncology, 2016, 18, 153-159.	0.6	86
1224	Cancer Neoantigens and Applications for Immunotherapy. Clinical Cancer Research, 2016, 22, 807-812.	3.2	188
1225	Immune checkpoint inhibitors: a new frontier in bladder cancer. World Journal of Urology, 2016, 34, 49-55.	1.2	15
1226	Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clinical Cancer Research, 2016, 22, 886-894.	3.2	705
1227	Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Annals of Oncology, 2016, 27, 134-140.	0.6	88
1228	Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. JAMA Dermatology, 2016, 152, 45.	2.0	539
1229	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clinical Cancer Research, 2016, 22, 470-478.	3.2	168

#	Article	IF	Citations
1230	Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials. Critical Reviews in Oncology/Hematology, 2016, 97, 65-71.	2.0	30
1231	Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neuro-Oncology, 2016, 18, 368-378.	0.6	31
1232	PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncology, 2016, 18, 195-205.	0.6	463
1233	Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase. Journal of Investigative Dermatology, 2016, 136, 255-263.	0.3	160
1234	A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clinical Cancer Research, 2016, 22, 609-620.	3.2	388
1235	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2016, 26, 1-133.	2.4	10,674
1236	Personalized approaches to active immunotherapy in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 72-82.	3.3	41
1237	Studying cancer metastasis: Existing models, challenges and future perspectives. Critical Reviews in Oncology/Hematology, 2016, 97, 107-117.	2.0	36
1238	Clinical significance of CD70 expression on T cells in human T-lymphotropic virus type-1 carriers and adult T cell leukemia/ lymphoma patients. Leukemia and Lymphoma, 2016, 57, 685-691.	0.6	4
1239	Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary, 2016, 19, 82-92.	1.6	259
1240	CTLA-4 Limits Anti-CD20â€“Mediated Tumor Regression. Clinical Cancer Research, 2017, 23, 193-203.	3.2	35
1241	A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nature Reviews Clinical Oncology, 2017, 14, 115-128.	12.5	95
1242	A case of arthritis under pembrolizumab. Joint Bone Spine, 2017, 84, 243-244.	0.8	14
1243	Designing therapeutic cancer vaccines by mimicking viral infections. Cancer Immunology, Immunotherapy, 2017, 66, 203-213.	2.0	36
1244	Principles of Kinase Inhibitor Therapy for Solid Tumors. Annals of Surgery, 2017, 265, 311-319.	2.1	10
1245	Vitiligo-like lesions occurring in patients receiving anti-programmed cell deathâ€“1 therapies are clinically and biologically distinct from vitiligo. Journal of the American Academy of Dermatology, 2017, 76, 863-870.	0.6	128
1246	Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E970-E979.	3.3	172
1247	Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses InÂVitro. Molecular Therapy - Nucleic Acids, 2017, 6, 221-232.	2.3	12

#	Article	IF	Citations
1248	Pembrolizumabâ€™s non-cross resistance mechanism of action successfully overthrown ipilimumab. Critical Reviews in Oncology/Hematology, 2017, 111, 1-6.	2.0	8
1249	Immunomodulatory Activity of VEGF in Cancer. International Review of Cell and Molecular Biology, 2017, 330, 295-342.	1.6	153
1250	Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncology, The, 2017, 18, 212-220.	5.1	307
1251	Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. European Journal of Cancer, 2017, 73, 1-8.	1.3	397
1252	Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy. Immunotherapy, 2017, 9, 115-121.	1.0	104
1253	The development of dendritic cell vaccine-based immunotherapies for glioblastoma. Seminars in Immunopathology, 2017, 39, 225-239.	2.8	42
1254	Experimental animal modeling for immuno-oncology. , 2017, 173, 34-46.		44
1255	Effect of cryopreservation on delineation of immune cell subpopulations in tumor specimens as determined by multiparametric single cell mass cytometry analysis. BMC Immunology, 2017, 18, 6.	0.9	31
1256	Novel immune check point inhibiting antibodies in cancer therapyâ€"Opportunities and challenges. Drug Resistance Updates, 2017, 30, 39-47.	6.5	98
1257	Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy. Human Antibodies, 2017, 25, 131-146.	0.6	14
1258	Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1â€"Resistant Tumors Leading to Tumor Eradication. Cancer Immunology Research, 2017, 5, 127-136.	1.6	17
1259	Lymph Node Metastasisâˆ—â€”Funded in part by the Nathanson/Rands Chair in Breast Cancer Research. Artwork by Kelly Rosso, MD, and Dhananjay Chitale, MD.. , 2017, , 235-261.		5
1260	Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. Oncogene, 2017, 36, 3334-3345.	2.6	83
1261	Curing tumor-bearing mice by shifting a Th2 to a Th1 anti-tumor response. Human Antibodies, 2017, 25, 147-153.	0.6	4
1262	Radiotherapy and immunotherapy: a beneficial liaison?. Nature Reviews Clinical Oncology, 2017, 14, 365-379.	12.5	760
1263	Increased <scp>PD</scp>â€Ł1 expression in breast and colon cancer stem cells. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 602-604.	0.9	84
1264	Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia, 2017, 31, 2181-2190.	3.3	188
1265	<scp>PD</scp>â€‍1 expression by canine T cells and functional effects of <scp>PD</scp>â€‍1 blockade. Veterinary and Comparative Oncology, 2017, 15, 1487-1502.	0.8	51

#	Article	IF	Citations
1266	Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligandÂ1 expression in bone marrow stromal cells. Molecular Oncology, 2017, 11, 358-372.	2.1	43
1268	Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Review of Anticancer Therapy, 2017, 17, 387-394.	1.1	128
1269	PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research, 2017, 23, 4270-4279.	3.2	117
1270	Potential immunotherapy targets in recurrent cervical cancer. Gynecologic Oncology, 2017, 145, 462-468.	0.6	19
1271	Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy. Clinical Cancer Research, 2017, 23, 3575-3584.	3.2	78
1273	PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunology, Immunotherapy, 2017, 66, 551-564.	2.0	253
1274	Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge. Revue De Medecine Interne, 2017, 38, 513-525.	0.6	36
1275	Standard of care in immunotherapy trials: Challenges and considerations. Human Vaccines and Immunotherapeutics, 2017, 13, 2164-2178.	1.4	4
1276	Characterization of the Antiâ€“PD-1 Antibody REGN2810 and Its Antitumor Activity in HumanPD-1Knock-In Mice. Molecular Cancer Therapeutics, 2017, 16, 861-870.	1.9	92
1277	T cell costimulatory receptor CD28 is a primary target for PD-1â€“mediated inhibition. Science, 2017, 355, 1428-1433.	6.0	1,229
1278	Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases. Expert Review of Anticancer Therapy, 2017, 17, 347-356.	1.1	18
1279	Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). Cancer Chemotherapy and Pharmacology, 2017, 79, 651-660.	1.1	76
1280	The Balance between CD8+ T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose. Molecular Therapy, 2017, 25, 880-891.	3.7	50
1281	Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncology, The, 2017, 18, 623-630.	5.1	425
1282	Exhaustion-associated regulatory regions in CD8 ⁺ tumor-infiltrating T cells. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2776-E2785.	3.3	242
1283	Combination immunotherapy: a road map. , 2017, 5, 16.		325
1284	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Science Translational Medicine, 2017, 9, .	5.8	689
1285	Reactivation of dormant anti-tumor immunity â€“ a clinical perspective of therapeutic immune checkpoint modulation. Cell Communication and Signaling, 2017, 15, 5.	2.7	34

#	Article	IF	Citations
1286	LAG-3 Protein Expression in Nonâ€“Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. Journal of Thoracic Oncology, 2017, 12, 814-823.	0.5	192
1287	Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials. Oncology, 2017, 92, 50-62.	0.9	180
1288	Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients. Annals of Surgical Oncology, 2017, 24, 947-951.	0.7	26
1289	A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. Cancer Treatment Reviews, 2017, 54, 58-67.	3.4	324
1290	Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. Molecular Imaging and Biology, 2017, 19, 903-914.	1.3	91
1291	Timâ€3 and its role in regulating antiâ€tumor immunity. Immunological Reviews, 2017, 276, 97-111.	2.8	599
1292	<scp>TAM</scp> receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunological Reviews, 2017, 276, 165-177.	2.8	125
1293	The CD47â€SIRPÎ± signaling axis as an innate immune checkpoint in cancer. Immunological Reviews, 2017, 276, 145-164.	2.8	410
1294	The proportion of circulating CD45RO + CD8 + memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab. European Journal of Cancer, 2017, 75, 268-279.	1.3	62
1295	The expanding role of immunotherapy. Cancer Treatment Reviews, 2017, 54, 74-86.	3.4	100
1296	Cancer Clinical Trials: The Rear-View Mirror and the Crystal Ball. Cell, 2017, 168, 575-578.	13.5	13
1297	Interferon-Î±-inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity. Scientific Reports, 2017, 7, 42145.	1.6	12
1298	Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy. Journal of Hematology and Oncology, 2017, 10, 81.	6.9	114
1299	Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. EBioMedicine, 2017, 18, 56-61.	2.7	83
1300	Clinical Features of Acquired Resistance to Antiâ€“PD-1 Therapy in Advanced Melanoma. Cancer Immunology Research, 2017, 5, 357-362.	1.6	40
1301	Targeting the immune system in glioblastoma. Expert Review of Precision Medicine and Drug Development, 2017, 2, 121-131.	0.4	0
1302	A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis. Journal of Immunotherapy, 2017, 40, 108-113.	1.2	10
1304	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood, 2017, 129, 3419-3427.	0.6	335

#	Article	IF	Citations
1305	Childhood Acute Lymphoblastic Leukemia. , 2017, , .		2
1306	Indicators of responsiveness to immune checkpoint inhibitors. Scientific Reports, 2017, 7, 807.	1.6	70
1307	Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Deathâ€“1 (antiâ€“PD-1) Therapy With or Without Ipilimumab. American Journal of Dermatopathology, 2017, 39, 23-27.	0.3	28
1308	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunology Research, 2017, 5, 417-424.	1.6	400
1309	Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. Annals of Oncology, 2017, 28, 1388-1398.	0.6	70
1310	Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies. American Journal of Surgical Pathology, 2017, 41, 643-654.	2.1	146
1311	TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas. Tumor Biology, 2017, 39, 101042831769835.	0.8	13
1312	The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). International Journal of Cancer, 2017, 141, 594-603.	2.3	91
1313	The swinging pendulum of cancer immunotherapy personalization. Personalized Medicine, 2017, 14, 259-270.	0.8	3
1314	Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-Î³-induced immunologic dormancy of tumor-repopulating cells. Nature Communications, 2017, 8, 15207.	5.8	147
1315	Patterns of PDâ€1, PDâ€L1, and PDâ€L2 expression in pediatric solid tumors. Pediatric Blood and Cancer, 2017, 64, e26613.	0.8	43
1316	Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies. Cancer Immunology, Immunotherapy, 2017, 66, 1113-1121.	2.0	29
1317	The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 221-230.	3.3	23
1318	Immunobiology and Immune Based Therapies of Melanoma. , 2017, , 871-890.		0
1319	Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy. Advanced Drug Delivery Reviews, 2017, 114, 33-42.	6.6	81
1320	Signaling by Antibodies: Recent Progress. Annual Review of Immunology, 2017, 35, 285-311.	9.5	167
1321	The use of immunotherapy in the treatment of melanoma. Journal of Hematology and Oncology, 2017, 10, 88.	6.9	89
1322	The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series. Cancer Immunology, Immunotherapy, 2017, 66, 1153-1162.	2.0	34

#	Article	IF	Citations
1323	MITF suppression by CH5552074 inhibits cell growth in melanoma cells. Cancer Chemotherapy and Pharmacology, 2017, 79, 1187-1193.	1.1	10
1324	The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma. Medicine (United States), 2017, 96, e6398.	0.4	43
1325	Murinization and H Chain Isotype Matching of the Anti-GITR Antibody DTA-1 Reduces Immunogenicity-Mediated Anaphylaxis in C57BL/6 Mice. Journal of Immunology, 2017, 198, 4502-4512.	0.4	3
1326	Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discovery, 2017, 7, 832-851.	7.7	49
1327	The next generation of immunotherapy: keeping lung cancer in check. Journal of Hematology and Oncology, 2017, 10, 87.	6.9	84
1328	Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 29-39.	1.3	66
1329	Evasion of host immune defenses by human papillomavirus. Virus Research, 2017, 231, 21-33.	1.1	142
1330	PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clinical Cancer Research, 2017, 23, 3158-3167.	3.2	426
1331	Transcriptional and epigenetic regulation of T cell hyporesponsiveness. Journal of Leukocyte Biology, 2017, 102, 601-615.	1.5	39
1332	Sequencing Treatment in BRAF V600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. Journal of Immunotherapy, 2017, 40, 31-35.	1.2	85
1333	Combinatorial immunotherapy and nanoparticle mediated hyperthermia. Advanced Drug Delivery Reviews, 2017, 114, 175-183.	6.6	91
1334	PD-L1 Expression in Pancreatic Cancer. Journal of the National Cancer Institute, 2017, 109, djw304.	3.0	43
1335	Antibody blood-brain barrier efflux is modulated by glycan modification. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 2228-2239.	1.1	17
1336	Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: AÂRENAPE study. European Journal of Surgical Oncology, 2017, 43, 1915-1923.	0.5	23
1337	CD8 T Cells. , 2017, , 131-142.		0
1338	PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature, 2017, 545, 495-499.	13.7	1,489
1339	Imaging Studies in Immunotherapy. , 2017, , 149-179.		1
1340	Therapeutic Vaccine of Gastric Cancer. , 2017, , 131-147.		0

#	Article	IF	Citations
1342	DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discovery, 2017, 7, 675-693.	7.7	519
1343	Antibodies Against Immune Checkpoint Molecules RestoreÂFunctions of Tumor-Infiltrating T Cells in HepatocellularÂCarcinomas. Gastroenterology, 2017, 153, 1107-1119.e10.	0.6	309
1344	Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. Cancer Treatment Reviews, 2017, 58, 22-33.	3.4	76
1345	Dacarbazine-Loaded Hollow Mesoporous Silica Nanoparticles Grafted with Folic Acid for Enhancing Antimetastatic Melanoma Response. ACS Applied Materials & Interfaces, 2017, 9, 21673-21687.	4.0	53
1346	Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. OncoImmunology, 2017, 6, e1312240.	2.1	68
1347	Ubiquitination in melanoma pathogenesis and treatment. Cancer Medicine, 2017, 6, 1362-1377.	1.3	24
1348	Interaction of molecular alterations with immune response in melanoma. Cancer, 2017, 123, 2130-2142.	2.0	24
1349	Association Between Anesthesiology Volumes and Early and Late Outcomes After Cystectomy for Bladder Cancer: A Population-Based Study. Anesthesia and Analgesia, 2017, 125, 147-155.	1.1	15
1350	Checkpoint Blockade Immunotherapy for Glioblastoma. , 2017, , 261-300.		2
1351	A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy. Cell Reports, 2017, 19, 1874-1887.	2.9	104
1352	Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Annals of Oncology, 2017, 28, 1988-1995.	0.6	326
1353	Pembrolizumab in cervical cancer: latest evidence and clinical usefulness. Therapeutic Advances in Medical Oncology, 2017, 9, 431-439.	1.4	73
1354	New insights into the role of <scp>EMT</scp> in tumor immune escape. Molecular Oncology, 2017, 11, 824-846.	2.1	332
1355	Advancing Immune and Cell-Based Therapies Through Imaging. Molecular Imaging and Biology, 2017, 19, 379-384.	1.3	20
1356	Drug-biomarker co-development in oncology â€“ 20 years and counting. Drug Resistance Updates, 2017, 30, 48-62.	6.5	48
1357	Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nature Reviews Clinical Oncology, 2017, 14, 463-482.	12.5	945
1358	Promising immunotherapies for esophageal cancer. Expert Opinion on Biological Therapy, 2017, 17, 723-733.	1.4	25
1359	Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro-Oncology, 2017, 19, 1047-1057.	0.6	325

#	Article	IF	Citations
1360	Immunomodulation for glioblastoma. Current Opinion in Neurology, 2017, 30, 361-369.	1.8	21
1361	Association of Surgical Treatment, Systemic Therapy, and Survival in Patients With Abdominal Visceral Melanoma Metastases, 1965-2014. JAMA Surgery, 2017, 152, 672.	2.2	57
1362	Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome. Annals of Diagnostic Pathology, 2017, 28, 54-59.	0.6	21
1363	Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma â€" A case report. Respiratory Medicine Case Reports, 2017, 20, 95-97.	0.2	11
1364	Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. International Immunopharmacology, 2017, 46, 210-219.	1.7	102
1365	Assessment of penetration potential of pH responsive double walled biodegradable nanogels coated with eucalyptus oil for the controlled delivery of 5-fluorouracil: In vitro and ex vivo studies. Journal of Controlled Release, 2017, 253, 122-136.	4.8	82
1366	Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Pharmacological Research, 2017, 120, 1-9.	3.1	46
1367	Pembrolizumab use for the treatment of advanced melanoma. Expert Opinion on Biological Therapy, 2017, 17, 765-780.	1.4	10
1368	Nivolumab for adult individuals with Hodgkin lymphoma (an exemplar rapid review using) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 422 Td (	1.5	3
1369	Immunotherapy in malignant melanoma: recent approaches and new perspectives. Melanoma Management, 2017, 4, 39-48.	0.1	7
1370	Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. British Journal of Cancer, 2017, 116, 1141-1147.	2.9	112
1371	Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development. Clinical Cancer Research, 2017, 23, 1638-1646.	3.2	136
1372	Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncology, The, 2017, 18, 792-802.	5.1	203
1373	Obstacles Posed by the Tumor Microenvironment to TÂcell Activity: A Case for Synergistic Therapies. Cancer Cell, 2017, 31, 311-325.	7.7	502
1375	Biomarkers and Immunotherapeutic Targets in Glioblastoma. World Neurosurgery, 2017, 102, 494-506.	0.7	29
1376	Immune Checkpoint Inhibitors in Gliomas. Current Oncology Reports, 2017, 19, 23.	1.8	27
1377	Novel agents in classical Hodgkin lymphoma. Leukemia and Lymphoma, 2017, 58, 2275-2286.	0.6	14
1378	Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Investigational New Drugs, 2017, 35, 529-536.	1.2	128

#	Article	IF	Citations
1380	Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Annals of Oncology, 2017, 28, 583-589.	0.6	510
1381	Immuno-Oncology: The Third Paradigm in Early Drug Development. Targeted Oncology, 2017, 12, 125-138.	1.7	22
1382	Driving gene-engineered T cell immunotherapy of cancer. Cell Research, 2017, 27, 38-58.	5.7	232
1383	Systemic therapy of brain metastases: nonâ€“small cell lung cancer, breast cancer, and melanoma. Neuro-Oncology, 2017, 19, i1-i24.	0.6	171
1384	PD-1 blockade modulates chimeric antigen receptor (CAR)â€“modified T cells: refueling the CAR. Blood, 2017, 129, 1039-1041.	0.6	393
1385	Molecular Pathways: The Necrosomeâ€”A Target for Cancer Therapy. Clinical Cancer Research, 2017, 23, 1132-1136.	3.2	35
1386	Ex Vivo Engineering of the Tumor Microenvironment. Cancer Drug Discovery and Development, 2017, , .	0.2	4
1387	Microfluidics and Future of Cancer Diagnostics. Cancer Drug Discovery and Development, 2017, , 55-70.	0.2	1
1388	Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. Clinical Oncology, 2017, 29, 218-230.	0.6	49
1389	Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM SM. Clinical Genitourinary Cancer, 2017, 15, 31-41.e4.	0.9	31
1390	Signaling and Immune Regulation in Melanoma Development and Responses to Therapy. Annual Review of Pathology: Mechanisms of Disease, 2017, 12, 75-102.	9.6	30
1391	Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma. Cancer Immunology Research, 2017, 5, 118-126.	1.6	56
1392	Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update. Liver Cancer, 2017, 6, 1-12.	4.2	60
1393	Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. OncoImmunology, 2017, 6, e1264565.	2.1	102
1394	Localized Multiâ€Component Delivery Platform Generates Local and Systemic Antiâ€Tumor Immunity. Advanced Functional Materials, 2017, 27, 1604366.	7.8	40
1395	Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. Cancer Immunology Research, 2017, 5, 17-28.	1.6	130
1396	<scp>PD</scp> â€L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Molecular Medicine, 2017, 9, 167-180.	3.3	172
1397	Humanized Mouse Models of Clinical Disease. Annual Review of Pathology: Mechanisms of Disease, 2017, 12, 187-215.	9.6	437

#	Article	IF	Citations
1398	Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma. Scientific Reports, 2017, 7, 14049.	1.6	37
1399	Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. Cancer Immunology Research, 2017, 5, 1133-1140.	1.6	114
1400	A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry. Future Science OA, 2017, 3, FSO244.	0.9	24
1401	Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncology, The, 2017, 18, 1493-1501.	5.1	921
1402	Nonconventional patterns of benefit of solid tumors treated with PD-(L)1 inhibitors: a systematic review. Immunotherapy, 2017, 9, 995-1004.	1.0	14
1403	001 INCOME-ASSOCIATED DISCREPANCIES IN MELANOMA SURVIVAL. Journal of Investigative Dermatology Symposium Proceedings, 2017, 18, S85.	0.8	0
1404	Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimineâ€“Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth. ACS Nano, 2017, 11, 10135-10146.	7.3	84
1405	Gene editing in T cell therapy. Journal of Genetics and Genomics, 2017, 44, 415-422.	1.7	15
1406	Recent advances in malignant melanoma. Internal Medicine Journal, 2017, 47, 1114-1121.	0.5	40
1407	Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender. Current Hematologic Malignancy Reports, 2017, 12, 424-431.	1.2	11
1408	Cutting the Brakes: Immunotherapy With PD-1 Inhibitors. Clinical Skin Cancer, 2017, 2, 24-31.	0.1	2
1409	Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. Critical Reviews in Oncology/Hematology, 2017, 119, 1-12.	2.0	141
1410	Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases. Annals of Surgical Oncology, 2017, 24, 3991-4000.	0.7	102
1411	PDâ€Ł1 expression in nonâ€ssmall cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. Cancer Cytopathology, 2017, 125, 896-907.	1.4	164
1412	Endocrine side effects of cancer immunotherapy. Endocrine-Related Cancer, 2017, 24, T331-T347.	1.6	131
1413	Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms. Cellular Immunology, 2017, 322, 1-14.	1.4	114
1414	Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences. Immunological Reviews, 2017, 280, 249-279.	2.8	155
1415	Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. Journal of Immunotherapy, 2017, 40, 334-340.	1.2	16

#	Article	IF	Citations
1416	Kaposiâ€™s Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes. MBio, 2017, 8, .	1.8	57
1417	High frequency of brain metastases after adjuvant therapy for highâ€risk melanoma. Cancer Medicine, 2017, 6, 2576-2585.	1.3	27
1418	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nature Communications, 2017, 8, 1050.	5.8	115
1419	Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. Scientific Reports, 2017, 7, 13380.	1.6	208
1420	Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells. American Journal of Clinical Pathology, 2017, 148, 441-449.	0.4	19
1422	Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value. Scientific Reports, 2017, 7, 11671.	1.6	57
1423	T Cells Deficient in Diacylglycerol Kinase Î¶ Are Resistant to PD-1 Inhibition and Help Create Persistent Host Immunity to Leukemia. Cancer Research, 2017, 77, 5676-5686.	0.4	17
1424	Novel Immunologic Approaches to Melanoma Treatment. Actas Dermo-sifiliogrÃ¡ficas, 2017, 108, 708-720.	0.2	0
1425	CD155T/TIGIT Signaling Regulates CD8+ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer. Cancer Research, 2017, 77, 6375-6388.	0.4	218
1426	Enhancing CD8+ T Cell Fatty Acid Catabolism withinÂa Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell, 2017, 32, 377-391.e9.	7.7	419
1427	Immunotherapy in managing metastatic melanoma: which treatment when?. Expert Opinion on Biological Therapy, 2017, 17, 1523-1538.	1.4	13
1428	Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional OncologyÂProcedures. Journal of Vascular and Interventional Radiology, 2017, 28, 1487-1494.	0.2	33
1429	From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. Clinical Cancer Research, 2017, 23, 4980-4991.	3.2	14
1430	Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities. Clinical Cancer Research, 2017, 23, 4992-5002.	3.2	41
1431	Immunobiology of the IL-15/IL-15RÎ± complex as an antitumor and antiviral agent. Cytokine and Growth Factor Reviews, 2017, 38, 10-21.	3.2	108
1432	Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics. Nanomedicine, 2017, 12, 2349-2365.	1.7	57
1433	Pembrolizumabâ€induced hepatitis: diagnosis and treatment. JDDG - Journal of the German Society of Dermatology, 2017, 15, 933-935.	0.4	4
1434	Immune Checkpoint Inhibitors in Organ Transplant Patients. Journal of Immunotherapy, 2017, 40, 277-281.	1.2	120

#	Article	IF	Citations
1435	PD-L1 Expression in Premalignant and Malignant Trophoblasts From Gestational Trophoblastic Diseases Is Ubiquitous and Independent of Clinical Outcomes. International Journal of Gynecological Cancer, 2017, 27, 554-561.	1.2	66
1436	Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone. Clinical Orthopaedics and Related Research, 2017, 475, 3071-3081.	0.7	14
1437	Programmed cell deathâ€1 (PDâ€1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cellâ€“intrinsic PDâ€1. Hepatology, 2017, 66, 1920-1933.	3.6	142
1438	Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review. Cancer Treatment Reviews, 2017, 59, 71-78.	3.4	88
1439	A firstâ€inâ€human phase I, multicenter, openâ€label, doseâ€escalation study of the oral RAF/VEGFRâ€2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from <scp>BRAF</scp> mutation status. Cancer Medicine, 2017, 6, 1904-1914.	1.3	24
1440	Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. Cancer Chemotherapy and Pharmacology, 2017, 80, 591-598.	1.1	47
1441	Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab. Journal of Dermatological Science, 2017, 88, 225-231.	1.0	67
1442	Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Laboratory Investigation, 2017, 97, 1063-1071.	1.7	156
1443	Novedades en inmunologÃa del melanoma. Actas Dermo-sifiliogrÃ¡ficas, 2017, 108, 708-720.	0.2	6
1444	Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncology, The, 2017, 18, 1202-1210.	5.1	211
1445	Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 834-851.	0.2	47
1446	ChimiothÃ©rapies personnalisÃ©es du cancer bronchiqueÂ: ce que le radiologue doit connaÃ®tre. Diagnostic and Interventional Imaging, 2017, 98, 146-156.	0.0	0
1448	A review of serious adverse effects under treatment with checkpoint inhibitors. Current Opinion in Oncology, 2017, 29, 136-144.	1.1	56
1449	PDâ€1 inhibitorâ€associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculationâ€”Report of 4 cases. Journal of Cutaneous Pathology, 2017, 44, 851-856.	0.7	21
1450	Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Scientific Reports, 2017, 7, 5532.	1.6	166
1451	Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells. Cell Reports, 2017, 20, 1017-1028.	2.9	156
1452	Critical role of gliomaâ€associated oncogene homolog 1 in maintaining invasive and mesenchymalâ€like properties of melanoma cells. Cancer Science, 2017, 108, 1602-1611.	1.7	16
1454	Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era. Cancer Journal (Sudbury, Mass), 2017, 23, 63-67.	1.0	8

#	Article	IF	Citations
1455	Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapyâ€"Summary of Advances and Future Directions for Studying These Drugs. Cancer Journal (Sudbury, Mass), 2017, 23, 3-9.	1.0	5
1456	Immunotherapy in Nonâ€"Small Cell Lung Cancer Treatment. Journal of Thoracic Imaging, 2017, 32, 300-312.	0.8	47
1457	Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2310-2325.	3.3	46
1458	Immunotherapy of cancers comes of age. Expert Review of Clinical Immunology, 2017, 13, 1001-1015.	1.3	84
1459	Immunotherapy for Uveal Melanoma. International Ophthalmology Clinics, 2017, 57, 29-39.	0.3	10
1460	Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Annals of Oncology, 2017, 28, 2377-2385.	0.6	631
1461	Advances in the Management of Melanoma. Current Dermatology Reports, 2017, 6, 288-296.	1.1	1
1462	Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data. Clinical Trials, 2017, 14, 611-620.	0.7	7
1463	Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy. Cell, 2017, 171, 1678-1691.e13.	13.5	467
1465	Dacarbazine nanoparticle topical delivery system for the treatment of melanoma. Scientific Reports, 2017, 7, 16517.	1.6	51
1466	Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells. Scientific Reports, 2017, 7, 16345.	1.6	16
1467	Surgical resection of metastatic melanoma in the era of immunotherapy and targeted therapy. Melanoma Management, 2017, 4, 61-68.	0.1	20
1468	Novel Early Phase Clinical Trial Design in Oncology. Pharmaceutical Medicine, 2017, 31, 297-307.	1.0	3
1469	Pembrolizumab in the treatment of advanced urothelial cancer. Future Oncology, 2017, 13, 2745-2758.	1.1	4
1470	Cardiotoxicity of immune checkpoint inhibitors. ESMO Open, 2017, 2, e000247.	2.0	186
1471	Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events. Case Reports in Oncology, 2017, 10, 296-300.	0.3	10
1472	Targeting Immune Checkpoint. , 2017, , 781-785.		1
1473	Clinics, prognosis and new therapeutic options in patients with mucosal melanoma. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Ov	0.4	50

#	Article	IF	Citations
1474	Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nature Nanotechnology, 2017, 12, 877-882.	15.6	541
1475	Posttranscriptional Control of PD-L1 Expression by 17Î²-Estradiol via PI3K/Akt Signaling Pathway in ERÎ±-Positive Cancer Cell Lines. International Journal of Gynecological Cancer, 2017, 27, 196-205.	1.2	68
1477	Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell â€œmissing selfâ€• recognition. Immunogenetics, 2017, 69, 547-556.	1.2	30
1478	The new paradigm of systemic therapies for metastatic melanoma. Journal of the American Academy of Dermatology, 2017, 77, 356-368.	0.6	34
1479	Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyteâ€“Associated Protein Blockade. Clinical Cancer Research, 2017, 23, 6190-6202.	3.2	82
1480	Programmed Death Ligand 1 Expression in Paired Nonâ€“Small Cell Lung Cancer Tumor Samples. Clinical Lung Cancer, 2017, 18, e473-e479.	1.1	35
1481	pH responsive biodegradable nanogels for sustained release of bleomycin. Bioorganic and Medicinal Chemistry, 2017, 25, 4595-4613.	1.4	59
1482	Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nature Reviews Clinical Oncology, 2017, 14, 655-668.	12.5	787
1483	Proteasome beta-4 subunit contributes to the development of melanoma and is regulated by miR-148b. Tumor Biology, 2017, 39, 101042831770576.	0.8	8
1484	The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting. , 2017, 5, .		11
1485	Genomic profiling of colorectal cancers and the future of personalized treatment. Colorectal Cancer, 2017, 6, 11-22.	0.8	1
1486	Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma. Medicine (United States), 2017, 96, e7325.	0.4	80
1487	A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer. Annals of Oncology, 2017, 28, 298-304.	0.6	37
1488	The safety of anti PD-1 therapeutics for the treatment of melanoma. Expert Opinion on Drug Safety, 2017, 16, 41-53.	1.0	17
1489	Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 11-20.	1.3	88
1490	Using Model-Based â€œLearn and Confirmâ€•to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 21-28.	1.3	85
1491	Immunotherapy for Lung Malignancies. Chest, 2017, 151, 891-897.	0.4	17
1492	Treatment of brain metastases in the modern genomic era. , 2017, 170, 64-72.		40

#	Article	IF	Citations
1493	Immunotherapy in melanoma: Recent advances and future directions. European Journal of Surgical Oncology, 2017, 43, 604-611.	0.5	216
1494	Leveraging the immune system to treat advanced thyroid cancers. Lancet Diabetes and Endocrinology,the, 2017, 5, 469-481.	5.5	58
1495	<scp>PD</scp>â€1 inhibitor gastroenterocolitis: case series and appraisal of â€˜immunomodulatory gastroenterocolitisâ€™. Histopathology, 2017, 70, 558-567.	1.6	198
1496	TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy. Immunological Investigations, 2017, 46, 172-182.	1.0	40
1497	Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 132-140.	1.1	18
1498	Immunotherapy of melanoma. European Journal of Surgical Oncology, 2017, 43, 594-603.	0.5	21
1499	Targeting <scp>CTLA</scp>â€4, <scp>PD</scp>â€L1 and <scp>IDO</scp> to modulate immune responses in vitiligo. Experimental Dermatology, 2017, 26, 630-634.	1.4	20
1500	PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2017, 23, 454-465.	3.2	126
1501	OMIPâ€037: 16â€color panel to measure inhibitory receptor signatures from multiple human immune cell subsets. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2017, 91, 175-179.	1.1	21
1502	Global chemotherapy development for gastric cancer. Gastric Cancer, 2017, 20, 92-101.	2.7	38
1503	Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 5-7.	1.3	23
1504	Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nature Reviews Urology, 2017, 14, 15-25.	1.9	210
1505	Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell Research, 2017, 27, 147-150.	5.7	111
1506	Prognostic impact of the putative cancer stem cell markers ABCG 2, CD 133, ALDH 1A1 and CD 44V7/8 in metastatic melanoma. British Journal of Dermatology, 2017, 177, 1447-1449.	1.4	5
1507	Deep Data Stream Analysis Model and Algorithm With Memory Mechanism. IEEE Access, 2017, 5, 84-93.	2.6	4
1508	Does sunlight protect us from cancer?. Photochemical and Photobiological Sciences, 2017, 16, 416-425.	1.6	4
1509	Leveraging Physiology for Precision Drug Delivery. Physiological Reviews, 2017, 97, 189-225.	13.1	125
1510	A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. CNS Oncology, 2017, 6, 29-43.	1.2	34

#	Article	IF	Citations
1511	Are we entering the era of combination therapy for melanoma?. Melanoma Management, 2017, 4, 5-8.	0.1	0
1512	Tâ€'cell immunoglobulin and mucin domainâ€'containing proteinâ€'3 and galectinâ€'9 protein expression: Potential prognostic significance in esophageal squamous cell carcinoma for Chinese patients. Oncology Letters, 2017, 14, 8007-8013.	0.8	11
1513	Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.4	2
1514	Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update. Oncology, 2017, 93, 147-159.	0.9	83
1515	Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery. Current Pharmaceutical Design, 2017, 23, 4716-4725.	0.9	11
1516	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. European Journal of Cancer, 2017, 86, 37-45.	1.3	183
1518	Why cure, why now?. Journal of Medical Ethics, 2017, 43, 67-70.	1.0	17
1519	Transcriptional response profiles of paired tumor-normal samples offer novel perspectives in pan-cancer analysis. Oncotarget, 2017, 8, 41334-41347.	0.8	22
1521	Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Frontiers in Pharmacology, 2017, 8, 49.	1.6	459
1522	Immune Checkpoint in Glioblastoma: Promising and Challenging. Frontiers in Pharmacology, 2017, 8, 242.	1.6	133
1523	Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. Journal of Cancer, 2017, 8, 410-416.	1.2	176
1524	Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis. Therapeutics and Clinical Risk Management, 2017, Volume 13, 1259-1271.	0.9	16
1525	Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know. Korean Journal of Radiology, 2017, 18, 42.	1.5	33
1526	Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?. Current Cancer Drug Targets, 2017, 18, 5-15.	0.8	4
1527	Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. Lung Cancer: Targets and Therapy, 2017, Volume 8, 1-11.	1.3	6
1528	Cancer immunology and melanoma immunotherapy. Anais Brasileiros De Dermatologia, 2017, 92, 830-835.	0.5	8
1529	Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy. Drug Design, Development and Therapy, 2017, Volume 11, 2537-2549.	2.0	6
1530	Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. ImmunoTargets and Therapy, 2017, Volume 6, 73-82.	2.7	121

#	Article	IF	Citations
1531	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. World Journal of Gastroenterology, 2017, 23, 4675.	1.4	91
1532	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. Frontiers in Immunology, 2017, 8, 1597.	2.2	225
1533	An Efficient Electroporation Protocol for the Genetic Modification of Mammalian Cells. Frontiers in Bioengineering and Biotechnology, 2016, 4, 99.	2.0	45
1534	PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells. BioMed Research International, 2017, 2017, 1-8.	0.9	13
1535	Epigenetic Strategies to Boost Cancer Immunotherapies. International Journal of Molecular Sciences, 2017, 18, 1108.	1.8	29
1536	Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models. Frontiers in Immunology, 2017, 8, 829.	2.2	159
1537	Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma. Frontiers in Immunology, 2017, 8, 1617.	2.2	43
1538	Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy. Frontiers in Immunology, 2017, 8, 1897.	2.2	55
1539	Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. Frontiers in Oncology, 2017, 7, 67.	1.3	28
1540	Targeting Cancer Stem Cells and Their Niche: Current Therapeutic Implications and Challenges in Pancreatic Cancer. Stem Cells International, 2017, 2017, 1-9.	1.2	11
1541	CD80 Expressed by CD8⁺ T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8⁺ T Cells. Journal of Immunology Research, 2017, 2017, 1-6.	0.9	33
1542	Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-Î± in Chinese Resected Stage III Malignant Melanoma. Journal of Immunology Research, 2017, 2017, 1-8.	0.9	10
1543	PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma. Oncotarget, 2017, 8, 52889-52900.	0.8	82
1544	High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients. International Journal of Biological Sciences, 2017, 13, 1172-1179.	2.6	45
1545	Acute Hyperglycemia Associated with Anti-Cancer Medication. Endocrinology and Metabolism, 2017, 32, 23.	1.3	48
1546	Therapeutic and Prognostic Applications. , 0, , 287-295.		0
1547	Therapy of Melanoma. , 2017, , 91-142.		0
1548	Challenging the standard of care in advanced melanoma: focus on pembrolizumab. Cancer Management and Research, 2017, Volume 9, 433-442.	0.9	15

#	Article	IF	Citations
1549	4-Thiazolidinone derivative Les-3833 effectively inhibits viability of human melanoma cells through activating apoptotic mechanisms. Croatian Medical Journal, 2017, 58, 129-139.	0.2	13
1550	Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Management and Research, 2017, Volume 9, 207-213.	0.9	128
1551	Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model. International Journal of Nanomedicine, 2017, Volume 12, 8337-8351.	3.3	19
1552	Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. OncoTargets and Therapy, 2017, Volume 10, 3697-3708.	1.0	6
1553	Targeted therapy for soft tissue sarcomas in adolescents and young adults. Adolescent Health, Medicine and Therapeutics, 2017, Volume 8, 41-55.	0.7	11
1554	Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model. PLoS ONE, 2017, 12, e0178479.	1.1	112
1555	Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme. PLoS ONE, 2017, 12, e0181538.	1.1	34
1556	Radiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcoma. PLoS ONE, 2017, 12, e0189697.	1.1	40
1557	Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. OncoImmunology, 2017, 6, e1344805.	2.1	142
1558	Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy. Neurologia Medico-Chirurgica, 2017, 57, 321-330.	1.0	16
1559	Sustained Oligoclonal T Cell Expansion Correlates with Durable Response to Immune Checkpoint Blockade in Lung Cancer. Journal of Cancer Science & Therapy, 2017, 9, .	1.7	5
1560	Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma. Oncotarget, 2017, 8, 96649-96655.	0.8	22
1561	IFN-Î³â€“related mRNA profile predicts clinical response to PD-1 blockade. Journal of Clinical Investigation, 2017, 127, 2930-2940.	3.9	2,560
1562	Zwei FÃlle einer wiederholten Anwendung von Nivolumab nach einer Pneumonitis als immunvermittelte Nebenwirkung. Karger Kompass Pneumologie, 2017, 5, 185-188.	0.0	0
1563	Cancer Immunotherapy. , 2017, , 32-65.		1
1564	Immune Checkpoint Blockade and Adaptive Immune Resistance in Cancer. , 0, , .		3
1565	Molecular Prognostic Factors in Gastric Cancer. , 2017, , .		0
1566	The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy. Molecular and Clinical Oncology, 2017, 7, 1112-1118.	0.4	6

#	Article	IF	Citations
1567	Immune checkpoints, their control by immunotherapy and ovarian cancer. Wspolczesna Onkologia, 2017, 3, 189-196.	0.7	2
1568	PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. Medical Science Monitor, 2017, 23, 1208-1216.	0.5	49
1569	Evidence from a meta-analysis: is nivolumab neurotoxic in cancer patients?. OncoTargets and Therapy, 2017, Volume 10, 1335-1344.	1.0	3
1570	Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. Oncotarget, 2017, 8, 110693-110707.	0.8	115
1571	Management of intracranial melanomas in the era of precision medicine. Oncotarget, 2017, 8, 89326-89347.	0.8	16
1572	Combined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas. Medical Science Monitor, 2017, 23, 3593-3602.	0.5	20
1573	PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget, 2017, 8, 2171-2186.	0.8	234
1574	The soy-derived peptide Lunasin inhibits invasive potential of melanoma initiating cells. Oncotarget, 2017, 8, 25525-25541.	0.8	28
1575	Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget, 2017, 8, 91779-91794.	0.8	298
1576	Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. Oncotarget, 2017, 8, 41932-41946.	0.8	95
1577	Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class Iiâ€“Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. Journal of Clinical Oncology, 2017, 35, 3322-3329.	0.8	204
1578	PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget, 2017, 8, 24644-24651.	0.8	146
1579	Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. Journal of Clinical Oncology, 2017, 35, 3823-3829.	0.8	413
1580	Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. Journal of Clinical Oncology, 2017, 35, 1542-1549.	0.8	527
1581	Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. Oncotarget, 2017, 8, 75675-75686.	0.8	42
1582	Durable complete response to nivolumab in a patient with HIV and metastatic non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, E540-E542.	0.6	28
1583	Genetic and immune features of resectable malignant brainstem gliomas. Oncotarget, 2017, 8, 82571-82582.	0.8	12
1584	Targeting Melanoma with Cancer-Killing Viruses. The Open Virology Journal, 2017, 11, 28-47.	1.8	8

#	Article	IF	Citations
1585	Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer. Translational Research, 2018, 196, 62-70.	2.2	9
1586	Vaccination-induced skin-resident memory CD8⁺T cells mediate strong protection against cutaneous melanoma. OncoImmunology, 2018, 7, e1442163.	2.1	62
1587	Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 222-234.	8.2	82
1588	Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors. Current Oncology Reports, 2018, 20, 24.	1.8	35
1589	Generation of tumor antigen-specific murine CD8+ T cells with enhanced anti-tumor activity via highly efficient CRISPR/Cas9 genome editing. International Immunology, 2018, 30, 141-154.	1.8	9
1590	Pembrolizumab in Asiaâ€Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from <scp>KEYNOTE</scp>â€012. Cancer Science, 2018, 109, 771-776.	1.7	48
1591	Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine. Immunotherapy, 2018, 10, 373-382.	1.0	10
1592	Necroptotic cancer cells-mimicry nanovaccine boosts anti-tumor immunity with tailored immune-stimulatory modality. Biomaterials, 2018, 164, 80-97.	5.7	78
1593	Checkpoint Inhibitors in Breast Cancer - Current Status and Future Directions. Breast Care, 2018, 13, 27-31.	0.8	8
1594	Diabetes and Blood Glucose Disorders Under Anti-PD1. Journal of Immunotherapy, 2018, 41, 232-240.	1.2	27
1595	Imaging in neuro-oncology. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641875986.	1.5	41
1596	Immunotherapy in Lung Cancer and the Role of Imaging. Seminars in Ultrasound, CT and MRI, 2018, 39, 314-321.	0.7	4
1597	Improving immunotherapy for colorectal cancer using dendritic cells combined with anti-programmed death-ligand inÃ¯Â¿Â½vitro. Oncology Letters, 2018, 15, 5345-5351.	0.8	10
1598	How to Design Phase I Trials in Oncology. , 2018, , 165-187.		0
1600	Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma. Lung Cancer, 2018, 121, 18-24.	0.9	24
1601	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clinical Cancer Research, 2018, 24, 4960-4967.	3.2	222
1602	Towards predictive biomarkers for immunotherapy response in breast cancer patients. Breast Cancer Management, 2018, 7, BMT05.	0.2	4
1604	An early history of T cell-mediated cytotoxicity. Nature Reviews Immunology, 2018, 18, 527-535.	10.6	179

#	Article	IF	Citations
1605	Morphology of Immunomodulation in Breast Cancer Tumor Draining Lymph Nodes Depends on Stage and Intrinsic Subtype. Scientific Reports, 2018, 8, 5321.	1.6	9
1606	Digital image analysis improves precision of <scp>PD</scp>â€L1 scoring in cutaneous melanoma. Histopathology, 2018, 73, 397-406.	1.6	54
1607	Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade. Nature Communications, 2018, 9, 1538.	5.8	49
1608	Long noncoding RNAs in cancerâ€immunity cycle. Journal of Cellular Physiology, 2018, 233, 6518-6523.	2.0	119
1609	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer Cell, 2018, 33, 581-598.	7.7	393
1610	Metastasisâ€specific patterns of response and progression with antiâ€<scp>PD</scp>â€1 treatment in metastatic melanoma. Pigment Cell and Melanoma Research, 2018, 31, 404-410.	1.5	34
1611	Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer. Cancer Immunology, Immunotherapy, 2018, 67, 1897-1910.	2.0	42
1612	The gut microbiota influences anticancer immunosurveillance and general health. Nature Reviews Clinical Oncology, 2018, 15, 382-396.	12.5	389
1613	MicroRNA-374b inhibits liver cancer progression via down regulating programmed cell death-1 expression on cytokine-induced killer cells. Oncology Letters, 2018, 15, 4797-4804.	0.8	29
1614	Therapeutic prospects of targeting myeloidâ€derived suppressor cells and immune checkpoints in cancer. Immunology and Cell Biology, 2018, 96, 888-897.	1.0	43
1615	PDâ€1 Blockade Cellular Vesicles for Cancer Immunotherapy. Advanced Materials, 2018, 30, e1707112.	11.1	196
1616	Role of PD-1 during effector CD8 T cell differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4749-4754.	3.3	327
1617	Cancer immunotherapyâ€targeted glypicanâ€3 or neoantigens. Cancer Science, 2018, 109, 531-541.	1.7	40
1618	Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Nonâ€“Small Cell Lung Carcinoma. Archives of Pathology and Laboratory Medicine, 2018, 142, 1388-1393.	1.2	3
1619	Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1. Veterinary Immunology and Immunopathology, 2018, 198, 19-25.	0.5	31
1620	Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization. Melanoma Research, 2018, 28, 89-95.	0.6	13
1622	Systemic treatments for metastatic cutaneous melanoma. The Cochrane Library, 2020, 2020, CD011123.	1.5	136
1623	Synthetic Immunobiotics: A Future Success Story in Small Molecule-Based Immunotherapy?. ACS Infectious Diseases, 2018, 4, 664-672.	1.8	7

#	Article	IF	Citations
1624	Overview of metastatic disease of the central nervous system. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 149, 3-23.	1.0	28
1625	PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations. EBioMedicine, 2018, 28, 97-104.	2.7	55
1626	IL-2 and Beyond in Cancer Immunotherapy. Journal of Interferon and Cytokine Research, 2018, 38, 45-68.	0.5	83
1627	Clinical Development of PD-1 in Advanced Melanoma. Cancer Journal (Sudbury, Mass), 2018, 24, 7-14.	1.0	37
1628	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401774974.	1.4	200
1629	Role of immune-checkpoint inhibitors in lung cancer. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346581775007.	1.0	88
1630	Recent advances and opportunities in proteomic analyses of tumour heterogeneity. Journal of Pathology, 2018, 244, 628-637.	2.1	21
1631	Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. Lancet Oncology, The, 2018, 19, 229-239.	5.1	111
1632	Established, emerging and elusive molecular targets in the treatment of lung cancer. Journal of Pathology, 2018, 244, 565-577.	2.1	15
1633	Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncology, The, 2018, 19, 405-415.	5.1	305
1635	Checkpoint Inhibitors, Palliative Care, or Hospice. Current Oncology Reports, 2018, 20, 2.	1.8	8
1636	Pediatric patients with cutaneous melanoma: A European study. Pediatric Blood and Cancer, 2018, 65, e26974.	0.8	26
1637	Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clinical Cancer Research, 2018, 24, 1805-1815.	3.2	45
1638	Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer Journal (Sudbury, Mass), 2018, 24, 47-53.	1.0	287
1639	Toxicities Associated With PD-1/PD-L1 Blockade. Cancer Journal (Sudbury, Mass), 2018, 24, 36-40.	1.0	72
1640	Merkel cell carcinoma: An update and review. Journal of the American Academy of Dermatology, 2018, 78, 445-454.	0.6	90
1641	Pembrolizumab for the treatment of bladder cancer. Expert Review of Anticancer Therapy, 2018, 18, 107-114.	1.1	12
1642	PD1 Checkpoint Blockade in Melanoma: From Monotherapy to Combination Therapies. , 2018, , 321-331.		0

#	Article	IF	Citations
1643	Co-stimulation Agonists via CD137, OX40, GITR, and CD27 for Immunotherapy of Cancer. , 2018, , 429-446.		0
1644	Immune Therapies in Phase 1 Trials. , 2018, , 547-563.		0
1645	Melanoma: Immunotherapy in Advanced Melanoma and in the Adjuvant Setting. , 2018, , 579-591.		0
1646	Assessing T Cell Receptor Affinity and Avidity Against Tumor Antigens. , 2018, , 665-679.		2
1647	Cancer Immunosurveillance by Natural Killer Cells and Other Innate Lymphoid Cells. , 2018, , 163-180.		3
1648	Dermatologic Reactions to Immune Checkpoint Inhibitors. American Journal of Clinical Dermatology, 2018, 19, 345-361.	3.3	426
1649	Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors. OncoImmunology, 2018, 7, e1417721.	2.1	33
1650	Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices. Journal of Immunotherapy, 2018, 41, 86-95.	1.2	28
1651	Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. Chemical Reviews, 2018, 118, 1599-1663.	23.0	64
1652	Dosimetry Prediction for Clinical Translation of 64Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression. Scientific Reports, 2018, 8, 633.	1.6	41
1653	High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nature Medicine, 2018, 24, 144-153.	15.2	564
1654	Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. OncoImmunology, 2018, 7, e1405205.	2.1	124
1655	Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients. Clinical and Translational Oncology, 2018, 20, 966-974.	1.2	31
1656	High response rate to PD-1 blockade in desmoplastic melanomas. Nature, 2018, 553, 347-350.	13.7	269
1657	Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. International Immunology, 2018, 30, 13-22.	1.8	74
1658	The Basics of Cancer Immunotherapy. , 2018, , .		5
1659	Therapeutic Targets of FDA-Approved Immunotherapies in Oncology. , 2018, , 21-37.		3
1660	Melanoma Immunotherapy. , 2018, , 39-57.		0

#	Article	IF	Citations
1661	Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitor Therapy. , 2018, , 143-152.		1
1663	Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends. Oncology Research and Treatment, 2018, 41, 286-290.	0.8	6
1664	Noninvasive detection of PD-L1 on circulating tumor cells in patient blood samples. Future Oncology, 2018, 14, 1237-1240.	1.1	5
1665	Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma. British Journal of Cancer, 2018, 118, 1329-1336.	2.9	75
1666	CHECKPOINT INHIBITOR IMMUNE THERAPY. Retina, 2018, 38, 1063-1078.	1.0	252
1667	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. , 2018, , 1461-1505.		0
1668	Precision Medicine Based on Next-Generation Sequencing and Master Controllers. , 2018, , 1577-1611.		1
1669	Role of Tumor-Stromal Interactions in Pancreatic Cancer Invasion and Metastases. , 2018, , 539-552.		0
1670	Harnessing and Optimizing the Interplay between Immunotherapy and Radiotherapy to Improve Survival Outcomes. Molecular Cancer Research, 2018, 16, 1209-1214.	1.5	7
1671	Pseudoprogression and hyperprogression after checkpoint blockade. International Immunopharmacology, 2018, 58, 125-135.	1.7	121
1672	Engineering nanoparticle strategies for effective cancer immunotherapy. Biomaterials, 2018, 178, 597-607.	5.7	117
1673	Chemokines and cancer: new immune checkpoints for cancer therapy. Current Opinion in Immunology, 2018, 51, 140-145.	2.4	109
1674	Hierarchical Nanoassemblies-Assisted Combinational Delivery of Cytotoxic Protein and Antibiotic for Cancer Treatment. Nano Letters, 2018, 18, 2294-2303.	4.5	71
1675	Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 90-94.	0.6	8
1676	Programmed Cell Death-Ligand 1 (PD-L1) Expression in Anal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 638-642.	0.6	33
1677	The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Breast Cancer, 2018, 25, 34-42.	1.3	88
1678	Metaâ€Analysis of the Risk of Immuneâ€Related Adverse Events With Anticytotoxic Tâ€Lymphocyteâ€Associated Antigen 4 and Antiprogrammed Death 1 Therapies. Clinical Pharmacology and Therapeutics, 2018, 103, 318-331.	2.3	22
1679	Evaluation of the dosing strategies of biologic agents and the theoretical impact of dose rounding. Journal of Oncology Pharmacy Practice, 2018, 24, 47-55.	0.5	5

#	Article	IF	Citations
1680	Prognostic role of histological regression in primary cutaneous melanoma: a systematic review and meta-analysis. British Journal of Dermatology, 2018, 178, 357-362.	1.4	44
1681	Tumor infiltrating lymphocytes in early breast cancer. Breast, 2018, 37, 207-214.	0.9	108
1682	PD-1 and cancer: molecular mechanisms and polymorphisms. Immunogenetics, 2018, 70, 73-86.	1.2	100
1683	PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry. Journal of Clinical Pathology, 2018, 71, 46-51.	1.0	17
1684	Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients. Clinical Immunology, 2018, 189, 43-51.	1.4	27
1685	Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients. Journal of Dermatological Science, 2018, 89, 60-66.	1.0	52
1686	Regulation and Dysregulation of Chromosome Structure in Cancer. Annual Review of Cancer Biology, 2018, 2, 21-40.	2.3	26
1687	In-vitro effect of pembrolizumab on different T regulatory cell subsets. Clinical and Experimental Immunology, 2018, 191, 189-197.	1.1	42
1688	A filamentous bacteriophage targeted to carcinoembryonic antigen induces tumor regression in mouse models of colorectal cancer. Cancer Immunology, Immunotherapy, 2018, 67, 183-193.	2.0	25
1689	Clinical significance of programmed cell deathâ€ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. International Journal of Cancer, 2018, 142, 822-832.	2.3	55
1690	Frequent PD-L1 Expression in Malignant Melanomas of the Vulva. International Journal of Gynecological Pathology, 2018, 37, 477-481.	0.9	10
1691	The diverse functions of the PD1 inhibitory pathway. Nature Reviews Immunology, 2018, 18, 153-167.	10.6	1,210
1692	Establishment of the Method for Screening Small Molecule Inhibitors Blocking the Interaction Between PD-1 and Its Ligand PD-L1. Lecture Notes in Electrical Engineering, 2018, , 695-703.	0.3	1
1693	The application and mechanism of PD pathway blockade for cancer therapy. Postgraduate Medical Journal, 2018, 94, 53-60.	0.9	10
1694	Management of Toxicities of Targeted Therapies. , 2018, , 490-500.e3.		2
1695	Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSFâ€“expressing tumor cells. Neuro-Oncology, 2018, 20, 44-54.	0.6	51
1696	18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 95-101.	3.3	46
1697	PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?. OncoImmunology, 2018, 7, e1364828.	2.1	243

#	Article	IF	Citations
1698	Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma model. OncoImmunology, 2018, 7, e1376154.	2.1	22
1699	Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. Future Oncology, 2018, 14, 417-430.	1.1	55
1700	Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer. Cell Cycle, 2018, 17, 191-199.	1.3	10
1701	Evolution of early phase clinical trials in oncology. Journal of Molecular Medicine, 2018, 96, 31-38.	1.7	13
1702	Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab). Current Problems in Dermatology, 2018, 53, 82-92.	0.8	22
1703	Nanoscale Tuning of VCAM-1 Determines VLA-4â€“Dependent Melanoma Cell Plasticity on RGD Motifs. Molecular Cancer Research, 2018, 16, 528-542.	1.5	14
1704	Implications of the tumor immune microenvironment for staging and therapeutics. Modern Pathology, 2018, 31, 214-234.	2.9	278
1705	Immune checkpoint inhibitors in advanced nonâ€“small cell lung cancer. Cancer, 2018, 124, 248-261.	2.0	94
1707	Blockade of PD-1 effectively inhibits in vivo malignant transformation of oral mucosa. OncoImmunology, 2018, 7, e1388484.	2.1	23
1708	Hepatocellular carcinoma in the era of immunotherapy. Current Problems in Cancer, 2018, 42, 40-48.	1.0	135
1709	Humanized mice in studying efficacy and mechanisms of PDâ€1â€targeted cancer immunotherapy. FASEB Journal, 2018, 32, 1537-1549.	0.2	260
1710	<scp>PD</scp>â€L1 expression is mainly regulated by interferon gamma associated with <scp>JAK</scp>â€<scp>STAT</scp> pathway in gastric cancer. Cancer Science, 2018, 109, 43-53.	1.7	239
1711	Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives. American Journal of Clinical Dermatology, 2018, 19, 303-317.	3.3	78
1712	Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers. Laboratory Investigation, 2018, 98, 41-50.	1.7	30
1713	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Investigational New Drugs, 2018, 36, 638-646.	1.2	149
1714	A novel immunization strategy using cytokine/chemokines induces new effective systemic immune responses, and frequent complete regressions of human metastatic melanoma. OncoImmunology, 2018, 7, e1386827.	2.1	3
1715	Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes. Cancer Immunology Research, 2018, 6, 59-68.	1.6	26
1716	A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma. Investigational New Drugs, 2018, 36, 103-113.	1.2	19

#	Article	IF	Citations
1718	Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. Gastric Cancer, 2018, 21, 31-40.	2.7	75
1719	Checkpoint inhibitor-associated autoimmunity. Best Practice and Research in Clinical Rheumatology, 2018, 32, 781-802.	1.4	13
1720	Reasons not to perform subxiphoid video-assisted thoracic surgery. Journal of Visualized Surgery, 0, 4, 214-214.	0.2	3
1721	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. Journal of Clinical Oncology, 2018, 36, 850-858.	0.8	288
1722	Combination Immunotherapy Development in Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 197-207.	1.8	39
1726	Tumor Regression and Cure Depends on Sustained Th1 Responses. Journal of Immunotherapy, 2018, 41, 369-378.	1.2	26
1727	Hematological adverse events related to the immune system with immune checkpoint inhibitors, a comprehensive review as a basis for clinical guidelines. Hematologie, 2018, 24, 183-193.	0.0	0
1728	Dendritic cells loaded with tumor derived exosomes for cancer immunotherapy. Oncotarget, 2018, 9, 2887-2894.	0.8	69
1730	Current Perspectives on Novel Drug Carrier Systems and Therapies for Management of Pancreatic Cancer: An Updated Inclusive Review. Critical Reviews in Therapeutic Drug Carrier Systems, 2018, 35, 195-292.	1.2	12
1731	Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer. Frontiers in Immunology, 2018, 9, 3081.	2.2	116
1733	Efficacy and safety of PD-1 inhibitors for treating advanced melanoma: a systematic review and meta-analysis. Immunotherapy, 2018, 10, 1293-1302.	1.0	14
1734	Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma. Oncotarget, 2018, 9, 7949-7960.	0.8	49
1735	Monoclonal antibodies for the treatment of non-hematological tumors: a safety review. Expert Opinion on Drug Safety, 2018, 17, 1197-1209.	1.0	11
1737	Harnessing immune checkpoints for cancer therapy. Immunotherapy, 2018, 10, 1265-1284.	1.0	9
1738	The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies. Current Treatment Options in Oncology, 2018, 19, 70.	1.3	17
1739	Analysis of PD-1 related immune transcriptional profile in different cancer types. Cancer Cell International, 2018, 18, 218.	1.8	15
1740	Total HLA Class I Antigen Loss with the Downregulation of Antigen-Processing Machinery Components in Two Newly Established Sarcomatoid Hepatocellular Carcinoma Cell Lines. Journal of Immunology Research, 2018, 2018, 1-12.	0.9	4
1741	A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay. Translational Lung Cancer Research, 2018, 7, 616-630.	1.3	41

#	Article	IF	Citations
1742	Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells. Frontiers in Immunology, 2018, 9, 2821.	2.2	76
1743	Artificial T Cell Mimetics to Combat Melanoma Tumor Growth. American Journal of Advanced Drug Delivery, 2018, 06, .	0.1	2
1744	The Era of Immune Checkpoint Therapy: From Cancer to Viral Infectionâ€"A Mini Comment on the 2018 Medicine Nobel Prize. Virologica Sinica, 2018, 33, 467-471.	1.2	9
1745	Immune checkpoint inhibitors in cancer therapy. Journal of Biomedical Research, 2018, 32, 317.	0.7	101
1747	Prognostic Value of Lymphocyte Activation Gene-3 (LAG-3) Expression in Esophageal Squamous Cell Carcinoma. Journal of Cancer, 2018, 9, 4287-4293.	1.2	34
1748	CD38 is methylated in prostate cancer and regulates extracellular NAD+. Cancer & Metabolism, 2018, 6, 13.	2.4	28
1749	Immunotherapy for melanoma. Onkologe, 2018, 24, 99-103.	0.7	1
1750	Clinical and histopathologic features of paraneoplastic granuloma annulare in association with solid organ malignancies: A caseâ€"control study. Journal of the American Academy of Dermatology, 2018, 79, 913-920.e1.	0.6	17
1751	The application of nanotechnology in immune checkpoint blockade for cancer treatment. Journal of Controlled Release, 2018, 290, 28-45.	4.8	67
1752	Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes and Development, 2018, 32, 1267-1284.	2.7	1,326
1753	Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis. Lung Cancer, 2018, 125, 212-217.	0.9	114
1754	Bifunctional PD-1 Ã— Î±CD3 Ã— Î±CD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia. Blood, 2018, 132, 2484-2494.	0.6	73
1755	Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. International Journal of Nanomedicine, 2018, Volume 13, 6049-6058.	3.3	404
1756	Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. Frontiers in Pharmacology, 2018, 9, 1050.	1.6	48
1757	A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell, 2018, 175, 313-326.	13.5	985
1758	The comprehensive molecular landscape of the immunologic co-stimulator B7 and TNFR ligand receptor families in colorectal cancer: immunotherapeutic implications with microsatellite instability. OncoImmunology, 2018, 7, e1488566.	2.1	13
1759	Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy. Cancer Immunology Research, 2018, 6, 1401-1416.	1.6	28
1760	In situ administration of cytokine combinations induces tumor regression in mice. EBioMedicine, 2018, 37, 38-46.	2.7	10

#	Article	IF	Citations
1761	Immune cells in the tumour: new routes of retinoids for chemoprevention and chemotherapeutics. British Journal of Pharmacology, 2018, 175, 4285-4294.	2.7	8
1762	Pan-tumor genomic biomarkers for PD-1 checkpoint blockadeâ€“based immunotherapy. Science, 2018, 362, .	6.0	1,575
1763	Liver Toxicity with Cancer Checkpoint Inhibitor Therapy. Seminars in Liver Disease, 2018, 38, 366-378.	1.8	31
1764	Limited Phenotypic and Functional Plasticity of Influenza Virusâ€“Specific Memory CD8+T Cells during Activation in an Alternative Cytokine Environment. Journal of Immunology, 2018, 201, 3282-3293.	0.4	2
1765	Personalized vaccination against ovarian cancer: what are the possibilities?. Expert Review of Vaccines, 2018, 17, 955-958.	2.0	7
1766	Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. Genome Medicine, 2018, 10, 79.	3.6	36
1767	Role of the immunosuppressive microenvironment in immunotherapy. Advances in Radiation Oncology, 2018, 3, 520-526.	0.6	107
1768	A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. British Journal of Cancer, 2018, 119, 1200-1207.	2.9	83
1769	Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy. Cancer Immunology, Immunotherapy, 2018, 67, 1845-1851.	2.0	28
1770	Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. Gynecologic Oncology, 2018, 151, 381-389.	0.6	99
1771	8 Surgical Implications of Systemic Therapy for Skin Cancer. , 2018, , .		0
1772	Capturing functional long non-coding RNAs through integrating large-scale causal relations from gene perturbation experiments. EBioMedicine, 2018, 35, 369-380.	2.7	19
1773	The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review. BMC Gastroenterology, 2018, 18, 135.	0.8	44
1774	Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. European Journal of Cancer, 2018, 103, 7-16.	1.3	63
1775	Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response. Expert Opinion on Biological Therapy, 2018, 18, 1061-1071.	1.4	27
1776	Immune Checkpoint Molecules, Personalized Immunotherapy, and Autoimmune Diabetes. Trends in Molecular Medicine, 2018, 24, 931-941.	3.5	34
1777	Recent advances in applying nanotechnologies for cancer immunotherapy. Journal of Controlled Release, 2018, 288, 239-263.	4.8	60
1778	Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. Frontiers in Immunology, 2018, 9, 1878.	2.2	127

#	Article	IF	Citations
1779	Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance. Frontiers in Oncology, 2018, 8, 322.	1.3	137
1780	Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification. Scientific Reports, 2018, 8, 13166.	1.6	46
1781	Immunotherapy in melanoma. Immunotherapy, 2018, 10, 987-998.	1.0	22
1782	Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia. Blood Advances, 2018, 2, 1187-1190.	2.5	8
1783	Role of Imaging in Early-Phase Trials. , 2018, , 129-149.		1
1784	Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy. Cellular Physiology and Biochemistry, 2018, 47, 721-734.	1.1	131
1785	TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. OncoImmunology, 2018, 7, e1466769.	2.1	217
1786	Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer. Cancer Research, 2018, 78, 4282-4291.	0.4	83
1787	PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT). American Journal of Surgical Pathology, 2018, 42, 843-854.	2.1	54
1788	Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy. Oncogene, 2018, 37, 4941-4954.	2.6	83
1789	<scp>BRAF</scp> and <scp>MEK</scp> inhibitor therapy eliminates Nestinâ€expressing melanoma cells in human tumors. Pigment Cell and Melanoma Research, 2018, 31, 708-719.	1.5	9
1790	Prospects of Gene Therapy to Treat Melanoma. Advances in Cancer Research, 2018, 138, 213-237.	1.9	17
1791	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clinical Cancer Research, 2018, 24, 4416-4428.	3.2	89
1792	Epithelial-mesenchymal transition-converted tumor cells can induce T-cell apoptosis through upregulation of programmed death ligand 1 expression in esophageal squamous cell carcinoma. Cancer Medicine, 2018, 7, 3321-3330.	1.3	21
1793	Effective Immunotherapy in Bone Marrow Metastatic Melanoma Presenting with Disseminated Intravascular Coagulopathy. Case Reports in Immunology, 2018, 2018, 1-8.	0.2	5
1794	Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy. British Journal of Cancer, 2018, 119, 193-199.	2.9	21
1795	Receptors That Inhibit Macrophage Activation: Mechanisms and Signals of Regulation and Tolerance. Journal of Immunology Research, 2018, 2018, 1-14.	0.9	21
1796	Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade. ELife, 2018, 7, .	2.8	98

#	Article	IF	Citations
1797	T Lymphocyteâ€“Based Cancer Immunotherapeutics. International Review of Cell and Molecular Biology, 2018, 341, 201-276.	1.6	22
1798	Early-drug development in the era of immuno-oncology: are we ready to face the challenges?. Annals of Oncology, 2018, 29, 1727-1740.	0.6	20
1799	Pembrolizumabâ€induced sarcoidal infusion site reaction. Journal of Cutaneous Pathology, 2018, 45, 727-729.	0.7	9
1800	Blockade of the Checkpoint Inhibitor Pathways and Activated T-Cell Therapy in Brain Tumors. , 2018, , 669-680.		0
1801	Issues in Response Assessment of Brain Tumor Chemotherapy. , 2018, , 715-727.		2
1802	Immunotherapy Response Assessment in Neuro-Oncology (iRANO). , 2018, , 761-766.		1
1803	Cancer Vaccines. , 2018, , 161-184.e6.		2
1804	Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management. Journal of Skin Cancer, 2018, 2018, 1-13.	0.5	21
1805	The Single-Cell Phenotypic Identity of Human CD8+ and CD4+ T Cells. International Review of Cell and Molecular Biology, 2018, 341, 63-124.	1.6	77
1806	Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers. Current Urology Reports, 2018, 19, 68.	1.0	12
1807	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. British Journal of Cancer, 2018, 119, 153-159.	2.9	329
1808	Expression and clinical significance of PDâ€1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PDâ€1 monoclonal antibody. International Journal of Oncology, 2018, 52, 2079-2092.	1.4	10
1809	Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 1569-1576.	0.5	206
1810	PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study. BMC Cancer, 2018, 18, 652.	1.1	13
1811	Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts. Frontiers in Immunology, 2018, 9, 1614.	2.2	23
1812	Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. , 2018, 6, 35.		172
1813	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
1814	Checkpoint Blockade Rescues the Repressive Effect of Histone Deacetylases Inhibitors on Î³Î´ T Cell Function. Frontiers in Immunology, 2018, 9, 1615.	2.2	21

#	Article	IF	Citations
1815	The use of SAMe in chemotherapy-induced liver injury. Critical Reviews in Oncology/Hematology, 2018, 130, 70-77.	2.0	21
1816	Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study. Journal of the American Academy of Dermatology, 2018, 79, 1047-1052.	0.6	95
1817	Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy. Theranostics, 2018, 8, 3559-3570.	4.6	85
1818	High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma. OncoImmunology, 2018, 7, e1475874.	2.1	20
1819	Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report. , 2018, 6, 53.		2
1820	A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma. , 2018, 6, 76.		14
1821	Lymphatic vessel density is associated with CD8⁺ T cell infiltration and immunosuppressive factors in human melanoma. OncoImmunology, 2018, 7, e1462878.	2.1	47
1822	Pathways in melanoma development. Italian Journal of Dermatology and Venereology, 2018, 153, 68-76.	0.1	4
1823	Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma. Molecular and Clinical Oncology, 2018, 9, 75-81.	0.4	12
1824	Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors. Journal of Cancer, 2018, 9, 205-212.	1.2	9
1825	Cardiotoxicity of Anticancer Therapeutics. Frontiers in Cardiovascular Medicine, 2018, 5, 9.	1.1	68
1826	The Role of the Insulin-Like Growth Factor 1 Pathway in Immune Tumor Microenvironment and Its Clinical Ramifications in Gynecologic Malignancies. Frontiers in Endocrinology, 2018, 9, 297.	1.5	17
1827	Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model. Frontiers in Immunology, 2018, 9, 416.	2.2	91
1828	Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme. Frontiers in Immunology, 2018, 9, 727.	2.2	55
1829	Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma. Frontiers in Immunology, 2018, 9, 1370.	2.2	49
1830	Dendritic Cells Actively Limit Interleukin-10 Production Under Inflammatory Conditions via DC-SCRIPT and Dual-Specificity Phosphatase 4. Frontiers in Immunology, 2018, 9, 1420.	2.2	16
1831	Association Between Programed Cell Death-1 and CD4+ T Cell Alterations in Different Phases of Ischemic Stroke Patients. Frontiers in Cellular Neuroscience, 2018, 12, 170.	1.8	7
1832	Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study. Frontiers in Oncology, 2018, 8, 18.	1.3	34

#	Article	IF	Citations
1833	Mechanisms and Therapy for Cancer Metastasis to the Brain. Frontiers in Oncology, 2018, 8, 161.	1.3	123
1834	Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. , 2018, 6, 46.		135
1835	Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. Biomedicines, 2018, 6, 26.	1.4	16
1836	Glioblastoma under Siege: An Overview of Current Therapeutic Strategies. Brain Sciences, 2018, 8, 15.	1.1	104
1837	Clinical Importance of Epsteinâ€“Barr Virus-Associated Gastric Cancer. Cancers, 2018, 10, 167.	1.7	63
1838	Dual TGFâ€Î² and PDâ€1 blockade synergistically enhances MAGEâ€A3â€specific CD8⁺ T cell response in esophageal squamous cell carcinoma. International Journal of Cancer, 2018, 143, 2561-2574.	2.3	68
1839	Naturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas. International Journal of Molecular Sciences, 2018, 19, 394.	1.8	78
1840	Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity. Immunotherapy, 2018, 10, 797-805.	1.0	20
1842	Future Developments in Neoadjuvant Therapy for Triple-Negative Breast Cancer. Surgical Clinics of North America, 2018, 98, 773-785.	0.5	10
1843	Vaccine Therapy of High-Grade Gliomas. Progress in Neurological Surgery, 2018, 32, 101-111.	1.3	4
1844	Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. Acta Pharmacologica Sinica, 2018, 39, 1693-1698.	2.8	39
1845	Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer). The Cochrane Library, 2018, 7, CD012556.	1.5	13
1846	Microbial biomarkers for immune checkpoint blockade therapy against cancer. Journal of Gastroenterology, 2018, 53, 999-1005.	2.3	15
1847	Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors. Diagnostic Pathology, 2018, 13, 30.	0.9	43
1848	Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype. Molecular Cancer, 2018, 17, 59.	7.9	63
1849	Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma. Inflammation and Regeneration, 2018, 38, 3.	1.5	35
1850	Gender and Dermatology. , 2018, , .		4
1851	Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma (Review). Oncology Letters, 2018, 15, 7497-7505.	0.8	50

#	Article	IF	Citations
1852	Immune checkpoint receptors: homeostatic regulators of immunity. Hepatology International, 2018, 12, 223-236.	1.9	43
1853	Immuneâ€related Adverse Events in Cancer Patients. Academic Emergency Medicine, 2018, 25, 819-827.	0.8	18
1854	Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. Journal of Hematology and Oncology, 2018, 11, 15.	6.9	155
1855	PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. Journal of Hematology and Oncology, 2018, 11, 16.	6.9	96
1856	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. , 2018, 6, 8.		936
1857	Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. , 2018, 6, 18.		153
1858	Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy. Scientific Reports, 2018, 8, 7485.	1.6	19
1859	Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. Aids, 2018, 32, 1491-1497.	1.0	136
1860	Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. , 2018, 6, 32.		111
1861	Biology and Sex Disparities in Melanoma Outcomes. , 2018, , 193-213.		0
1862	Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer. Journal of Breast Cancer, 2018, 21, 124.	0.8	54
1863	Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. Experimental and Molecular Medicine, 2018, 50, 1-13.	3.2	152
1864	Design considerations for early-phase clinical trials of immune-oncology agents. , 2018, 6, 81.		44
1865	Implementation of cellâ€free tumor DNA sequencing from the cerebrospinal fluid to guide treatment in a patient with primary leptomeningeal melanoma: A case report. Molecular and Clinical Oncology, 2018, 9, 58-61.	0.4	8
1867	Dendritic cell vaccines for high-grade gliomas. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1299-1313.	0.9	42
1868	Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment. Journal of Cancer, 2018, 9, 1614-1622.	1.2	17
1869	Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients. American Journal of Transplantation, 2018, 18, 3065-3071.	2.6	41
1870	Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy. Frontiers in Immunology, 2018, 9, 1774.	2.2	125

#	Article	IF	Citations
1871	Engineering Platforms for T Cell Modulation. International Review of Cell and Molecular Biology, 2018, 341, 277-362.	1.6	8
1872	Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy. Molecular Pharmaceutics, 2018, 15, 4426-4433.	2.3	37
1873	Upregulation of PDâ€'L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300â€'mediated NFâ€'Î²B signaling. International Journal of Oncology, 2018, 53, 1469-1480.	1.4	63
1874	A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety. Biochimie, 2018, 151, 54-66.	1.3	13
1875	Surgery for Stage IV Metastatic Melanoma. , 2018, , 467-481.		1
1878	Current Immunotherapy of Melanoma. , 2018, , 567-576.		0
1879	Immune-Related Adverse Toxicities and Clinical Management. , 2018, , 577-589.		0
1880	Clinical relevance of <scp>PD</scp>â€'L1 expression in gallbladder cancer: a potential target for therapy. Histopathology, 2018, 73, 622-633.	1.6	31
1881	Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies. Scientific Reports, 2018, 8, 8810.	1.6	13
1882	Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. PLoS ONE, 2018, 13, e0192704.	1.1	82
1883	Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. Current Medicinal Chemistry, 2018, 25, 1327-1339.	1.2	99
1884	Profiles of brain metastases: Prioritization of therapeutic targets. International Journal of Cancer, 2018, 143, 3019-3026.	2.3	31
1885	Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy. Cardiology in Review, 2019, 27, 97-107.	0.6	19
1886	Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective. Clinical Pharmacology and Therapeutics, 2019, 105, 582-597.	2.3	8
1887	Immune checkpoints and cancer in the immunogenomics era. Briefings in Functional Genomics, 2019, 18, 133-139.	1.3	19
1888	Programmed death-1 ligands and tumor infiltrating T lymphocytes in primary and lymph node metastasis of esophageal cancer patients. Ecological Management and Restoration, 2019, 32, .	0.2	11
1889	Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper. Journal of Geriatric Oncology, 2019, 10, 389-397.	0.5	20
1890	Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer. Annals of Surgery, 2019, 270, 309-316.	2.1	191

#	Article	IF	Citations
1891	TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2. Frontiers in Immunology, 2019, 10, 1644.	2.2	24
1892	Melanoma Immunology and Immunotherapy. , 2019, , 651-665.		0
1893	Molecular Diagnostics in Melanocytic Neoplasia. , 2019, , 629-650.		0
1894	High Affinity of Chlorin e6 to Immunoglobulin G for Intraoperative Fluorescence Image-Guided Cancer Photodynamic and Checkpoint Blockade Therapy. ACS Nano, 2019, 13, 10242-10260.	7.3	78
1895	Immune signature profiling identified prognostic factors for gastric cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 463-470.	0.7	56
1896	Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone. Cancer Immunology, Immunotherapy, 2019, 68, 1417-1428.	2.0	23
1897	Microshell Enhanced Acoustic Adjuvants for Immunotherapy in Glioblastoma. Advanced Therapeutics, 2019, 2, 1900066.	1.6	6
1898	TREM1/Dap12-based CAR-T cells show potent antitumor activity. Immunotherapy, 2019, 11, 1043-1055.	1.0	24
1899	Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations. Frontiers in Pharmacology, 2019, 10, 726.	1.6	20
1900	Novel Delivery Systems for Checkpoint Inhibitors. Medicines (Basel, Switzerland), 2019, 6, 74.	0.7	24
1901	Role of tumor gene mutations in treatment response to immune checkpoint blockades. Precision Clinical Medicine, 2019, 2, 100-109.	1.3	11
1902	Drug Delivery: Localized and Systemic Therapeutic Strategies with Polymer Systems. Polymers and Polymeric Composites, 2019, , 1079-1134.	0.6	3
1903	Cellular Therapy for Melanoma. , 2019, , 1-33.		0
1904	Pseudoprogression presenting as intestinal perforation in nonâ€‘small cell lung cancer treated with antiâ€‘PDâ€‘1: A case report. Molecular and Clinical Oncology, 2019, 11, 132-134.	0.4	9
1905	Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Medicine, 2019, 8, 4986-4999.	1.3	27
1906	SREBP1-dependent de novo fatty acid synthesis gene expression is elevated in malignant melanoma and represents a cellular survival trait. Scientific Reports, 2019, 9, 10369.	1.6	33
1907	Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer. JAMA Network Open, 2019, 2, e197621.	2.8	25
1908	Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade. Journal of Dental Research, 2019, 98, 1073-1080.	2.5	9

#	Article	IF	Citations
1909	Engineering nanoparticles to locally activate T cells in the tumor microenvironment. Science Immunology, 2019, 4, .	5.6	180
1910	T Cell Dysfunction in Cancer Immunity and Immunotherapy. Frontiers in Immunology, 2019, 10, 1719.	2.2	219
1911	Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma. Oncologist, 2019, 24, e1197-e1211.	1.9	15
1912	Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent. Cancers, 2019, 11, 872.	1.7	50
1913	Biohybrid Nanoparticles to Negotiate with Biological Barriers. Small, 2019, 15, e1902333.	5.2	22
1914	Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma. Journal of Bone Oncology, 2019, 17, 100245.	1.0	17
1915	Development of 99mTc-conjugated JS001 antibody for in vivo mapping of PD-1 distribution in murine. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2178-2181.	1.0	8
1916	Drug-Induced Injury, Polyps, Congenital, and Miscellaneous Disorders. , 2019, , 289-306.		0
1917	Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer. Frontiers in Immunology, 2019, 10, 1401.	2.2	71
1918	A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer. Thyroid, 2019, 29, 1615-1622.	2.4	51
1919	PD-1 inhibitors dependent CD8⁺ T cells inhibit mouse colon cancer cell metastasis . OncoTargets and Therapy, 2019, Volume 12, 6961-6971.	1.0	11
1920	The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis. Frontiers in Oncology, 2019, 9, 897.	1.3	29
1921	Phase I trials: not all are made equal. Nature Reviews Clinical Oncology, 2019, 16, 717-717.	12.5	1
1922	Peptide-based materials for cancer immunotherapy. Theranostics, 2019, 9, 7807-7825.	4.6	77
1923	Immune regulation and cytotoxic T cell activation of IL-10 agonists â€“ Preclinical and clinical experience. Seminars in Immunology, 2019, 44, 101325.	2.7	30
1924	Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. Theranostics, 2019, 9, 7906-7923.	4.6	100
1925	A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer. Frontiers in Oncology, 2019, 9, 1066.	1.3	43
1926	Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival. Gynecologic Oncology, 2019, 155, 483-488.	0.6	10

#	Article	IF	Citations
1927	Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports. BMC Cancer, 2019, 19, 1019.	1.1	48
1928	Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer. Medicina (Lithuania), 2019, 55, 723.	0.8	18
1929	Testing Immune-Related Adverse Events in Cancer Immunotherapy. Clinics in Laboratory Medicine, 2019, 39, 669-683.	0.7	3
1930	Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?. European Journal of Cancer, 2019, 122, 72-90.	1.3	97
1931	Application Of Adoptive Immunotherapy In Ovarian Cancer . OncoTargets and Therapy, 2019, Volume 12, 7975-7991.	1.0	4
1932	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. JNCI Cancer Spectrum, 2019, 3, pkz071.	1.4	4
1933	Comprehensive immune characterization and Tâ€cell receptor repertoire heterogeneity of retroperitoneal liposarcoma. Cancer Science, 2019, 110, 3038-3048.	1.7	31
1934	Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial. Cancer Science, 2019, 110, 3049-3060.	1.7	20
1935	The role of exosomal PD-L1 in tumor progression and immunotherapy. Molecular Cancer, 2019, 18, 146.	7.9	236
1936	Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. , 2019, 7, 225.		16
1937	Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma. Molecular Medicine Reports, 2019, 20, 3773-3781.	1.1	38
1938	Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC. Molecular Therapy, 2019, 27, 1906-1918.	3.7	35
1939	Immune Checkpoints of the B7 Family. Part 1. General Characteristics and First Representatives: B7-1, B7-2, B7-H1, B7-H2, and B7-DC. Russian Journal of Bioorganic Chemistry, 2019, 45, 225-240.	0.3	6
1940	Ultrathin Metal-Organic-Layer Mediated Radiotherapy-Radiodynamic Therapy. Matter, 2019, 1, 1331-1353.	5.0	78
1941	TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Antiâ€“PD-1 Therapy in Melanoma. Cancer Immunology Research, 2019, 7, 1672-1686.	1.6	85
1942	Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. Frontiers in Immunology, 2019, 10, 2109.	2.2	32
1943	Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients. Cancer Immunology, Immunotherapy, 2019, 68, 1585-1596.	2.0	37
1944	The Diverse Function of PD-1/PD-L Pathway Beyond Cancer. Frontiers in Immunology, 2019, 10, 2298.	2.2	244

#	Article	IF	Citations
1945	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. Journal of Clinical Medicine, 2019, 8, 1534.	1.0	41
1946	LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint. Cell Death and Disease, 2019, 10, 731.	2.7	153
1947	Programmed death-ligand 1 and survival in colorectal cancers: A meta-analysis. International Journal of Biological Markers, 2019, 34, 356-363.	0.7	8
1948	Current Perspectives in Cancer Immunotherapy. Cancers, 2019, 11, 1472.	1.7	149
1949	In Vivo Administration of Recombinant Human Granulocyte Colony-Stimulating Factor Increases the Immune Effectiveness of Dendritic Cell-Based Cancer Vaccination. Vaccines, 2019, 7, 120.	2.1	9
1950	Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors. International Journal of Molecular Sciences, 2019, 20, 4654.	1.8	29
1951	Radiosurgery and Immunotherapy in the Treatment of Brain Metastases. World Neurosurgery, 2019, 130, 615-622.	0.7	13
1952	Challenges with Novel Clinical Trial Designs: Master Protocols. Clinical Cancer Research, 2019, 25, 2049-2057.	3.2	35
1953	Immune therapy of melanoma: Overview of therapeutic vaccines. Journal of Cellular Physiology, 2019, 234, 14612-14621.	2.0	25
1954	Pseudomonas Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patientâ€™s Bedside to Evaluation in Preclinical Models. Toxins, 2019, 11, 20.	1.5	37
1955	Treated Gliomas. , 2019, , 136-152.		0
1956	GITR ligation enhances functionality of tumorâ€infiltrating T cells in hepatocellular carcinoma. International Journal of Cancer, 2019, 145, 1111-1124.	2.3	42
1957	PDâ€1/PDâ€L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway. Cell Proliferation, 2019, 52, e12571.	2.4	94
1958	Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis . Cancer Management and Research, 2019, Volume 11, 3957-3969.	0.9	5
1959	Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis . OncoTargets and Therapy, 2019, Volume 12, 3671-3682.	1.0	40
1960	Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma. Journal of Controlled Release, 2019, 306, 15-28.	4.8	84
1961	Recent advances in the clinical development of immune checkpoint blockade therapy. Cellular Oncology (Dordrecht), 2019, 42, 609-626.	2.1	76
1962	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncology, The, 2019, 20, 1083-1097.	5.1	611

#	Article	IF	Citations
1963	Functional T cell activation by smart nanosystems for effective cancer immunotherapy. Nano Today, 2019, 27, 28-47.	6.2	34
1964	Targeted Gene Sequencing Panels: Applicability for Neoantigen Profiling of Colon and Rectal Adenocarcinoma. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2019, 13, 146-153.	0.2	1
1965	Immunopotentiator Aikejia improves the therapeutic efficacy of PD-1/PD-L1 immunosuppressive pathway in CT26.WT cancer cell. Journal of Cancer, 2019, 10, 3472-3480.	1.2	4
1966	PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. Journal of Translational Medicine, 2019, 17, 207.	1.8	13
1967	Checkpoint Inhibitors. Deutsches Ärzteblatt International, 2019, 116, 119-126.	0.6	83
1968	A good start of immunotherapy in esophageal cancer. Cancer Medicine, 2019, 8, 4519-4526.	1.3	67
1969	Tumor-Derived Extracellular Vesicles Inhibit Natural Killer Cell Function in Pancreatic Cancer. Cancers, 2019, 11, 874.	1.7	85
1970	Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma. Cancer Immunology, Immunotherapy, 2019, 68, 1171-1178.	2.0	48
1971	The 100 top-cited studies in cancer immunotherapy. Artificial Cells, Nanomedicine and Biotechnology, 2019, 47, 2282-2292.	1.9	26
1972	Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage IIIâ€“IV melanoma. , 2019, 7, 145.		261
1973	Cardiotoxicity of Immune Checkpoint Inhibitors. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 32.	0.4	42
1974	Immune cell therapy for hepatocellular carcinoma. Journal of Hematology and Oncology, 2019, 12, 52.	6.9	90
1975	The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors. Journal of Oncology, 2019, 2019, 1-13.	0.6	21
1976	High-Plex Predictive Marker Discovery for Melanoma Immunotherapyâ€“Treated Patients Using Digital Spatial Profiling. Clinical Cancer Research, 2019, 25, 5503-5512.	3.2	117
1977	Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles. Frontiers in Medicine, 2019, 6, 113.	1.2	25
1978	LNK suppresses interferon signaling in melanoma. Nature Communications, 2019, 10, 2230.	5.8	21
1979	Tumor suppression of novel antiâ€“PD-1 antibodies mediated through CD28 costimulatory pathway. Journal of Experimental Medicine, 2019, 216, 1525-1541.	4.2	23
1980	Development of immune checkpoint therapy for cancer. Journal of Experimental Medicine, 2019, 216, 1244-1254.	4.2	125

#	Article	IF	Citations
1981	Pembrolizumab for the Treatment of Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 143-154.	4.2	25
1982	PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?. Cancer Letters, 2019, 457, 74-85.	3.2	15
1983	Programmed cell death ligandâ€1 (PDâ€L1) expression in extrahepatic biliary tract cancers: a comparative study using 22C3, SP263 and E1L3N antiâ€PDâ€L1 antibodies. Histopathology, 2019, 75, 526-536.	1.6	17
1984	Intratumoral regulatory T cells: markers, subsets and their impact on antiâ€tumor immunity. Immunology, 2019, 157, 232-247.	2.0	79
1985	The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitorâ€"Related Thyroid Disorders. Cancer Immunology Research, 2019, 7, 1214-1220.	1.6	44
1986	Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically. Cancer Immunology Research, 2019, 7, 1064-1078.	1.6	104
1987	Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis. Progress in Retinal and Eye Research, 2019, 72, 100761.	7.3	37
1988	Baseline TSH Level is Associated with Risk of Antiâ€"PD-1â€"Induced Thyroid Dysfunction. Endocrine Practice, 2019, 25, 824-829.	1.1	31
1989	VIGLA-M: visual gene expression data analytics. BMC Bioinformatics, 2019, 20, 150.	1.2	8
1990	Immunometabolism: A new target for improving cancer immunotherapy. Advances in Cancer Research, 2019, 143, 195-253.	1.9	30
1991	Prophylactic and therapeutic strategies for Epsteinâ€"Barr virus-associated diseases: emerging strategies for clinical development. Expert Review of Vaccines, 2019, 18, 457-474.	2.0	26
1992	The nephrotoxicity of new immunotherapies. Expert Review of Clinical Pharmacology, 2019, 12, 513-521.	1.3	12
1993	Introduction to Mathematical Oncology. JCO Clinical Cancer Informatics, 2019, 3, 1-4.	1.0	23
1994	Management of immune related adverse events induced by immune checkpoint inhibition. Cancer Letters, 2019, 456, 80-87.	3.2	36
1995	CD8+ T cell exhaustion. Seminars in Immunopathology, 2019, 41, 327-337.	2.8	169
1996	Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors. Neuro-Oncology Practice, 2019, 6, 340-345.	1.0	7
1997	Co-stimulatory and co-inhibitory pathways in cancer immunotherapy. Advances in Cancer Research, 2019, 143, 145-194.	1.9	53
1998	Next-Generation Cancer Immunotherapy Targeting Glypican-3. Frontiers in Oncology, 2019, 9, 248.	1.3	86

#	Article	IF	Citations
1999	Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. , 2019, 7, 80.		65
2000	<scp>MYC</scp> in Germinal Centerâ€derived lymphomas: Mechanisms and therapeutic opportunities. Immunological Reviews, 2019, 288, 178-197.	2.8	42
2001	DEPDC1B knockdown inhibits the development of malignant melanoma through suppressing cell proliferation and inducing cell apoptosis. Experimental Cell Research, 2019, 379, 48-54.	1.2	27
2002	PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Human Vaccines and Immunotherapeutics, 2019, 15, 1111-1122.	1.4	297
2003	Combination therapy with dacarbazine and statins improved the survival rate in mice with metastatic melanoma. Journal of Cellular Physiology, 2019, 234, 17975-17989.	2.0	20
2004	Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. CNS Oncology, 2019, 8, CNS28.	1.2	169
2005	Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS ONE, 2019, 14, e0212513.	1.1	294
2006	Divergent <scp>SATB</scp>1 expression across human life span and tissue compartments. Immunology and Cell Biology, 2019, 97, 498-511.	1.0	20
2007	Surface-Functionalized Modified Copper Sulfide Nanoparticles Enhance Checkpoint Blockade Tumor Immunotherapy by Photothermal Therapy and Antigen Capturing. ACS Applied Materials & Interfaces, 2019, 11, 13964-13972.	4.0	105
2009	Targeting immune cells for cancer therapy. Redox Biology, 2019, 25, 101174.	3.9	151
2010	The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy. Trends in Immunology, 2019, 40, 292-309.	2.9	61
2011	Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma. Frontiers in Oncology, 2019, 8, 656.	1.3	32
2012	Renal toxicities associated with pembrolizumab. CKJ: Clinical Kidney Journal, 2019, 12, 81-88.	1.4	101
2013	Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer. Frontiers in Oncology, 2019, 9, 196.	1.3	44
2014	Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunology, Immunotherapy, 2019, 68, 917-926.	2.0	59
2015	A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer. Cancer Immunology Research, 2019, 7, 784-796.	1.6	141
2016	Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. Journal of Clinical Oncology, 2019, 37, 2162-2170.	0.8	202
2017	A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151). Translational Oncology, 2019, 12, 828-835.	1.7	90

#	Article	IF	Citations
2018	Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. Molecules, 2019, 24, 1190.	1.7	163
2019	Selection and expression of CD40 single chain variable fragment by phage display and evaluation of tumor specific immune activation. International Immunopharmacology, 2019, 71, 224-232.	1.7	3
2020	Oxytocin involves in chronic stress-evoked melanoma metastasis via Î²-arrestin 2-mediated ERK signaling pathway. Carcinogenesis, 2019, 40, 1395-1404.	1.3	19
2021	Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. Cancer Medicine, 2019, 8, 2146-2156.	1.3	74
2022	Growth and differentiation factor 15 regulates PD-L1 expression in glioblastoma . Cancer Management and Research, 2019, Volume 11, 2653-2661.	0.9	20
2023	Programmed Cell Deathâ€“Ligand 1 Overexpression in Thyroid Cancer. Endocrine Practice, 2019, 25, 279-286.	1.1	16
2024	Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. Advanced Healthcare Materials, 2019, 8, e1801320.	3.9	43
2025	Clinical Trial Outcomes. JACC: Heart Failure, 2019, 7, 272-273.	1.9	6
2026	The prognostic landscape of interactive biological processes presents treatment responses in cancer. EBioMedicine, 2019, 41, 120-133.	2.7	6
2027	Cardiac Complications in Immune Checkpoint Inhibition Therapy. Frontiers in Cardiovascular Medicine, 2019, 6, 3.	1.1	65
2028	Genomic Analysis of Circulating Tumor DNAÂUsing a Melanoma-Specific UltraSEEK Oncogene Panel. Journal of Molecular Diagnostics, 2019, 21, 418-426.	1.2	18
2029	Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment (Review). Oncology Letters, 2019, 17, 2583-2591.	0.8	16
2030	A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4+ T and Natural Killer Cells. Cancer Research, 2019, 79, 783-794.	0.4	14
2031	Abnormal Expression of c-Myc Oncogene in NK Cells in Patients with Cancer. International Journal of Molecular Sciences, 2019, 20, 756.	1.8	14
2032	Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells. BMC Cancer, 2019, 19, 153.	1.1	35
2033	Drug Delivery: Localized and Systemic Therapeutic Strategies with Polymer Systems. Polymers and Polymeric Composites, 2019, , 1-56.	0.6	1
2034	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1bâ€“2 trial. Lancet Oncology, The, 2019, 20, 371-382.	5.1	327
2035	Impact of Immunotherapy after Resection of Pancreatic Cancer. Journal of the American College of Surgeons, 2019, 229, 19-27.e1.	0.2	11

#	Article	IF	Citations
2036	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature Medicine, 2019, 25, 477-486.	15.2	932
2037	Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review. Current Problems in Cancer, 2019, 43, 487-494.	1.0	9
2038	Nonâ€Thermal Plasma as a Unique Delivery System of Shortâ€Lived Reactive Oxygen and Nitrogen Species for Immunogenic Cell Death in Melanoma Cells. Advanced Science, 2019, 6, 1802062.	5.6	177
2039	Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers. Thyroid, 2019, 29, 523-529.	2.4	31
2040	New Strategies for Therapeutic Cancer Vaccines. Anti-Cancer Agents in Medicinal Chemistry, 2019, 19, 213-221.	0.9	8
2041	Recent advances in nanosized drug delivery systems for overcoming the barriers to anti-PD immunotherapy of cancer. Nano Today, 2019, 29, 100801.	6.2	48
2042	Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2. JCO Clinical Cancer Informatics, 2019, 3, 1-10.	1.0	6
2043	The CCâ€² loop of IgV domains of the immune checkpoint receptors, plays a key role in receptor:ligand affinity modulation. Scientific Reports, 2019, 9, 19191.	1.6	15
2044	Odds ratio of programmed cell death-1 or ligand 1 inhibitor-related endocrine dysfunction in patients with lung cancer. Medicine (United States), 2019, 98, e18310.	0.4	2
2045	Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses In Vitro. Journal of Immunology Research, 2019, 2019, 1-12.	0.9	12
2046	Tumor PD-L1 Induction by Resveratrol/Piceatannol May Function as a Search, Enhance, and Engage (â€œSEEâ€) Signal to Facilitate the Elimination of â€œCold, Non-Responsiveâ€•Low PD-L1-Expressing Tumors by PD-L1 Blockade. International Journal of Molecular Sciences, 2019, 20, 5969.	1.8	9
2047	Immune-Mediated Colitis. Current Treatment Options in Gastroenterology, 2019, 17, 506-523.	0.3	6
2048	A DNA Aptamer Targeting Galectin-1 as a Novel Immunotherapeutic Strategy for Lung Cancer. Molecular Therapy - Nucleic Acids, 2019, 18, 991-998.	2.3	31
2049	CD4⁺ and CD8a⁺ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models. Theranostics, 2019, 9, 8221-8238.	4.6	59
2050	Melanoma. Anti-Cancer Drugs, 2019, 30, 543-553.	0.7	1
2051	Melanoma vaccines: clinical status and immune endpoints. Melanoma Research, 2019, 29, 109-118.	0.6	19
2052	Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies. Liver Cancer, 2019, 8, 413-426.	4.2	40
2053	An update on adjuvant systemic therapies in melanoma. Melanoma Management, 2019, 6, MMT28.	0.1	10

#	Article	IF	Citations
2054	Postoperative adjuvant therapy for resectable esophageal cancer. Medicine (United States), 2019, 98, e15485.	0.4	6
2055	Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. Nature Immunology, 2019, 20, 1494-1505.	7.0	83
2056	Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nature Immunology, 2019, 20, 1425-1434.	7.0	336
2057	Immunotherapy for cancer in people living with HIV. Aids, 2019, 33, F13-F19.	1.0	61
2058	BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes. , 2019, 7, 313.		67
2059	Effect and changes in PDâ€1 expression of CD19 CARâ€Ti¿½cells from Ti¿½cells highly expressing PDâ€1 combined with reducedâ€dose PDâ€1 inhibitor. Oncology Reports, 2019, 41, 3455-3463.	1.2	15
2060	Toxicities in Immune Checkpoint Inhibitors. , 2019, , 205-226.		2
2061	Immune Checkpoints. , 2019, , 19-43.		0
2062	The applications of anti-CD20 antibodies to treat various B cells disorders. Biomedicine and Pharmacotherapy, 2019, 109, 2415-2426.	2.5	43
2063	Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes. Cancer Letters, 2019, 444, 20-34.	3.2	13
2064	Promising immunotherapy: Highlighting cytokineâ€induced killer cells. Journal of Cellular Biochemistry, 2019, 120, 8863-8883.	1.2	11
2065	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. Journal of the National Cancer Institute, 2019, 111, 118-128.	3.0	49
2066	Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 199-224.	3.3	53
2067	Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus. JAMA Oncology, 2019, 5, 546.	3.4	366
2068	Immunotherapies and Novel Combinations. , 2019, , 643-653.		0
2069	Neural regulation of drug resistance in cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 20-28.	3.3	8
2070	Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. Journal of Hematology and Oncology, 2019, 12, 7.	6.9	113
2071	T-cell receptor gene-modified cells: past promises, present methodologies and future challenges. Cytotherapy, 2019, 21, 341-357.	0.3	10

#	Article	IF	Citations
2072	Tumor Microenvironmental pH and Enzyme Dual Responsive Polymer-Liposomes for Synergistic Treatment of Cancer Immuno-Chemotherapy. Biomacromolecules, 2019, 20, 882-892.	2.6	68
2073	PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers. Human Pathology, 2019, 86, 108-114.	1.1	20
2074	Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity. OncoImmunology, 2019, 8, e1539614.	2.1	17
2075	Hepatotoxicity and Recurrent NSTEMI While on Pembrolizumab for Metastatic Giant Cell Bone Tumor. American Journal of the Medical Sciences, 2019, 357, 343-347.	0.4	22
2076	Immunotherapy in pancreatic cancer: New hope or mission impossible?. Cancer Letters, 2019, 445, 57-64.	3.2	26
2077	Melanoma: Where we are and where we go. Journal of Cellular Physiology, 2019, 234, 3307-3320.	2.0	53
2078	Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer. Seminars in Immunopathology, 2019, 41, 21-30.	2.8	49
2079	Guidelines of care for the management of primary cutaneous melanoma. Journal of the American Academy of Dermatology, 2019, 80, 208-250.	0.6	400
2080	Phase Iâ€“II Trial Design for Biologic Agents Using Conditional Auto-Regressive Models for Toxicity and Efficacy. Journal of the Royal Statistical Society Series C: Applied Statistics, 2019, 68, 331-345.	0.5	5
2081	Immune checkpoint blockade resistance-related B2M hotspot mutations in microsatellite-unstable colorectal carcinoma. Pathology Research and Practice, 2019, 215, 209-214.	1.0	28
2082	Spinal cord astrocytomas: progresses in experimental and clinical investigations for developing recovery neurobiology-based novel therapies. Experimental Neurology, 2019, 311, 135-147.	2.0	16
2083	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway. Journal of Medicinal Chemistry, 2019, 62, 1715-1730.	2.9	92
2084	EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions. Gastric Cancer, 2019, 22, 486-496.	2.7	72
2085	Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies. Wiener Medizinische Wochenschrift, 2019, 169, 314-322.	0.5	5
2086	Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition. Ocular Immunology and Inflammation, 2020, 28, 217-227.	1.0	55
2087	Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events. Journal of the American Academy of Dermatology, 2020, 82, 311-316.	0.6	55
2088	The emerging role of epigenetic therapeutics in immuno-oncology. Nature Reviews Clinical Oncology, 2020, 17, 75-90.	12.5	260
2089	Response of patients with melanoma to immune checkpoint blockadeÂâ€“ insights gleaned from analysis of a new mathematical mechanistic model. Journal of Theoretical Biology, 2020, 485, 110033.	0.8	17

#	Article	IF	Citations
2090	Descriptive comparison of hospital formulary decisions with published oncology valuation methods. Journal of Oncology Pharmacy Practice, 2020, 26, 891-905.	0.5	0
2091	Advances of functional nanomaterials for cancer immunotherapeutic applications. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1574.	3.3	10
2092	Current Clinical Trials in the Treatment of Advanced Melanomas. Surgical Clinics of North America, 2020, 100, 201-208.	0.5	3
2093	Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients. Annals of Surgical Oncology, 2020, 27, 599-607.	0.7	33
2094	Techniques for the generation of humanized mouse models for immuno-oncology. Methods in Enzymology, 2020, 636, 351-368.	0.4	5
2095	Quantitative evaluation of tumor-specific T cells in tumors and lymphoid tissues. Methods in Enzymology, 2020, 635, 149-166.	0.4	4
2096	Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?. Kidney International, 2020, 97, 62-74.	2.6	121
2097	Current Immunotherapeutic Strategies in Cancer. Recent Results in Cancer Research, 2020, , .	1.8	4
2098	Current Development of Monoclonal Antibodies in Cancer Therapy. Recent Results in Cancer Research, 2020, 214, 1-70.	1.8	16
2099	Fatal Simultaneous Multi-organ Failure Following Pembrolizumab Treatment for Refractory Thymoma. Clinical Lung Cancer, 2020, 21, e74-e77.	1.1	16
2100	Combination of attenuated Salmonella carrying PDâ€1 siRNA with nifuroxazide for colon cancer therapy. Journal of Cellular Biochemistry, 2020, 121, 1973-1985.	1.2	29
2101	Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens. Journal of Cancer, 2020, 11, 41-50.	1.2	3
2102	RNA Nanotechnology-Mediated Cancer Immunotherapy. Theranostics, 2020, 10, 281-299.	4.6	100
2103	TIMâ€3: An emerging target in the liver diseases. Scandinavian Journal of Immunology, 2020, 91, e12825.	1.3	21
2104	Prevalence of NRAS Mutation, PD-L1 Expression and Amplification, and Overall Survival Analysis in 36 Primary Vaginal Melanomas. Oncologist, 2020, 25, e291-e301.	1.9	13
2105	Listeria-based hepatocellular carcinoma vaccine facilitates anti-PD-1 therapy by regulating macrophage polarization. Oncogene, 2020, 39, 1429-1444.	2.6	52
2106	Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy. CNS Drugs, 2020, 34, 127-145.	2.7	26
2107	The renal adverse effects of cancer immunotherapy. Journal of Nephrology, 2020, 33, 467-481.	0.9	6

#	Article	IF	Citations
2108	Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry. Lung Cancer, 2020, 140, 107-112.	0.9	21
2109	PD-1 Imposes Qualitative Control of Cellular Transcriptomes in Response to T Cell Activation. Molecular Cell, 2020, 77, 937-950.e6.	4.5	35
2110	Stereotactic body radiation therapy and minimally invasive surgery in the management of spinal metastases: A change in the paradigm. NeurocirugÃa (English Edition), 2020, 31, 119-131.	0.1	2
2111	Tumour associated glycans: A route to boost immunotherapy?. Clinica Chimica Acta, 2020, 502, 167-173.	0.5	24
2112	Single injection of IL-12 coacervate as an effective therapy against B16-F10 melanoma in mice. Journal of Controlled Release, 2020, 318, 270-278.	4.8	30
2113	Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer. International Journal of Gynecological Pathology, 2020, 39, 26-35.	0.9	69
2114	PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. Biomedicine and Pharmacotherapy, 2020, 121, 109625.	2.5	92
2115	Functionalization of Nanomaterials and Their Application in Melanoma Cancer Theranostics. ACS Biomaterials Science and Engineering, 2020, 6, 167-181.	2.6	28
2116	Programmed Cell Death-1/Ligand-1 PET Imaging. PET Clinics, 2020, 15, 35-43.	1.5	34
2118	CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils. International Journal of Cancer, 2020, 146, 1730-1740.	2.3	51
2119	Patched 1-interacting Peptide Represses Fibrosis in Pancreatic Cancer to Augment the Effectiveness of Immunotherapy. Journal of Immunotherapy, 2020, 43, 121-133.	1.2	15
2120	Restoration and Enhancement of Immunogenic Cell Death of Cisplatin by Coadministration with Digoxin and Conjugation to HPMA Copolymer. ACS Applied Materials & Interfaces, 2020, 12, 1606-1616.	4.0	30
2121	A promising start for checkpoint inhibitors in childhood malignancies. Lancet Oncology, The, 2020, 21, 13-14.	5.1	1
2122	Multiplex immunofluorescence staining and image analysis assay for diffuse large B cell lymphoma. Journal of Immunological Methods, 2020, 478, 112714.	0.6	38
2123	Structure and Optimization of Checkpoint Inhibitors. Cancers, 2020, 12, 38.	1.7	37
2124	Benign lymph node microenvironment is associated with response to immunotherapy. Precision Clinical Medicine, 2020, 3, 44-53.	1.3	10
2125	Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. Science Translational Medicine, 2020, 12, .	5.8	142
2126	Established fibrous peritoneal metastasis in an immunocompetent mouse model similar to clinical immune microenvironment of gastric cancer. BMC Cancer, 2020, 20, 1014.	1.1	11

#	Article	IF	Citations
2127	Bromodomain-containing protein 4 regulates interleukin-34 expression in mouse ovarian cancer cells. Inflammation and Regeneration, 2020, 40, 25.	1.5	4
2128	Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review. Immunotherapy, 2020, 12, 1303-1312.	1.0	11
2129	Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy. Molecular Therapy - Nucleic Acids, 2020, 22, 298-309.	2.3	181
2130	Programmed cell death protein 1 (PD-1)-inhibition in hepatocellular carcinoma (HCC): a single center experience. Scandinavian Journal of Gastroenterology, 2020, 55, 1057-1062.	0.6	15
2131	MicroRNAs and Their Influence on the ZEB Family: Mechanistic Aspects and Therapeutic Applications in Cancer Therapy. Biomolecules, 2020, 10, 1040.	1.8	51
2132	Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma. JAMA Oncology, 2020, 6, 1256.	3.4	38
2133	Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. Science Immunology, 2020, 5, .	5.6	36
2134	Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. Clinical Cancer Research, 2020, 26, 5153-5161.	3.2	58
2135	Tâ€cell receptor repertoire analysis for the diagnosis and treatment of solid tumor: A methodology and clinical applications. Cancer Communications, 2020, 40, 473-483.	3.7	25
2136	Analysis of singleâ€cell RNAseq identifies transitional states of T cells associated with hepatocellular carcinoma. Clinical and Translational Medicine, 2020, 10, e133.	1.7	17
2137	Selected updates in molecular and genomic pathology of esophageal cancer. Annals of the New York Academy of Sciences, 2020, 1482, 225-235.	1.8	2
2138	Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease. Seminars in Cancer Biology, 2022, 83, 57-76.	4.3	33
2139	A review of the research progress in T-lymphocyte immunity and cervical cancer. Translational Cancer Research, 2020, 9, 2026-2036.	0.4	9
2140	Machine learning: an approach to preoperatively predict PD-1/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers. ESMO Open, 2020, 5, e000910.	2.0	38
2141	Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes. Frontiers in Immunology, 2020, 11, 578877.	2.2	76
2142	Enhancing Combined Immunotherapy and Radiotherapy through Nanomedicine. Bioconjugate Chemistry, 2020, 31, 2668-2678.	1.8	13
2143	Photoâ€Enhanced CRISPR/Cas9 System Enables Robust PDâ€L1 Gene Disruption in Cancer Cells and Cancer Stemâ€Like Cells for Efficient Cancer Immunotherapy. Small, 2020, 16, e2004879.	5.2	21
2144	Identification of Sex Differences in Tumor-Specific T Cell Infiltration in Bladder Tumor-Bearing Mice Treated with BCG Immunotherapy. Bladder Cancer, 2020, 6, 507-524.	0.2	3

#	Article	IF	Citations
2145	Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (donâ€™t) know. Journal of Experimental and Clinical Cancer Research, 2020, 39, 236.	3.5	44
2146	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nature Communications, 2020, 11, 6262.	5.8	50
2147	Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma. Journal of Immunology Research, 2020, 2020, 1-9.	0.9	12
2148	Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors. Archivum Immunologiae Et Therapiae Experimentalis, 2020, 68, 36.	1.0	26
2149	Tumor-Associated CD163⁺ M2 Macrophage Infiltration is Highly Associated with PD-L1 Expression in Cervical Cancer . Cancer Management and Research, 2020, Volume 12, 5831-5843.	0.9	8
2150	Phospholipase C-like protein 2 (PLC-L2) is associated with cytolytic ability of CD8⁺ T cells and prognosis of prostate cancer. Materials Express, 2020, 10, 725-732.	0.2	0
2151	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. Journal of Autoimmunity, 2020, 114, 102514.	3.0	37
2152	Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8+ T cells in early clinical stages of chronic lymphocytic leukemia. Immunologic Research, 2020, 68, 269-279.	1.3	14
2153	Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatmentâ€”Current Progress, Strategy, and Future Perspective. Frontiers in Immunology, 2020, 11, 1508.	2.2	60
2154	Progress in Neoantigen Targeted Cancer Immunotherapies. Frontiers in Cell and Developmental Biology, 2020, 8, 728.	1.8	28
2155	Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer. Frontiers in Immunology, 2020, 11, 2039.	2.2	187
2156	Is there a link between very early changes of primary and secondary lymphoid organs in ¹⁸F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?. , 2020, 8, e000656.		21
2157	Lowâ€dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resourceâ€constrained setting. Hematological Oncology, 2020, 38, 726-736.	0.8	20
2158	Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma. OncoImmunology, 2020, 9, 1824645.	2.1	31
2159	Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma. Journal of Immunology Research, 2020, 2020, 1-12.	0.9	16
2160	RNA-electroporated T cells for cancer immunotherapy. OncoImmunology, 2020, 9, 1792625.	2.1	6
2161	The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies. Frontiers in Oncology, 2020, 10, 546604.	1.3	15
2162	Multifunctional Nanoparticles Boost Cancer Immunotherapy Based on Modulating the Immunosuppressive Tumor Microenvironment. ACS Applied Materials & Interfaces, 2020, 12, 50734-50747.	4.0	49

#	Article	IF	Citations
2163	Safety of pembrolizumab for resected stage III melanoma. Expert Opinion on Drug Safety, 2020, 19, 1221-1227.	1.0	3
2164	Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets. Cancer Biology and Medicine, 2020, 17, 583-598.	1.4	6
2165	Anti-PD-1 Therapy Does Not Influence Hearing Ability in the Most Sensitive Frequency Range, but Mitigates Outer Hair Cell Loss in the Basal Cochlear Region. International Journal of Molecular Sciences, 2020, 21, 6701.	1.8	4
2166	Critical Analysis of Non-Thermal Plasma-Driven Modulation of Immune Cells from Clinical Perspective. International Journal of Molecular Sciences, 2020, 21, 6226.	1.8	17
2167	Beyond Antoni: A Surgeon's Guide to the Vestibular Schwannoma Microenvironment. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, 001-010.	0.4	4
2168	Immunostimulatory biomaterials to boost tumor immunogenicity. Biomaterials Science, 2020, 8, 5516-5537.	2.6	11
2169	Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody. Molecular Cancer Therapeutics, 2020, 19, 2105-2116.	1.9	10
2170	Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review. Gut Pathogens, 2020, 12, 43.	1.6	43
2171	Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade. Science Translational Medicine, 2020, 12, .	5.8	34
2172	Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy . Drug Design, Development and Therapy, 2020, Volume 14, 3625-3649.	2.0	80
2173	A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies . Cancer Management and Research, 2020, Volume 12, 6493-6509.	0.9	19
2175	The Effect of Intestinal Microbiome on the Effectiveness of Antitumor Immunotherapy. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2020, 14, 241-251.	0.2	0
2176	Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. Cancers, 2020, 12, 3837.	1.7	9
2177	An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer. Nature Communications, 2020, 11, 6352.	5.8	67
2178	Targeting macrophage priming by polyphyllin VII triggers anti-tumor immunity via STING-governed cytotoxic T-cell infiltration in lung cancer. Scientific Reports, 2020, 10, 21360.	1.6	17
2179	Bone Scintigraphy in Pembrolizumab-Induced Inflammatory Arthritis. Clinical Nuclear Medicine, 2020, 45, 999-1000.	0.7	2
2180	Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges. Cancers, 2020, 12, 3173.	1.7	36
2181	TMEM205 Is an Independent Prognostic Factor and Is Associated With Immune Cell Infiltrates in Hepatocellular Carcinoma. Frontiers in Genetics, 2020, 11, 575776.	1.1	15

#	Article	IF	Citations
2182	iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and antiâ€“PD-1 therapy. Science Translational Medicine, 2020, 12, .	5.8	133
2183	Future of immune checkpoint inhibitors: focus on tumor immune microenvironment. Annals of Translational Medicine, 2020, 8, 1095-1095.	0.7	27
2184	Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 338-357.	4.2	96
2185	Clinical significance of the combined measurement of serum B7-H1 and interleukin-10 in colorectal cancer patients. Medicine (United States), 2020, 99, e20044.	0.4	3
2186	Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 687-696.	1.4	20
2187	Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. Cancer Letters, 2020, 485, 1-13.	3.2	10
2188	FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma. International Journal of Clinical Oncology, 2020, 25, 1612-1623.	1.0	19
2189	Scientifically based combination therapies with immunoâ€oncology checkpoint inhibitors. British Journal of Clinical Pharmacology, 2020, 86, 1711-1725.	1.1	6
2190	Immune Escape Mediated by Exosomal PDâ€Ł1 in Cancer. Advanced Biology, 2020, 4, e2000017.	3.0	19
2191	Adult immuno-oncology: using past failures to inform the future. Neuro-Oncology, 2020, 22, 1249-1261.	0.6	19
2192	Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?. British Journal of Clinical Pharmacology, 2020, 86, 1753-1768.	1.1	7
2193	Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle. Pharmaceutical Research, 2020, 37, 109.	1.7	23
2194	Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma. Theranostics, 2020, 10, 6530-6543.	4.6	31
2195	Myeloid Cell-Derived Arginase in Cancer Immune Response. Frontiers in Immunology, 2020, 11, 938.	2.2	249
2196	Principles of Immunotherapy in Non-Small Cell Lung Cancer. Thoracic Surgery Clinics, 2020, 30, 187-198.	0.4	19
2197	Human cancer germline antigen-specific cytotoxic T cellâ€”what can we learn from patient. Cellular and Molecular Immunology, 2020, 17, 684-692.	4.8	12
2198	Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-Î³, CXCL9 and CXCL10. , 2020, 8, e000599.		69
2199	Design, synthesis and biological evaluation of 2-methyl-(1,1â€²-biphenyl)-pyrimidine conjugates. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127328.	1.0	7

#	Article	IF	Citations
2200	Circulating immune cell phenotype dynamics reflect the strength of tumorâ€“immune cell interactions in patients during immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16072-16082.	3.3	60
2201	Primary tumor characteristics and nextâ€generation sequencing mutations as biomarkers for melanoma immunotherapy response. Pigment Cell and Melanoma Research, 2020, 33, 878-888.	1.5	5
2202	Molecular engineering of anti-PD-L1 peptide and photosensitizer for immune checkpoint blockade photodynamic-immunotherapy. Chemical Engineering Journal, 2020, 400, 125995.	6.6	36
2203	Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. Annals of Surgical Oncology, 2020, 27, 4122-4130.	0.7	7
2204	Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. , 2020, 8, e000453.		80
2205	Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study. Journal of Clinical Medicine, 2020, 9, 1769.	1.0	25
2206	Immune Cell Profiling in Cancer Using Multiplex Immunofluorescence and DigitalÂAnalysis Approaches. , 0, , .		0
2207	CTL Attenuation Regulated by PS1 in Cancer-Associated Fibroblast. Frontiers in Immunology, 2020, 11, 999.	2.2	13
2208	Use of Immuno-Oncology in Melanoma. Current Oncology, 2020, 27, 51-58.	0.9	10
2209	The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer. Cancer Immunology, Immunotherapy, 2020, 69, 2477-2499.	2.0	62
2210	Regulation of Cancer Immune Checkpoints. Advances in Experimental Medicine and Biology, 2020, , .	0.8	7
2211	Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy. Frontiers in Immunology, 2020, 11, 364.	2.2	50
2212	Fatty Acid Oxidation Controls CD8+ Tissue-Resident Memory T-cell Survival in Gastric Adenocarcinoma. Cancer Immunology Research, 2020, 8, 479-492.	1.6	116
2213	IL-18 immunoadjuvanted xenogeneic canine MMP-7 DNA vaccine overcomes immune tolerance and supresses the growth of murine mammary tumor. International Immunopharmacology, 2020, 82, 106370.	1.7	7
2214	Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials. British Journal of Cancer, 2020, 122, 1309-1314.	2.9	77
2215	Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor. Medicine (United States), 2020, 99, e19440.	0.4	3
2216	Assessing the binding properties of the anti-PD-1 antibody landscape using label-free biosensors. PLoS ONE, 2020, 15, e0229206.	1.1	21
2217	Upregulated immuno-modulator PD-L1 in malignant peripheral nerve sheath tumors provides a potential biomarker and a therapeutic target. Cancer Immunology, Immunotherapy, 2020, 69, 1307-1313.	2.0	6

#	Article	IF	Citations
2218	Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors. Current Treatment Options in Oncology, 2020, 21, 29.	1.3	11
2219	The multifarious roles of the chemokine CXCL14 in cancer progression and immune responses. Molecular Carcinogenesis, 2020, 59, 794-806.	1.3	58
2220	Intra-Tumoral Delivery of IL-27 Using Adeno-Associated Virus Stimulates Anti-tumor Immunity and Enhances the Efficacy of Immunotherapy. Frontiers in Cell and Developmental Biology, 2020, 8, 210.	1.8	16
2221	Targeting Toll-like receptor 3 in dendritic cells for cancer immunotherapy. Expert Opinion on Biological Therapy, 2020, 20, 937-946.	1.4	19
2222	Programmed cell death ligandâ€1: A dynamic immune checkpoint in cancer therapy. Chemical Biology and Drug Design, 2020, 95, 552-566.	1.5	13
2223	Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer. Frontiers in Oncology, 2020, 10, 268.	1.3	68
2224	The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer. Expert Opinion on Drug Safety, 2020, 19, 233-242.	1.0	7
2225	Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses. Science Advances, 2020, 6, eaaz4204.	4.7	136
2226	Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function. PLoS ONE, 2020, 15, e0235518.	1.1	26
2228	The Value of Gastrointestinal Biopsy. , 2020, , 1-12.		0
2229	Gastrointestinal Involvement by Systemic Disease. , 2020, , 13-29.		0
2230	Radiation and the Gastrointestinal Tract. , 2020, , 30-51.		0
2231	Transplantation, Immunodeficiency, and Immunosuppression. , 2020, , 52-64.		0
2232	Gastrointestinal Ischemia and Vascular Disorders. , 2020, , 84-101.		0
2233	Paediatric Conditions. , 2020, , 102-115.		0
2234	Gastrointestinal Dysplasia. , 2020, , 116-130.		0
2235	Histology of Gastroesophageal Reflux Disease and Barrettâ€™s Oesophagus. , 2020, , 157-167.		0
2236	Infections of the Oesophagus and Rare Forms of Oesophagitis. , 2020, , 168-178.		0

#	Article	IF	Citations
2237	Assessment of Gastric Biopsies. , 2020, , 179-185.		0
2238	Types of Gastritis. , 2020, , 186-205.		0
2240	Inflammatory Bowel Disease and the Upper Gastrointestinal Tract. , 2020, , 236-244.		0
2241	Normal Lower Gastrointestinal Mucosa. , 2020, , 245-259.		0
2242	Infectious Disorders of the Lower Gastrointestinal Tract. , 2020, , 260-286.		0
2243	Jejunitis and Ileitis. , 2020, , 287-309.		0
2244	Microscopic Colitis. , 2020, , 310-324.		1
2245	Mimics of Inflammatory Bowel Disease. , 2020, , 357-387.		1
2246	Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin. International Immunopharmacology, 2020, 86, 106759.	1.7	15
2247	Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease. Molecular Therapy - Methods and Clinical Development, 2020, 18, 532-557.	1.8	67
2248	Adverse events associated with immune checkpoint inhibitors: a new era in autoimmune diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2020, 27, 187-193.	1.2	7
2249	Early stage triple negative breast cancer: Management and future directions. Seminars in Oncology, 2020, 47, 201-208.	0.8	23
2250	When is it OK to Stop Anti-Programmed Death 1 Receptor (PD-1) Therapy in Metastatic Melanoma?. American Journal of Clinical Dermatology, 2020, 21, 313-321.	3.3	3
2251	Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers, 2020, 12, 482.	1.7	112
2252	The emerging role of precision medicine in the treatment of endometrial cancer. Expert Review of Precision Medicine and Drug Development, 2020, 5, 87-93.	0.4	1
2253	Harnessing cancer immunotherapy during the unexploited immediate perioperative period. Nature Reviews Clinical Oncology, 2020, 17, 313-326.	12.5	60
2254	Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade. Cancer Immunology Research, 2020, 8, 506-517.	1.6	23
2255	The clinical potential of gene editing as a tool to engineer cellâ€based therapeutics. Clinical and Translational Medicine, 2020, 9, 15.	1.7	56

#	Article	IF	Citations
2256	HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties. MAbs, 2020, 12, 1724751.	2.6	25
2257	Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 91.	1.3	112
2258	Bioinformatics for Cancer Immunotherapy. Methods in Molecular Biology, 2020, , .	0.4	1
2259	Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial. Cancer Immunology, Immunotherapy, 2020, 69, 847-857.	2.0	15
2260	IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. Cancer Letters, 2020, 477, 19-30.	3.2	47
2261	Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist. Clinical Imaging, 2020, 63, 35-49.	0.8	3
2262	Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy. Cell Communication and Signaling, 2020, 18, 8.	2.7	16
2263	Peptide-based targeting of immunosuppressive cells in cancer. Bioactive Materials, 2020, 5, 92-101.	8.6	41
2264	Anti-PD-1 and Novel Combinations in the Treatment of Melanomaâ€"An Update. Journal of Clinical Medicine, 2020, 9, 223.	1.0	95
2265	Inhibitory Effect of Hesperidin on the Expression of Programmed Death Ligand (PD-L1) in Breast Cancer. Molecules, 2020, 25, 252.	1.7	47
2266	Baseline derived neutrophil-to-lymphocyte ratio as a prognostic biomarker for non-colorectal gastrointestinal cancer patients treated with immune checkpoint blockade. Clinical Immunology, 2020, 212, 108345.	1.4	18
2267	Improved treatment outcome and lower skin toxicity with intensity-modulated radiotherapy vs. 3D conventional radiotherapy in anal cancer. Strahlentherapie Und Onkologie, 2020, 196, 356-367.	1.0	8
2268	Mechanisms of checkpoint inhibition-induced adverse events. Clinical and Experimental Immunology, 2020, 200, 141-154.	1.1	33
2269	Predictive biomarkers of response to immune checkpoint inhibitors in melanoma. Expert Review of Anticancer Therapy, 2020, 20, 137-145.	1.1	16
2270	Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. BioMed Research International, 2020, 2020, 1-24.	0.9	38
2271	Angiocrine endothelium: from physiology to cancer. Journal of Translational Medicine, 2020, 18, 52.	1.8	53
2272	mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand) Tj ETQq0 0 0 rgBT /Overlock	1.6	10
2273	Dendritic cell therapy in cancer treatment; the state-of-the-art. Life Sciences, 2020, 254, 117580.	2.0	91

#	Article	IF	Citations
2274	Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. , 2020, 8, e000398.		125
2275	Dendritic Cells Pre-Pulsed with Wilmsâ€™ Tumor 1 in Optimized Culture for Cancer Vaccination. Pharmaceutics, 2020, 12, 305.	2.0	7
2276	Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28. British Journal of Pharmacology, 2020, 177, 2889-2903.	2.7	10
2277	Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models. Cancer Immunology, Immunotherapy, 2020, 69, 1781-1799.	2.0	56
2278	Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care. International Immunopharmacology, 2020, 83, 106417.	1.7	31
2279	Microenvironmental Determinants of Pancreatic Cancer. Physiological Reviews, 2020, 100, 1707-1751.	13.1	156
2280	Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma. , 2020, 8, e000205.		26
2281	Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial. Clinical Cancer Research, 2020, 26, 4250-4259.	3.2	104
2282	The Great Debate at â€œMelanoma Bridgeâ€, Naples, December 7th, 2019. Journal of Translational Medicine, 2020, 18, 171.	1.8	2
2283	Chimeric antigen receptor Tâ€cell therapy toxicities. British Journal of Clinical Pharmacology, 2021, 87, 2414-2424.	1.1	19
2284	Intratumoral immunotherapy with antiâ€PDâ€1 and TLR9 agonist induces systemic antitumor immunity without accelerating rejection of cardiac allografts. American Journal of Transplantation, 2021, 21, 60-72.	2.6	4
2285	Multiple Roles for Hepatitis B and C Viruses and the Host in the Development of Hepatocellular Carcinoma. Hepatology, 2021, 73, 27-37.	3.6	23
2286	A chemical conjugation of <scp>JQ</scp>â€1 and a <scp>TLR7</scp> agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation. International Journal of Cancer, 2021, 148, 437-447.	2.3	11
2287	Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma. Future Oncology, 2021, 17, 241-254.	1.1	4
2288	Immune Checkpoint Therapies for Melanoma. Hematology/Oncology Clinics of North America, 2021, 35, 99-109.	0.9	4
2289	The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. Critical Reviews in Oncology/Hematology, 2021, 157, 103160.	2.0	26
2290	Clinical characteristics and management of immune checkpoint inhibitorâ€related pneumonitis: A singleâ€institution retrospective study. Cancer Medicine, 2021, 10, 188-198.	1.3	11
2291	Intrahepatic cholangiocarcinoma: MRI texture signature as predictive biomarkers of immunophenotyping and survival. European Radiology, 2021, 31, 3661-3672.	2.3	20

#	Article	IF	Citations
2292	Immunostimulatory nanoparticle incorporating two immune agonists for the treatment of pancreatic tumors. Journal of Controlled Release, 2021, 330, 1095-1105.	4.8	34
2293	Distinct roles of programmed death ligand 1 alternative splicing isoforms in colorectal cancer. Cancer Science, 2021, 112, 178-193.	1.7	24
2294	A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC. Journal of Thoracic Oncology, 2021, 16, 419-427.	0.5	33
2295	MS4A1 expression and function in T cells in the colorectal cancer tumor microenvironment. Cellular Immunology, 2021, 360, 104260.	1.4	23
2296	Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy. Expert Review of Anticancer Therapy, 2021, 21, 229-238.	1.1	14
2297	Finding and characterizing a catalytic antibody light chain, H34, capable of degrading the PD-1 molecule. RSC Chemical Biology, 2021, 2, 220-229.	2.0	7
2298	Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding. Protein Expression and Purification, 2021, 177, 105766.	0.6	7
2299	Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. British Journal of Cancer, 2021, 124, 359-367.	2.9	590
2300	Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. Cellular and Molecular Life Sciences, 2021, 78, 867-887.	2.4	9
2301	Intratumoral Immunotherapy: From Trial Design to Clinical Practice. Clinical Cancer Research, 2021, 27, 665-679.	3.2	69
2302	Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint. Oncotarget, 0, 7, 41274-41284.	0.8	32
2303	PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy. OncoImmunology, 2021, 10, 1912892.	2.1	25
2304	Baseline monocyte and its classical subtype may predict efficacy of PD-1/PD-L1 inhibitor in cancers. Bioscience Reports, 2021, 41, .	1.1	4
2305	Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration. Journal of Cancer, 2021, 12, 417-427.	1.2	2
2306	PD-1 and PD-L2 expression predict relapse risk and poor survival in patients with stage III colorectal cancer. Cellular Oncology (Dordrecht), 2021, 44, 423-432.	2.1	9
2307	Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data. Expert Opinion on Drug Safety, 2021, 20, 489-497.	1.0	1
2308	A snapshot of the PD-1/PD-L1 pathway. Journal of Cancer, 2021, 12, 2735-2746.	1.2	105
2309	Epigenetic modulation of immunotherapy and implications in head and neck cancer. Cancer and Metastasis Reviews, 2021, 40, 141-152.	2.7	21

#	Article	IF	Citations
2310	Dendritic cell-based immunotherapies and their potential use in colorectal cancer immunotherapy. Journal of Microscopy and Ultrastructure, 2022, 10, 107.	0.1	4
2311	Reduced CD5 on CD8+ T Cells in Tumors but Not Lymphoid Organs Is Associated With Increased Activation and Effector Function. Frontiers in Immunology, 2020, 11, 584937.	2.2	4
2312	Vincristine upregulates PD-L1 and increases the efficacy of PD-L1 blockade therapy in diffuse large B-cell lymphoma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 691-701.	1.2	7
2313	Bioinformatic analysis of PLOD family member expression and prognostic value in non-small cell lung cancer. Translational Cancer Research, 2021, 10, 2707-2724.	0.4	7
2314	Application of Next Generation Sequencing in Laboratory Medicine. Annals of Laboratory Medicine, 2021, 41, 25-43.	1.2	99
2315	YY1 expression and PD-1 regulation in CD8 T lymphocytes. , 2021, , 289-309.		1
2316	Immunotherapy vs platinum for advanced or metastatic thymic carcinoma. Medicine (United States), 2021, 100, e23802.	0.4	0
2317	Pan-Cancer Molecular Characterization of m6A Regulators and Immunogenomic Perspective on the Tumor Microenvironment. Frontiers in Oncology, 2020, 10, 618374.	1.3	28
2318	Therapeutic strategies. , 2021, , 139-154.		0
2319	KCTD12 is a prognostic marker of breast cancer and correlates with tumor immune cell infiltration. Translational Cancer Research, 2021, 10, 261-272.	0.4	1
2320	Cancer Stem Cells in the Immune Microenvironment. Advances in Experimental Medicine and Biology, 2021, 1187, 245-266.	0.8	4
2321	PD-LI Promotes Retraction Fiber Formation and Determines Persistent Cell Migration by Altering Integrin Î²4 Dynamics. SSRN Electronic Journal, 0, , .	0.4	0
2322	Single-cell transcriptome analysis of the heterogeneous effects of differential expression of tumor PD-L1 on responding TCR-T cells. Theranostics, 2021, 11, 4957-4974.	4.6	4
2323	PLEKHA4 Promotes Wnt/Î²-Catenin Signalingâ€“Mediated G1â€“S Transition and Proliferation in Melanoma. Cancer Research, 2021, 81, 2029-2043.	0.4	13
2324	Response to PD-1 Immunotherapy in Metastatic Spiradenocarcinoma. JCO Precision Oncology, 2021, 5, 340-343.	1.5	1
2325	Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy. Frontiers in Immunology, 2020, 11, 622509.	2.2	148
2326	Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1. Nature Communications, 2021, 12, 1222.	5.8	62
2327	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. European Journal of Cancer, 2021, 144, 182-191.	1.3	57

#	Article	IF	Citations
2328	Efficacy and safety of Infliximab for steroidâ€'resistant immuneâ€'related adverse events: A retrospective study. Molecular and Clinical Oncology, 2021, 14, 65.	0.4	14
2329	Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Science Translational Medicine, 2021, 13, .	5.8	54
2330	Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety. Expert Review of Anticancer Therapy, 2021, 21, 583-590.	1.1	4
2331	ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation. Journal of Clinical Investigation, 2021, 131, .	3.9	107
2332	NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy. Scientific Reports, 2021, 11, 3258.	1.6	19
2333	Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma. Frontiers in Oncology, 2020, 10, 592811.	1.3	10
2334	The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma. Journal of Gastrointestinal Oncology, 2021, 12, 1-10.	0.6	65
2335	Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment. Frontiers in Immunology, 2020, 11, 585214.	2.2	30
2336	Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes. Frontiers in Immunology, 2020, 11, 629722.	2.2	75
2337	Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate. Veterinary Immunology and Immunopathology, 2021, 232, 110169.	0.5	17
2338	Pivotal Dose of Pembrolizumab: A Doseâ€Finding Strategy for Immunoâ€Oncology. Clinical Pharmacology and Therapeutics, 2021, 110, 200-209.	2.3	17
2339	Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation. European Journal of Medicinal Chemistry, 2021, 213, 113170.	2.6	32
2340	Phenotypic and Functional Analyses Guiding Combination Immune Checkpoint Immunotherapeutic Strategies in HTLV-1 Infection. Frontiers in Immunology, 2021, 12, 608890.	2.2	8
2341	Advances in Drug Resistance of Esophageal Cancer: From the Perspective of Tumor Microenvironment. Frontiers in Cell and Developmental Biology, 2021, 9, 664816.	1.8	17
2342	Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities. Annals of Translational Medicine, 2021, 9, 423-423.	0.7	6
2343	An in vivo method for diversifying the functions of therapeutic antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	3
2344	Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies. Cancers, 2021, 13, 1123.	1.7	11
2345	N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells. , 2021, 9, e002138.		21

#	Article	IF	Citations
2346	Clinical benefit of neoadjuvant antiâ€PDâ€1/PDâ€L1 utilization among different tumors. MedComm, 2021, 2, 60-68.	3.1	16
2347	Ocular Toxicity of Targeted Anticancer Agents. Drugs, 2021, 81, 771-823.	4.9	22
2348	Complement in Tumourigenesis and the Response to Cancer Therapy. Cancers, 2021, 13, 1209.	1.7	18
2349	Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression. Case Reports in Oncology, 2021, 14, 459-465.	0.3	9
2350	Comprehensive analysis of immune-related prognostic genes in the tumour microenvironment of hepatocellular carcinoma. BMC Cancer, 2021, 21, 331.	1.1	1
2352	An inhibitor of programmed death ligand 1 enhances natural killer cell-mediated immunity against malignant melanoma cells. PLoS ONE, 2021, 16, e0248870.	1.1	3
2353	IDO1â€mediated Trpâ€kynurenineâ€AhR signal activation induces stemness and tumor dormancy in oral squamous cell carcinomas. Oral Science International, 2022, 19, 31-43.	0.3	6
2354	PD-1/PD-L1 Expression Levels and Prognostic Significance in Chronic Lymphocytic Leukemia. Acibadem Universitesi Saglik Bilimleri Dergisi, 2021, 12, .	0.0	0
2355	Ocular surface disease associated with immune checkpoint inhibitor therapy. Ocular Surface, 2021, 20, 115-129.	2.2	12
2356	Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma. Expert Review of Anticancer Therapy, 2021, 21, 693-703.	1.1	3
2357	The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers. Molecules, 2021, 26, 2201.	1.7	23
2358	The Role of Systemic Therapy in Advanced Cutaneous Melanoma of the Head and Neck. Otolaryngologic Clinics of North America, 2021, 54, 329-342.	0.5	1
2359	A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors. Journal of Medical Toxicology, 2021, 17, 411-424.	0.8	54
2360	Challenges and perspectives for immunotherapy inÂoesophageal cancer: A look to the future (Review). International Journal of Molecular Medicine, 2021, 47, .	1.8	3
2361	Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. International Journal of Molecular Sciences, 2021, 22, 4557.	1.8	34
2362	CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway. Neurotherapeutics, 2021, 18, 1980-1994.	2.1	6
2363	Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor. , 2021, 9, e002371.		44
2364	Population-Based Frequency of Ophthalmic Adverse Events in Melanoma, Other Cancers, and After Immune Checkpoint Inhibitor Treatment. American Journal of Ophthalmology, 2021, 224, 282-291.	1.7	10

#	Article	IF	Citations
2365	Envisioning the immune system to determine its role in pancreatic ductal adenocarcinoma: Culprit or victim?. Immunology Letters, 2021, 232, 48-59.	1.1	2
2366	Programmed cell death 1 as prognostic marker and therapeutic target in upper gastrointestinal cancers. Pathology Research and Practice, 2021, 220, 153390.	1.0	2
2367	Gut Microbiome as a Predictor of the Anti-PD-1 Therapy Success: Metagenomic Data Analysis. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2021, 15, 161-165.	0.2	2
2368	Systems pharmacology: a combination strategy for improving efficacy of PD-1/PD-L1 blockade. Briefings in Bioinformatics, 2021, 22, .	3.2	5
2369	Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. Journal of Experimental and Clinical Cancer Research, 2021, 40, 172.	3.5	104
2370	Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy. Journal of Medicinal Chemistry, 2021, 64, 7507-7532.	2.9	18
2371	Immu-Mela: An open resource for exploring immunotherapy-related multidimensional genomic profiles in melanoma. Journal of Genetics and Genomics, 2021, 48, 361-368.	1.7	3
2372	Noninvasive evaluation of PD-L1 expression using Copper 64 labeled peptide WL12 by micro-PET imaging in Chinese hamster ovary cell tumor model. Bioorganic and Medicinal Chemistry Letters, 2021, 40, 127901.	1.0	9
2373	Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood. , 2021, 9, e002171.		12
2374	Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor. Cancer Letters, 2021, 506, 23-34.	3.2	12
2375	Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome. Clinical and Translational Oncology, 2021, 23, 2237-2252.	1.2	7
2376	The landscape of bispecific T cell engager in cancer treatment. Biomarker Research, 2021, 9, 38.	2.8	90
2377	Chromatin accessibility governs the differential response of cancer and TÂcells to arginine starvation. Cell Reports, 2021, 35, 109101.	2.9	20
2378	The role of CD47-SIRPÎ± immune checkpoint in tumor immune evasion and innate immunotherapy. Life Sciences, 2021, 273, 119150.	2.0	45
2379	EIF3H knockdown inhibits malignant melanoma through regulating cell proliferation, apoptosis and cell cycle. Experimental Cell Research, 2021, 402, 112488.	1.2	4
2380	Systemic Therapy for Head and Neck Skin Cancers. Face, 2021, 2, 121-130.	0.1	0
2381	Nephrotoxicity of immune checkpoint inhibitor therapy: a pharmacovigilance study. Nephrology Dialysis Transplantation, 2021, , .	0.4	1
2382	Epigenetic dysregulation of immune-related pathways in cancer: bioinformatics tools and visualization. Experimental and Molecular Medicine, 2021, 53, 761-771.	3.2	8

#	Article	IF	Citations
2383	CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1. Frontiers in Immunology, 2021, 12, 673912.	2.2	14
2384	Inhibition of Polyamine Biosynthesis Using Difluoromethylornithine Acts as a Potent Immune Modulator and Displays Therapeutic Synergy With PD-1-blockade. Journal of Immunotherapy, 2021, 44, 283-291.	1.2	6
2385	Cisplatin remodels the tumor immune microenvironment via the transcription factor EB in ovarian cancer. Cell Death Discovery, 2021, 7, 136.	2.0	8
2386	CD8 ⁺ T cell immunity blocks the metastasis of carcinogen-exposed breast cancer. Science Advances, 2021, 7, .	4.7	24
2387	Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer. , 2021, 9, e002131.		27
2388	Recent achievements in CAR-T cell immunotherapy for glioblastoma treatment. Medical Immunology (Russia), 2021, 23, 483-496.	0.1	1
2389	Association of Celiac Disease With Pembrolizumab. Cureus, 2021, 13, e15565.	0.2	5
2390	Beyond the single average tumor: Understanding IO combinations using a clinical QSP model that incorporates heterogeneity in patient response. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 684-695.	1.3	7
2391	Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). Immunotherapy, 2021, 13, 727-734.	1.0	11
2393	MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING. Cancer Discovery, 2021, 11, 2726-2737.	7.7	35
2394	Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1159-1169.	1.2	13
2395	Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions. Frontiers in Immunology, 2021, 12, 680407.	2.2	68
2396	A Comparative Retrospective Study of Immunotherapy RANO Versus Standard RANO Criteria in Glioblastoma Patients Receiving Immune Checkpoint Inhibitor Therapy. Frontiers in Oncology, 2021, 11, 679331.	1.3	4
2397	Pembrolizumab for the treatment of renal cell carcinoma. Expert Opinion on Biological Therapy, 2021, 21, 1157-1164.	1.4	2
2398	Liposomes as Versatile Platform for Cancer Theranostics: Therapy, Bio-imaging, and Toxicological Aspects. Current Pharmaceutical Design, 2021, 27, 1977-1991.	0.9	7
2399	Systematic literature review for the association of biomarkers with efficacy of anti-PD-1 inhibitors in advanced melanoma. Future Oncology, 2021, 17, 2683-2692.	1.1	2
2400	Optimization of the Administration Strategy for the Armed Oncolytic Adenovirus ZD55-IL-24 in Both Immunocompromised and Immunocompetent Mouse Models. Human Gene Therapy, 2021, , .	1.4	3
2401	Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nature Reviews Drug Discovery, 2022, 21, 495-508.	21.5	120

#	Article	IF	Citations
2402	Gut Microbiota in Cancer Immune Response and Immunotherapy. Trends in Cancer, 2021, 7, 647-660.	3.8	136
2403	Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using bi-Specific Antibodies and Therapeutic Vaccines. Biological Procedures Online, 2021, 23, 13.	1.4	17
2404	Trailblazing perspectives on targeting breast cancer stem cells. , 2021, 223, 107800.		20
2405	Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy. Frontiers in Immunology, 2021, 12, 665002.	2.2	1
2406	Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. Frontiers in Pharmacology, 2021, 12, 714483.	1.6	9
2407	Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry, 2022, 65, 1008-1046.	2.9	28
2408	High-affinity decoy PD-1 mutant screened from an epitope-specific cell library. Engineering, 2021, , .	3.2	1
2409	Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 655152.	1.8	85
2410	Inhibitors of immune checkpointsâ€”PD-1, PD-L1, CTLA-4â€”new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer and Metastasis Reviews, 2021, 40, 949-982.	2.7	72
2411	Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis. PLoS ONE, 2021, 16, e0255716.	1.1	17
2412	Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma. International Journal of Oral Science, 2021, 13, 24.	3.6	107
2413	TrendyGenes, a computational pipeline for the detection of literature trends in academia and drug discovery. Scientific Reports, 2021, 11, 15747.	1.6	4
2414	Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer. World Journal of Gastroenterology, 2021, 27, 5362-5375.	1.4	17
2415	Implantable optical fibers for immunotherapeutics delivery and tumor impedance measurement. Nature Communications, 2021, 12, 5138.	5.8	28
2416	Strategies to Improve the Antitumor Effect of Î³Î´ T Cell Immunotherapy for Clinical Application. International Journal of Molecular Sciences, 2021, 22, 8910.	1.8	18
2417	Synchronizing the use of allogeneic hematopoietic cell transplantation in checkpoint blockade therapy for Hodgkin lymphoma. Expert Review of Hematology, 2021, 14, 809-818.	1.0	1
2418	Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy. Frontiers in Oncology, 2021, 11, 727433.	1.3	57
2419	Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management. Expert Review of Anticancer Therapy, 2021, 21, 1211-1228.	1.1	1

#	Article	IF	Citations
2420	Identification of immune-related subtypes of colorectal cancer to improve antitumor immunotherapy. Scientific Reports, 2021, 11, 19432.	1.6	6
2421	PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma. International Immunopharmacology, 2021, 98, 107870.	1.7	13
2422	A Redoxâ€Responsive Nanovaccine Combined with A2A Receptor Antagonist for Cancer Immunotherapy. Advanced Healthcare Materials, 2021, 10, e2101222.	3.9	23
2423	Anticancer Activities of Hesperidin via Suppression of Up-Regulated Programmed Death-Ligand 1 Expression in Oral Cancer Cells. Molecules, 2021, 26, 5345.	1.7	15
2424	Advanced nanomedicine approaches applied for treatment of skin carcinoma. Journal of Controlled Release, 2021, 337, 589-611.	4.8	41
2425	Nivolumab exposure in a hemodialysis patient with metastatic melanoma. Melanoma Research, 2021, 31, 579-581.	0.6	3
2426	Prospects for the Global Elimination of Hepatitis B. Annual Review of Virology, 2021, 8, 437-458.	3.0	26
2427	Engineering Nanorobots for Tumorâ€Targeting Drug Delivery: From Dynamic Control to Stimuliâ€Responsive Strategy. ChemBioChem, 2021, 22, 3369-3380.	1.3	10
2428	Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab. Annals of Oncology, 2021, 32, 1618-1625.	0.6	15
2429	<scp>IgG4</scp>â€related disease is characterised by the overexpression of immunomodulatory proteins. Histopathology, 2022, 81, 486-495.	1.6	1
2430	Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. Cell Reports, 2021, 36, 109699.	2.9	37
2431	Identification of Mutation Landscape and Immune Cell Component for Liver Hepatocellular Carcinoma Highlights Potential Therapeutic Targets and Prognostic Markers. Frontiers in Genetics, 2021, 12, 737965.	1.1	4
2432	A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2021, 19, 434-446.	0.9	16
2433	Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study. Surgery Open Science, 2021, 6, 10-14.	0.5	4
2434	Immune checkpoints and reproductive immunology: Pioneers in the future therapy of infertility related Disorders?. International Immunopharmacology, 2021, 99, 107935.	1.7	19
2435	miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer. Cancer Letters, 2021, 518, 115-126.	3.2	34
2436	Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2021, 100, 102280.	3.4	10
2437	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. European Journal of Cancer, 2021, 157, 391-402.	1.3	13

#	Article	IF	Citations
2438	An evidence mapping and scientometric analysis of the top-100 most cited clinical trials of anti-PD-1/PD-L1 drugs to treat cancers. Biomedicine and Pharmacotherapy, 2021, 143, 112238.	2.5	7
2439	Ocular side effects of checkpoint inhibitors. Survey of Ophthalmology, 2021, 66, 951-959.	1.7	16
2440	The Tumor Infiltrating Lymphocytes (TILs): Did We Find the Missed Piece of the Huge Puzzle?. Open Journal of Obstetrics and Gynecology, 2021, 11, 146-161.	0.1	2
2441	Immunotyping and Quantification of Melanoma Tumorâ€“Infiltrating Lymphocytes. Methods in Molecular Biology, 2021, 2265, 515-528.	0.4	2
2442	Proteomic approaches to investigate gammaherpesvirus biology and associated tumorigenesis. Advances in Virus Research, 2021, 109, 201-254.	0.9	0
2443	Macrophage contributes to radiation-induced anti-tumor abscopal effect on transplanted breast cancer by HMGB1/TNF-Î± signaling factors. International Journal of Biological Sciences, 2021, 17, 926-941.	2.6	17
2444	Gut Microbiome and Drug Metabolism. Biomedical Chemistry Research and Methods, 2021, 4, e00146.	0.1	1
2445	Hypertrophic Lichen Planusâ€“like Eruption Following Pembrolizumab. , 2021, 107, E10-E11.		4
2446	Computational Deconvolution of Tumor-Infiltrating Immune Components with Bulk Tumor Gene Expression Data. Methods in Molecular Biology, 2020, 2120, 249-262.	0.4	18
2447	Targeted Therapies in Melanoma. Current Clinical Pathology, 2015, , 211-227.	0.0	4
2448	Integrating Molecular Biomarkers into Current Clinical Management in Melanoma. Methods in Molecular Biology, 2014, 1102, 27-42.	0.4	7
2449	The Era of Checkpoint Inhibition: Lessons Learned from Melanoma. Recent Results in Cancer Research, 2020, 214, 169-187.	1.8	7
2450	The Immune System and Pathogenesis of Melanoma and Non-melanoma Skin Cancer. Advances in Experimental Medicine and Biology, 2020, 1268, 211-226.	0.8	11
2451	Recent Advances in Skin Cancer Treatment in Older Adults. , 2015, , 97-103.		1
2452	MedikamentÃ¶se Tumortherapie in der Dermato-Onkologie. , 2014, , .		2
2453	Melanocytic Tumors. , 2014, , 1-3.		1
2454	Melanoma: From Tumor-Specific Mutations to a New Molecular Taxonomy and Innovative Therapeutics. , 2015, , 7-27.		2
2455	Antibody Therapies in Cancer. Advances in Experimental Medicine and Biology, 2016, 909, 1-67.	0.8	8

#	Article	IF	Citations
2456	Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. Advances in Experimental Medicine and Biology, 2020, 1248, 33-59.	0.8	232
2457	Mechanisms of Resistance to Checkpoint Blockade Therapy. Advances in Experimental Medicine and Biology, 2020, 1248, 83-117.	0.8	22
2458	Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy. Advances in Experimental Medicine and Biology, 2020, 1248, 143-166.	0.8	3
2459	Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists. Abdominal Radiology, 2020, 45, 2624-2636.	1.0	8
2460	Biologics and Their Interactions with Radiation. , 2012, , 83-94.		1
2461	Single-Cell RNA Sequencing Reveals a Dynamic Stromal Niche That Supports Tumor Growth. Cell Reports, 2020, 31, 107628.	2.9	186
2462	Radioterapia estreotÃ¡xica corporal y cirugÃa mÃnimamente invasiva en el manejo de las metÃ¡stasis espinales: un cambio de paradigma. Neurocirugia, 2020, 31, 119-131.	0.2	5
2463	MÃ©lanome â€" ThÃ©rapeutique par les mÃ©dications : anticorps anti-CTLA-4 et anti-PD1. Bulletin De L'Academie Nationale De Medecine, 2014, 198, 297-308.	0.0	4
2464	Translating current basic research into future therapies for neurofibromatosis type 1. British Journal of Cancer, 2020, 123, 178-186.	2.9	17
2465	Dramatic enhancement of the detection limits of bioassays via ultrafast deposition of polydopamine. Nature Biomedical Engineering, 2017, 1, .	11.6	93
2466	p110Î´ PI3K as a therapeutic target of solid tumours. Clinical Science, 2020, 134, 1377-1397.	1.8	15
2467	PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2. Journal of Cell Biology, 2020, 219, .	2.3	65
2468	An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgeryâ€"the BUMPER study. Neuro-Oncology Advances, 2020, 2, vdaa140.	0.4	6
2469	PD-L1 Expression in Extramammary Paget Disease: A Case Series. American Journal of Dermatopathology, 2021, 43, 21-26.	0.3	2
2470	The Role of Pembrolizumab in the Treatment of Sebaceous Carcinoma. International Ophthalmology Clinics, 2020, 60, 39-46.	0.3	4
2471	Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression. International Journal of Gynecological Pathology, 2021, 40, 148-155.	0.9	7
2478	Programmed Cell Death 1-Directed Immunotherapy for Enhancing T-Cell Function. Cold Spring Harbor Symposia on Quantitative Biology, 2013, 78, 239-247.	2.0	38
2479	Macrophage targeting in cancer. Annals of the New York Academy of Sciences, 2021, 1499, 18-41.	1.8	134

#	Article	IF	Citations
2480	Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. BMJ Case Reports, 2015, 2015, bcr2014208102.	0.2	38
2481	Effectiveness of Immunotherapies from Oyster Mushroom (Pleurotus species) in the Management of Immunocompromised Patients. International Journal of Immunology, 2015, 3, 8.	0.2	17
2482	Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3â€“CD8+ T cells. JCI Insight, 2020, 5, .	2.3	30
2483	Lymphocyte activation gene 3 and coronary artery disease. JCI Insight, 2016, 1, e88628.	2.3	32
2484	Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. JCI Insight, 2017, 2, .	2.3	62
2485	IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy. JCI Insight, 2018, 3, .	2.3	42
2486	Oncolytic viruses: overcoming translational challenges. Journal of Clinical Investigation, 2019, 129, 1407-1418.	3.9	70
2487	Pembrolizumab plus allogeneic NK cells in advanced nonâ€“small cell lung cancer patients. Journal of Clinical Investigation, 2020, 130, 2560-2569.	3.9	77
2488	Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity. Journal of Clinical Investigation, 2017, 127, 2725-2738.	3.9	75
2489	Dinaciclib induces immunogenic cell death and enhances anti-PD1â€“mediated tumor suppression. Journal of Clinical Investigation, 2018, 128, 644-654.	3.9	144
2490	Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. Journal of Clinical Investigation, 2018, 128, 4654-4668.	3.9	591
2491	Bibliometric Analysis of Tumor Immunotherapy Studies. Medical Science Monitor, 2018, 24, 3405-3414.	0.5	34
2492	Current options and future directions in the systemic treatment of metastatic melanoma. Journal of Community and Supportive Oncology, 2014, 12, 20-26.	0.1	5
2493	Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM). PLoS ONE, 2015, 10, e0121071.	1.1	185
2494	Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection. PLoS ONE, 2015, 10, e0124590.	1.1	9
2495	Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model. PLoS ONE, 2015, 10, e0129237.	1.1	17
2496	Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110. PLoS ONE, 2015, 10, e0141669.	1.1	19
2497	Modulating glioma-mediated myeloid-derived suppressor cell development with sulforaphane. PLoS ONE, 2017, 12, e0179012.	1.1	60

#	Article	IF	Citations
2498	Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors. PLoS ONE, 2018, 13, e0193832.	1.1	74
2499	TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. PLoS Pathogens, 2016, 12, e1005349.	2.1	271
2500	Novel Therapies in AML: Reason for Hope or Just Hype?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e341-e351.	1.8	10
2501	Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma. Journal of Clinical Medicine Research, 2016, 8, 63-75.	0.6	49
2502	Dendritic Cell-Based Cancer Immunotherapy Targeting Wilmsâ€™ Tumor 1 for Pediatric Cancer. , 0, , 113-130.		2
2503	Immuno-oncology: new possibilities of drug therapy for solid tumors. Onkologiya Zhurnal Imeni P A Gertsena, 2017, 6, 74.	0.0	3
2504	Avelumab inducing hypothyroidism and hypoadrenalism: A case report and review of literature. EXCLI Journal, 2018, 17, 526-530.	0.5	6
2505	Targeted Therapy for Cutaneous Melanoma: Beyond BRAF.... Journal of Patient-centered Research and Reviews, 2014, 1, 12-20.	0.6	3
2506	Nanoparticulate system for cancer therapy: An updated review. International Journal of Nanomaterials Nanotechnology and Nanomedicine, 2018, 4, 022-034.	0.2	4
2508	Romo1 is involved in the immune response of glioblastoma by regulating the function of macrophages. Aging, 2020, 12, 1114-1127.	1.4	16
2509	PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget, 2016, 7, 72961-72977.	0.8	258
2510	Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. Oncotarget, 2017, 8, 8807-8817.	0.8	68
2511	The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis. Oncotarget, 2016, 7, 81493-81511.	0.8	14
2512	The role of tumor microenvironment in therapeutic resistance. Oncotarget, 2017, 8, 3933-3945.	0.8	189
2513	PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients. Oncotarget, 2017, 8, 50782-50791.	0.8	10
2514	Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. Oncotarget, 2017, 8, 43555-43570.	0.8	10
2515	Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. Oncotarget, 2017, 8, 41242-41255.	0.8	89
2516	Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine?. Oncotarget, 2017, 8, 66601-66619.	0.8	22

#	Article	IF	Citations
2517	Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: a case report and literature review. Oncotarget, 2017, 8, 96453-96459.	0.8	8
2518	Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget, 2018, 9, 10284-10293.	0.8	44
2519	Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer. Oncotarget, 2018, 9, 5652-5664.	0.8	105
2520	Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. Oncotarget, 2018, 9, 25586-25596.	0.8	66
2521	PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma. Oncotarget, 2015, 6, 3479-3492.	0.8	146
2522	Hypomethylation and up-regulation ofPD-1in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation. Oncotarget, 2015, 6, 9612-9626.	0.8	166
2523	Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma. Oncotarget, 2015, 6, 11139-11149.	0.8	89
2524	ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget, 2015, 6, 22348-22360.	0.8	12
2525	Analysis of SDHD promoter mutations in various types of melanoma. Oncotarget, 2015, 6, 25868-25882.	0.8	9
2526	Extracting tumor tissue immune status from expression profiles: correlating renal cancer prognosis with tumor-associated immunome. Oncotarget, 2015, 6, 33191-33205.	0.8	3
2527	The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response. Oncotarget, 2016, 7, 29794-29803.	0.8	48
2528	Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy. Oncotarget, 0, 7, 42698-42715.	0.8	34
2529	New drugs: Pembrolizumab. Australian Prescriber, 2015, 38, 180-182.	0.5	2
2530	Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma. Cancer Biology and Medicine, 2020, 17, 555-568.	1.4	14
2531	What does the future hold for immunotherapy in cancer?. Annals of Translational Medicine, 2016, 4, 177-177.	0.7	9
2532	The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics. Annals of Translational Medicine, 2016, 4, 267-267.	0.7	17
2533	Melanoma immunotherapy dominates the field. Annals of Translational Medicine, 2016, 4, 269-269.	0.7	19
2534	Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). Chinese Clinical Oncology, 2016, 5, 57-57.	0.4	46

#	Article	IF	Citations
2535	Immunotherapy for nasopharyngeal cancerâ€"a review. Chinese Clinical Oncology, 2016, 5, 22-22.	0.4	60
2536	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. Translational Lung Cancer Research, 2018, 7, 428-436.	1.3	7
2537	Non-Classical Estrogen Signaling Inhibits Melanoma and Improves Response to PD-1 Blockade. SSRN Electronic Journal, 0, , .	0.4	1
2538	Efekt abskopalny â€" mechanizm i znaczenie we wspÃ³Å‚czesnej radioterapii.. Letters in Oncology Science, 2018, 15, 1-5.	0.8	4
2539	Nanoparticles in Melanoma. Current Medicinal Chemistry, 2014, 21, 3701-3716.	1.2	7
2540	Cancer Biomarker Discovery for Precision Medicine: New Progress. Current Medicinal Chemistry, 2020, 26, 7655-7671.	1.2	51
2541	Targeting PD-L1 Protein: Translation, Modification and Transport. Current Protein and Peptide Science, 2018, 20, 82-91.	0.7	20
2542	Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature. Recent Patents on Anti-Cancer Drug Discovery, 2019, 14, 100-112.	0.8	16
2543	Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 768-776.	0.9	6
2544	Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 1415-1430.	0.9	3
2545	The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art. Current Radiopharmaceuticals, 2020, 13, 24-31.	0.3	6
2546	The Positive Relationship Between Î³H2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma. In Vivo, 2018, 32, 171-177.	0.6	10
2547	Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents. Safety and Risk of Pharmacotherapy, 2020, 8, 9-22.	0.1	10
2548	The evolution of surgical management for vertebral column tumors. Journal of Neurosurgery: Spine, 2019, 30, 417-423.	0.9	15
2549	The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy Including Immuno-Checkpoint Inhibitors. Physiological Research, 2016, 65, S455-S462.	0.4	24
2550	Microenvironment-Dependent Gradient of CTL Exhaustion in the AE17sOVA Murine Mesothelioma Tumor Model. Frontiers in Immunology, 2019, 10, 3074.	2.2	6
2551	Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy. Frontiers in Oncology, 2019, 9, 263.	1.3	62
2553	The Impact of Immunological Checkpoint Inhibitors and Targeted Therapy on Chronic Pruritus in Cancer Patients. Biomedicines, 2021, 9, 2.	1.4	3

#	Article	IF	Citations
2554	The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options. Cancers, 2015, 7, 1154-1177.	1.7	20
2555	Immune evasion strategies used byHelicobacter pylori. World Journal of Gastroenterology, 2014, 20, 12753.	1.4	92
2556	Promises and paradoxes of regulatory T cells in inflammatory bowel disease. World Journal of Gastroenterology, 2015, 21, 11236.	1.4	48
2557	Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 748.	1.4	16
2558	Personalized medicine in gastric cancer: Where are we and where are we going?. World Journal of Gastroenterology, 2016, 22, 1160.	1.4	37
2559	Role of Tim-3 in hepatitis B virus infection: An overview. World Journal of Gastroenterology, 2016, 22, 2294-2303.	1.4	33
2560	Readerâ€'free ELISPOT assay for immunoâ€'monitoring in peptideâ€'based cancer vaccine immunotherapy. Biomedical Reports, 2020, 12, 244-250.	0.9	5
2561	Gene silencing of indoleamine 2,3â€'dioxygenase 1 inhibits lung cancer growth by suppressing Tâ€'cell exhaustion. Oncology Letters, 2020, 19, 3827-3838.	0.8	7
2562	Elevated levels of ILâ€'17A and ILâ€'35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with nonâ€'small cell lung cancer. Oncology Letters, 2020, 20, 611-622.	0.8	34
2563	New Systemic Treatment for Malignant Melanoma. Korean Journal of Medicine, 2013, 85, 357.	0.1	3
2564	Current status of novel agents in advanced gastroesophageal adenocarcinoma. Journal of Gastrointestinal Oncology, 2015, 6, 60-74.	0.6	19
2565	Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. Journal of Gastrointestinal Oncology, 2015, 6, 561-9.	0.6	61
2566	New therapeutic strategies for BRAF mutant colorectal cancers. Journal of Gastrointestinal Oncology, 2015, 6, 650-9.	0.6	21
2567	The past, present and future of immunotherapy against tumor. Translational Lung Cancer Research, 2015, 4, 253-64.	1.3	34
2568	Lung cancer biomarkers, targeted therapies and clinical assays. Translational Lung Cancer Research, 2015, 4, 503-14.	1.3	23
2569	Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Translational Lung Cancer Research, 2015, 4, 560-75.	1.3	303
2570	Genotyping of cutaneous melanoma. Chinese Clinical Oncology, 2014, 3, 27.	0.4	17
2571	Checkpoint inhibitors in the treatment of cutaneous malignant melanoma. Chinese Clinical Oncology, 2014, 3, 30.	0.4	6

#	Article	IF	Citations
2572	Treatment algorithm of metastatic mucosal melanoma. Chinese Clinical Oncology, 2014, 3, 38.	0.4	16
2573	Systemic therapies for melanoma brain metastases: which drug for whom and when?. Chinese Clinical Oncology, 2015, 4, 25.	0.4	20
2574	Predictive factors for immunotherapy in melanoma. Annals of Translational Medicine, 2015, 3, 208.	0.7	27
2575	Melanoma: oncogenic drivers and the immune system. Annals of Translational Medicine, 2015, 3, 265.	0.7	19
2576	Immune checkpoint inhibitors: therapeutic advances in melanoma. Annals of Translational Medicine, 2015, 3, 267.	0.7	47
2577	Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). Annals of Translational Medicine, 2015, 3, 322.	0.7	32
2578	Immune based therapy for melanoma. Indian Journal of Medical Research, 2016, 143, 135.	0.4	19
2579	Immune Checkpoint Blockers and Ovarian Cancer. Indian Journal of Medical and Paediatric Oncology, 2017, 38, 182-189.	0.1	4
2580	Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. Cancer Research and Treatment, 2017, 49, 246-254.	1.3	158
2581	Novel therapy for advanced gastric cancer. World Journal of Gastrointestinal Oncology, 2015, 7, 263.	0.8	6
2582	Is metastatic pancreatic cancer an untargetable malignancy?. World Journal of Gastrointestinal Oncology, 2016, 8, 297.	0.8	8
2583	Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. World Journal of Hepatology, 2015, 7, 980.	0.8	35
2584	Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. World Journal of Gastrointestinal Pathophysiology, 2019, 10, 17-28.	0.5	26
2585	Cancer immunology â€“ development of novel anti-cancer therapies. Swiss Medical Weekly, 2015, 145, w14066.	0.8	18
2586	Current status of cancer immunotherapy. Journal of Stem Cells and Regenerative Medicine, 2014, 10, 8-13.	2.2	17
2587	Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations. World Journal of Clinical Oncology, 2017, 8, 230.	0.9	52
2588	Novel anti-melanoma treatment: focus on immunotherapy. Chinese Journal of Cancer, 2014, 33, 458-465.	4.9	11
2589	Cancer immunotherapy in clinical practiceï¿½ï¿½the past, present, and future. Chinese Journal of Cancer, 2014, 33, 445-457.	4.9	38

#	Article	IF	Citations
2590	Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer. Journal of the Advanced Practitioner in Oncology, 2014, 5, 418-31.	0.2	48
2591	Pembrolizumab: First in Class for Treatment of Metastatic Melanoma. Journal of the Advanced Practitioner in Oncology, 2015, 6, 234-8.	0.2	3
2592	Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, S-1-S-5.	2.3	5
2593	Immune Checkpoint Inhibitors: Therapeutic Tools for Breast Cancer. Asian Pacific Journal of Cancer Prevention, 2016, 17, 905-910.	0.5	23
2594	Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints. Cancer Biology and Medicine, 2015, 12, 79-86.	1.4	28
2595	Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biology and Medicine, 2015, 12, 201-8.	1.4	67
2596	Cancer systems immunology. ELife, 2020, 9, .	2.8	14
2597	Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab. Cureus, 2016, 8, e631.	0.2	20
2598	Current Treatment Modalities Targeting Tumor Microenvironment in Castration-Resistant Prostate Cancer. Advances in Experimental Medicine and Biology, 2021, 1329, 295-323.	0.8	5
2599	Identification of Immune Subtypes for Predicting the Prognosis of Patients in Head and Neck Squamous Cell Carcinoma. Technology in Cancer Research and Treatment, 2021, 20, 153303382110458.	0.8	2
2601	Personalized gel-droplet monocyte vaccines for cancer immunotherapy. Lab on A Chip, 2021, 21, 4414-4426.	3.1	8
2602	Programmed death (PD)â€1/PDâ€ligand 1 blockade mediates antiangiogenic effects by tumorâ€derived CXCL10/11 as a potential predictive biomarker. Cancer Science, 2021, 112, 4853-4866.	1.7	6
2603	Metabolic regulation by PD-1 signaling promotes long-lived quiescent CD8 T cell memory in mice. Science Translational Medicine, 2021, 13, eaba6006.	5.8	33
2604	Multiplexed imaging reveals an IFN-Î³-driven inflammatory state in nivolumab-associated gastritis. Cell Reports Medicine, 2021, 2, 100419.	3.3	9
2605	Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy. Expert Review of Anticancer Therapy, 2021, 21, 1355-1370.	1.1	6
2606	Nanomedicines in B cell-targeting therapies. Acta Biomaterialia, 2022, 137, 1-19.	4.1	9
2607	Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach. , 2021, 9, e002545.		12
2608	Structureâ€“activity relationship and biological evaluation of 12ÂN-substituted aloperine derivatives as PD-L1 down-regulatory agents through proteasome pathway. Bioorganic Chemistry, 2021, 117, 105432.	2.0	1

#	Article	IF	Citations
2609	Nivolumab with Vaccine in Ipilimumab-Refractory or -Naive Melanoma. Journal of Vaccines & Vaccination, 2013, 04, .	0.3	0
2610	Melanom. , 2014, , 31-97.		0
2611	Immunotherapy of Malignant Melanoma. , 2014, , 139-154.		0
2612	Projections: Novel Therapies for HPV-Negative Cancers of the Head and Neck. , 2014, , 343-359.		0
2613	Cancer Immunotherapy: The Dawn of the Renaissance after the Medieval Dark Ages. Korean Journal of Medicine, 2014, 87, 284.	0.1	1
2614	BO-110, a dsRNA-Based Anticancer Agent. Advances in Delivery Science and Technology, 2014, , 453-470.	0.4	0
2615	Immunotherapy and Hepatocellular Carcinoma. Journal of Liver, 2014, 3, .	0.3	0
2616	How T Cells Single Out Tumor Cells: â€œAnd That Has Made All the Differenceâ€¦â€•, 2014, , 13-20.		0
2617	Prostate Cancer Vaccines Generated with the Disruptive RNActiveÂ® Technology Follow the Path Paved by Sipuleucel-T and Prostvac-VF. , 2014, , 155-169.		0
2618	Melanoma. Part II. Personalized Medicine: Using Molecular Tools to Guide Targeted Therapy. , 2014, , 97-131.		1
2619	Melanocytic Tumors. , 2014, , 2702-2704.		0
2620	Current Status of Immunotherapy in Gastroesophageal Cancer. , 2014, , 179-191.		0
2622	Melanoma: Historical Context. Cancer Drug Discovery and Development, 2015, , 1-23.	0.2	0
2623	Inflammation and Lung Cancer: Addressing Inflammation with Immunotherapy. , 2015, , 191-209.		0
2624	Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies. AIMS Public Health, 2015, 2, 86-114.	1.1	1
2625	T Cell Blockade Immunotherapy Against Cancer and Abscopal Effect in Combination Therapy. Cancer Drug Discovery and Development, 2015, , 211-229.	0.2	0
2626	Recent Updates in Cancer Immunotherapy. Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2015, 58, 449.	0.0	1
2627	Role of Co-inhibitory Molecules in Tumor Escape from CTL Attack. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 31-58.	0.1	0

#	Article	IF	Citations
2628	T Cell Modulation: Anti-PD-1 Antibodies for the Treatment of Cancer. Cancer Drug Discovery and Development, 2015, , 231-244.	0.2	0
2629	Progress in Clinical Use of CC Chemokine Receptor 4 Antibody for Regulatory T Cell Suppression. , 2015, , 207-227.		1
2630	Clinical Approach to Advanced Melanoma for Today and Tomorrow. , 2015, , 637-662.		0
2631	Ewolucja systemowego leczenia przeciwnowotworowego. Nowotwory, 2015, 65, 1-6.	0.1	0
2632	T Cell Tuning for Tumour Therapy: Enhancing Effector Function and Memory Potential of Therapeutic T cells. Current Gene Therapy, 2015, 15, 289-299.	0.9	0
2633	Managing Advanced Melanoma: Targeting the PD-1 Pathway with Pembrolizumab. Cancer Research Frontiers, 2015, 1, 127-137.	0.2	0
2634	Melanoma and immunotherapy. , 2015, , 199-212.		0
2636	Improving of Antitumor Immunity and Therapeutic Efficacy of Cancer Vaccines and Adoptive Immunotherapies Using Monoclonal Antibodies. MOJ Immunology, 2015, 2, .	11.0	0
2637	Immunotherapy in Melanoma. , 2016, , 207-236.		0
2639	The Long-Term Endocrine Sequelae of Multimodality Cancer Therapy. , 2016, , 1799-1832.		0
2641	Kutane Nebenwirkungen neuer Krebsmedikamente. , 2016, , 305-312.		0
2642	Targeted Cancer Therapy. Nishinihon Journal of Dermatology, 2016, 78, 221-228.	0.0	0
2643	Fast-track drug approval in inflammatory bowel diseases. Annals of Gastroenterology, 2016, 29, 439-444.	0.4	4
2644	T Cells. , 2016, , 57-94.		0
2645	Primary Mucosal Melanomas of the Head and Neck. , 2016, , 641-656.		0
2646	CD8 T Cells. , 2016, , 1-12.		0
2647	Controversies in the Surgical Management of Melanoma. , 2016, , 159-184.		0
2648	Impact of Comorbidity on Treatment Decision Making and Outcomes. , 2016, , 131-158.		0

#	Article	IF	Citations
2649	Risk of Musculoskeletal Complications in Cancer Patients Treated with Nivolumab. Immunotherapy (Los Angeles, Calif), 2016, 2, .	0.1	0
2650	Aiming the Immune System to Improve the Antitumor Efficacy of Radiation Therapy. , 2016, , 159-181.		0
2651	Head and Neck Cutaneous Melanoma. , 2016, , 657-663.		0
2652	Reinstating endogenous antitumor immunity: The concept of therapeutic management of cancer. Forum of Clinical Oncology, 2016, 7, 4-16.	0.1	0
2653	How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know. Journal of the Advanced Practitioner in Oncology, 2016, 7, .	0.2	3
2656	Malignant Melanoma in the Adolescent and Young Adult (AYA) Population. Pediatric Oncology, 2017, , 231-267.	0.5	0
2657	Monoclonal Antibodies in Pediatric Acute Lymphoblastic Leukemia. , 2017, , 201-237.		0
2658	Development of Cancer Vaccine and Targeted Immune Checkpoint Therapies. , 2017, , 225-241.		0
2659	T Cell Immune Responses in Skin. , 2017, , 121-135.		0
2660	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. , 2017, , 1-45.		0
2661	Immune Checkpoint Inhibitors in Melanoma Define a New Era in Immunotherapy Aiming for Cure. , 2017, , 427-436.		0
2662	A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy. SOJ Immunology, 2017, 5, 1-5.	0.2	0
2664	Advanced Care Provider and Nursing Approach to Assessment and Management of Immunotherapy-Related Dermatologic Adverse Events. Journal of the Advanced Practitioner in Oncology, 2017, 8, 138-145.	0.2	3
2665	Immune Checkpoint Blockade: Subjugation of the Masses. , 0, , .		0
2666	Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG. Oncotarget, 2017, 8, 44447-44464.	0.8	1
2670	Role of Tumor-Stromal Interactions in Pancreatic Cancer Invasion and Metastases. , 2018, , 1-14.		0
2671	Precision Medicine Based on Next Generation Sequencing and Master Controllers. , 2018, , 1-35.		0
2672	Immune check point inhibitors for head and neck cancer and its proper management on utilizing head and neck cancer collaborative program. Journal of Japanese Society of Oral Oncology, 2018, 30, 144-150.	0.0	0

#	Article	IF	Citations
2673	Immune check point inhibitors for head and neck cancer. Japanese Journal of Head and Neck Cancer, 2018, 44, 336-341.	0.0	0
2674	Photoimmunotherapy for Cancer Metastasis Treatment. Springer Theses, 2018, , 55-63.	0.0	0
2676	GASTRIC CANCER. CURRENT STATE OF MORBIDITY, DIAGNOSIS AND TREATMENT. Bulletin of Problems Biology and Medicine, 2018, 1.1, 62.	0.0	0
2678	ANALYSIS OF PROTEIN EXPRESSION OF PD-L1 IN MALIGNANT PLEURAL MESOTHELIOMA. Russian Journal of Oncology, 2018, 23, 4-9.	0.1	2
2679	çŸ¥ã£ã•¦ãŠãêŸã„éé¸éƒ¨ç–¾æ‚£ã®æœ€æ–°°æƒ…å±. Journal of Otolaryngology of Japan, 2018, 121, 941-943.	0.1	0
2680	Systemic Treatments for Lung Cancer Patients Receiving Hemodialysis. Journal of the Advanced Practitioner in Oncology, 2018, 9, .	0.2	1
2681	A repository of microbial marker genes related to human health and diseases for host phenotype prediction using microbiome data. , 2018, , .		2
2683	Introduction to Melanoma Immunology. , 2019, , 1-15.		0
2684	Molecular Diagnostics in Melanocytic Neoplasia. , 2019, , 1-22.		0
2685	Melanoma Immunology and Immunotherapy. , 2019, , 1-15.		0
2686	Dermatological Complications of Systemic Therapies for Melanoma. , 2019, , 1-22.		0
2687	Melanom. , 2019, , 45-134.		0
2688	Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. , 2019, , 1-24.		0
2689	Immunology of Melanoma. , 2019, , 1-32.		0
2690	Sentinel Lymph Node Biopsy for Eyelid and Conjunctival Malignancies. , 2019, , 261-277.		0
2691	Tackling Immunotherapy Resistance: Developing Rational Combinations of Immunotherapy and Targeted Drugs. Journal of Immunotherapy and Precision Oncology, 2019, 2, 23-35.	0.6	1
2692	Immunotherapy in the Management of Colorectal Cancer Liver Metastasis. , 2020, , 269-282.		0
2693	Solitary Thyroid Nodule. , 2020, , 193-303.		0

#	Article	IF	Citations
2694	Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. , 2020, , 1141-1164.		0
2695	Dermatological Complications of Systemic Therapies for Melanoma. , 2020, , 1337-1358.		0
2697	Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma. Aging, 2020, 12, 10663-10675.	1.4	7
2699	Checkpoint Inhibitor in a Melanoma Patient With Polyendocrinopathy and Gangrenous Gall Bladder With a Mass. Cureus, 2020, 12, e8786.	0.2	0
2702	Non-Neoplastic Diseases of the Anal Canal. , 2020, , 434-445.		0
2703	Normal Oesophageal, Gastric and Duodenal Mucosa. , 2020, , 131-156.		0
2704	Cemiplimab in advanced cutaneous squamous cell carcinoma. Dermatologic Therapy, 2021, 34, e15184.	0.8	4
2705	EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses. Pharmaceuticals, 2021, 14, 1081.	1.7	37
2706	Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma. Journal of Clinical Medicine, 2021, 10, 4994.	1.0	4
2707	Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications. Frontiers in Oncology, 2021, 11, 770561.	1.3	51
2708	Development of a novel humanized mouse model for improved evaluation of in vivo anti-cancer effects of anti-PD-1 antibody. Scientific Reports, 2021, 11, 21087.	1.6	7
2709	Immunology of Melanoma. , 2020, , 41-72.		0
2710	Platinum versus immunotherapy for unresectable esophageal cancer. Medicine (United States), 2020, 99, e23537.	0.4	0
2711	Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma. American Journal of Dermatopathology, 2021, 43, 423-428.	0.3	9
2713	Multidimensional indicators of scholarly impact in the skin oncology literature: is there a correlation between bibliometric and altmetric profiles?. Journal of Plastic Surgery and Hand Surgery, 2021, 55, 232-241.	0.4	3
2714	Abscopal effect in a patient with metastatic NSCLC following a course of radiation therapy to the brain. Meditsinskiy Sovet, 2020, , 188-193.	0.1	0
2715	Nonclinical drug development. , 2022, , 573-588.		0
2716	Cellular Therapy for Melanoma. , 2020, , 1267-1299.		0

#	Article	IF	Citations
2717	Tumor Microenvironment in Penile Cancer. Advances in Experimental Medicine and Biology, 2020, 1296, 291-307.	0.8	0
2719	Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View. , 2020, , 41-68.		0
2722	The Efficacy of Second-line Chemotherapy for Advanced or Metastatic Urothelial Cancer. Anticancer Research, 2020, 40, 1141-1146.	0.5	3
2724	Theoretical Substantiation of Personalized (Target) Therapy of Testicular Germ Cell Tumors. UkraÃ¯nsÊ¹kij Å¾urnal Medicini BÃ¬ologÃ¬Ã¯ Ta Sportu, 2020, 5, 228-236.	0.0	0
2725	Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy. Cancer Immunology, Immunotherapy, 2022, 71, 1549-1567.	2.0	20
2726	PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors. Clinical and Translational Oncology, 2022, 24, 586-596.	1.2	1
2727	Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy. BMC Cancer, 2021, 21, 1187.	1.1	6
2728	Tumorâ€immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas. Journal of Pathology, 2022, 256, 282-296.	2.1	11
2729	The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity. Science Immunology, 2021, 6, eabf4034.	5.6	22
2730	Approach to Reporting Inflammatory Bowel Disease Biopsies. , 2020, , 401-409.		1
2731	Ileal Pouch Anal Anastomosis. , 2020, , 410-416.		0
2732	Diverticular Disease, Mucosal Prolapse, and Related Conditions. , 2020, , 417-433.		0
2733	Drug-Induced Gastrointestinal Disease. , 2020, , 65-83.		0
2734	Melanoma and non-melanoma skin cancer among patients who attended at King Khalid University Hospital in Riyadh, Saudi Arabia from 2007 - 2018. Journal of King Abdulaziz University, Islamic Economics, 2020, 41, 709-714.	0.5	5
2737	Duodenitis. , 2020, , 206-214.		0
2738	Inflammatory Bowel Disease Diagnosis. , 2020, , 325-356.		1
2740	Novel insights on use of doxorubicin to treat chemoresistant TNBC by Immunotherapy. International Journal of Immunotherapy and Cancer Research, 2020, , 016-018.	0.4	0
2741	Complications of Inflammatory Bowel Disease. , 2020, , 388-400.		0

#	Article	IF	Citations
2742	Biomarkers Progress and Therapeutic Implications in Malignant Mesothelioma. , 0, , .		0
2743	Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. American Journal of Cancer Research, 2014, 4, 172-81.	1.4	58
2745	Optimizing dendritic cell-based approaches for cancer immunotherapy. Yale Journal of Biology and Medicine, 2014, 87, 491-518.	0.2	40
2746	A review of 2014 cancer drug approvals, with a look at 2015 and beyond. P and T, 2015, 40, 191-205.	1.0	12
2747	Upregulation of Immune Checkpoint Molecules, PD-1 and LAG-3, on CD4+ and CD8+ T Cells after Gastric Cancer Surgery. Yonago Acta Medica, 2015, 58, 39-44.	0.3	42
2750	Shedding light on the molecular determinants of response to anti-PD-1 therapy. Translational Lung Cancer Research, 2015, 4, 816-9.	1.3	18
2751	PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer. American Journal of Clinical and Experimental Urology, 2016, 4, 1-8.	0.4	22
2752	Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology, 2015, 29, 331-40.	0.4	45
2753	Immunotherapy for lung cancer: advances and prospects. American Journal of Clinical and Experimental Immunology, 2016, 5, 1-20.	0.2	28
2754	Visceral metastases and prostate cancer treatment: 'die hard,' 'tough neighborhoods,' or 'evil humors'?. Oncology, 2014, 28, 974-80.	0.4	13
2755	Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression. Oncology, 2015, 29, 908-20, 922.	0.4	50
2757	How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know. Journal of the Advanced Practitioner in Oncology, 2016, 7, 498-509.	0.2	6
2760	Artificial T Cell Mimetics to Combat Melanoma Tumor Growth. American Journal of Advanced Drug Delivery, 2018, 6, 21-32.	0.1	2
2761	Compound-therapy based on cancer-immunity cycle: promising prospects for antitumor regimens. American Journal of Cancer Research, 2019, 9, 212-218.	1.4	7
2762	A repository of microbial marker genes related to human health and diseases for host phenotype prediction using microbiome data. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2019, 24, 236-247.	0.7	4
2763	Systemic Treatments for Lung Cancer Patients Receiving Hemodialysis. Journal of the Advanced Practitioner in Oncology, 2018, 9, 614-629.	0.2	1
2764	Disulfiram combined with copper induces immunosuppression via PD-L1 stabilization in hepatocellular carcinoma. American Journal of Cancer Research, 2019, 9, 2442-2455.	1.4	12
2765	BRAF in malignant melanoma progression and metastasis: potentials and challenges. American Journal of Cancer Research, 2020, 10, 1103-1114.	1.4	10

#	Article	IF	Citations
2766	Ultrathin metal-organic layer-mediated radiotherapy-radiodynamic therapy enhances immunotherapy of metastatic cancers. Matter, 2019, 1, 1331-1353.	5.0	20
2767	GOLM1 upregulates expression of PD-L1 through EGFR/STAT3 pathway in hepatocellular carcinoma. American Journal of Cancer Research, 2020, 10, 3705-3720.	1.4	4
2768	Is AAV-delivered IL-27 a potential immunotherapeutic for cancer?. American Journal of Cancer Research, 2020, 10, 3565-3574.	1.4	1
2769	Gastrointestinal and liver adverse effects of anti-tumoral immune therapy: from recognition to treatment. Gastroenterology and Hepatology From Bed To Bench, 2021, 14, 195-199.	0.6	0
2770	Systemic Therapy of Advanced Melanoma. , 2021, , 219-237.		0
2771	Amplification of spatially isolated adenosine pathway by tumorâ€“macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma. Journal of Hematology and Oncology, 2021, 14, 200.	6.9	68
2772	Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy. Cancer Immunology, Immunotherapy, 2022, 71, 1681-1691.	2.0	7
2773	Chemokine level predicts the therapeutic effect of anti-PD-1 antibody (nivolumab) therapy for malignant melanoma. Archives of Dermatological Research, 2021, , 1.	1.1	1
2774	Successful Conversion Surgery Following Bullous Pemphigoid after Nivolumab for Advanced Gastric Cancer. Japanese Journal of Gastroenterological Surgery, 2021, 54, 802-812.	0.0	0
2775	Development and Verification of an Immune-Based Gene Signature for Risk Stratification and Immunotherapeutic Efficacy Assessment in Gastric Cancer. Disease Markers, 2021, 2021, 1-41.	0.6	1
2776	Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges. Molecular Therapy - Oncolytics, 2022, 24, 26-42.	2.0	26
2777	Antitumor effect on immune control points (PD-1/PD-L1) in malignant neoplasms. , 2021, 20, 78-84.	0.0	1
2778	Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer. Signal Transduction and Targeted Therapy, 2021, 6, 398.	7.1	84
2779	Pyroptosis-related gene mediated modification patterns and immune cell infiltration landscapes in cutaneous melanoma to aid immunotherapy. Aging, 2021, 13, 24379-24401.	1.4	12
2780	Imaging and quantifying analysis the binding behavior of PD-L1 at molecular resolution by atomic force microscopy. Analytica Chimica Acta, 2022, 1191, 339281.	2.6	5
2781	Therapie des Nierenzellkarzinoms: Das Spektrum erweitert sich. , 0, , .		0
2782	Analysis of human glioma-associated co-inhibitory immune checkpoints in glioma microenvironment and peripheral blood. International Journal of Immunopathology and Pharmacology, 2021, 35, 205873842110565.	1.0	5
2783	A Darwinian perspective on tumor immune evasion. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188671.	3.3	6

#	Article	IF	Citations
2784	Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma. Frontiers in Immunology, 2021, 12, 810388.	2.2	9
2785	Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments. , 2022, 10, e003735.		14
2786	Up-converted nano-gasholder with precise nitric oxide release remodels immunosuppressive microenvironment and potentiates tumor immunotherapy. Nano Today, 2022, 42, 101381.	6.2	10
2787	PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?. International Immunopharmacology, 2022, 103, 108484.	1.7	2
2788	Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases. Frontiers in Pharmacology, 2021, 12, 790963.	1.6	17
2789	Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma. International Journal of Molecular Sciences, 2022, 23, 1119.	1.8	10
2790	Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?. Journal of Hematology and Oncology, 2022, 15, 6.	6.9	17
2791	Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention. Journal of Oncology, 2022, 2022, 1-12.	0.6	1
2792	Crosslinked Protein Delivery Strategy with Precise Activity Regulation Properties for Cancer Therapy and Gene Editing. Advanced Healthcare Materials, 2022, 11, e2102329.	3.9	1
2793	Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia. , 2022, 10, e003392.		34
2794	A 25 Gene Panel Predicting the Benefits of Immunotherapy in Head and Neck Squamous Cell Carcinoma. SSRN Electronic Journal, 0, , .	0.4	0
2795	Expression of Immunomodulatory Checkpoint Molecules in Drug-Resistant Neuroblastoma: An Exploratory Study. Cancers, 2022, 14, 751.	1.7	5
2796	Pembrolizumab-related cholangitis with multiple fatal liver abscesses after endoscopic biliary drainage: a case report and review of the literature. Clinical Journal of Gastroenterology, 2022, 15, 475.	0.4	6
2797	CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review. Journal of the Neurological Sciences, 2022, 432, 120089.	0.3	10
2798	The Interplay Between Epigenetic Regulation and CD8+ T Cell Differentiation/Exhaustion for T Cell Immunotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 783227.	1.8	11
2799	Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment. Frontiers in Immunology, 2021, 12, 832942.	2.2	18
2800	Pioneer Role of Extracellular Vesicles as Modulators of Cancer Initiation in Progression, Drug Therapy, and Vaccine Prospects. Cells, 2022, 11, 490.	1.8	21
2801	Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias. Cells, 2022, 11, 139.	1.8	6

#	Article	IF	Citations
2802	Perspectives on the role of breast cancer susceptibility gene in breast cancer. International Journal of Clinical Oncology, 2022, 27, 495-511.	1.0	1
2803	Immunotherapy for glioblastoma: the promise of combination strategies. Journal of Experimental and Clinical Cancer Research, 2022, 41, 35.	3.5	85
2804	Establishment of operational tolerance to sustain antitumor immunotherapy. Journal of Heart and Lung Transplantation, 2022, 41, 568-577.	0.3	1
2805	The current landscape of immunotherapy for pediatric brain tumors. Nature Cancer, 2022, 3, 11-24.	5.7	21
2806	Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1. Frontiers in Immunology, 2021, 12, 806043.	2.2	7
2807	Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity. Journal of Clinical Investigation, 2022, 132, .	3.9	38
2808	IL-2 complex recovers steroid-induced inhibition in immunochemotherapy for head and neck cancer. Translational Oncology, 2022, 18, 101358.	1.7	5
2809	CHOROIDAL NEOVASCULAR MEMBRANES ASSOCIATED WITH PAPILLITIS IN A PATIENT ON CHECKPOINT INHIBITOR. Retinal Cases and Brief Reports, 2023, 17, 625-629.	0.3	1
2810	Current Immunotherapeutic Approaches for Malignant Gliomas. Brain Tumor Research and Treatment, 2022, 10, 1.	0.4	5
2811	Cilengitide, an Î±vÎ²3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model. Bioengineered, 2022, 13, 4557-4572.	1.4	6
2812	Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy. Frontiers in Immunology, 2022, 13, 840313.	2.2	19
2813	Microwave ablation combined with anti-PD-1 therapy enhances systemic antitumor immunity in a multitumor murine model of Hepa1-6. International Journal of Hyperthermia, 2022, 39, 278-286.	1.1	19
2814	Recent advance in nanomaterials for cancer immunotherapy. Chemical Engineering Journal, 2022, 435, 134145.	6.6	16
2815	Fluorescence imaging of tumor immune contexture in immune checkpoint blockade therapy. International Immunopharmacology, 2022, 106, 108617.	1.7	5
2816	Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ TÂcell population that sustains anti-tumor immunity. Immunity, 2021, 54, 2825-2841.e10.	6.6	57
2817	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. Immune Network, 2022, 22, e2.	1.6	53
2818	Anion Receptor-Mediated Multicomponent Synergistic Self-Assembly of Porphyrin for Efficient Phototherapy Elicit ÂTumor Immunotherapy. SSRN Electronic Journal, 0, , .	0.4	0
2819	Neurological complications of GI cancers. , 2022, , 365-386.		0

#	Article	IF	Citations
2822	Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. , 2022, 10, e003026.		38
2823	Role of Hypoxia in the Interferon Response. Frontiers in Immunology, 2022, 13, 821816.	2.2	5
2824	An artificial intelligence method to assess the tumor microenvironment with treatment outcomes for gastric cancer patients after gastrectomy. Journal of Translational Medicine, 2022, 20, 100.	1.8	8
2825	An Immune-Related Gene Pair Index Predicts Clinical Response and Survival Outcome of Immune Checkpoint Inhibitors in Melanoma. Frontiers in Immunology, 2022, 13, 839901.	2.2	1
2826	Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy. Frontiers in Bioengineering and Biotechnology, 2022, 10, 847901.	2.0	13
2827	Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2022, 13, 801909.	2.2	4
2828	Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1â€“Resistant Melanoma. Cancer Immunology Research, 2022, 10, 612-625.	1.6	12
2829	The immune microenvironment in gastric adenocarcinoma. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 451-467.	8.2	47
2830	Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ÃŸ-mediated suppression of immune checkpoint receptor expression. OncoImmunology, 2022, 11, 2054758.	2.1	7
2831	Tim-3 mediates T cell trogocytosis to limit antitumor immunity. Journal of Clinical Investigation, 2022, 132, .	3.9	25
2832	Evolution of surgical treatment of metastatic spine tumors. Journal of Neuro-Oncology, 2022, 157, 277-283.	1.4	0
2833	Risk of Immune-Related Pneumonitis with PD-1/PD-L1 Inhibitors in Different Cancer Types and Treatment Regimens: A Systematic Review and Meta-Analysis of 22 Randomized Controlled Trials. Chemotherapy, 2023, 68, 1-15.	0.8	0
2834	Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis. Lung Cancer, 2022, 167, 49-57.	0.9	7
2835	Ketogenic diet inhibits tumor growth by enhancing immune response, attenuating immunosuppression, inhibiting angiogenesis and EMT in CT26 colon tumor allografts mouse model. Journal of Functional Foods, 2022, 92, 105067.	1.6	5
2836	Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy. , 2021, 9, e003439.		10
2837	An immune-associated ten-long noncoding RNA signature for predicting overall survival in cervical cancer. Translational Cancer Research, 2021, 10, 5295-5306.	0.4	3
2838	HOXA-AS3 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells via the miR-455-5p/PD-L1 Axis. Journal of Immunology Research, 2021, 2021, 1-12.	0.9	13
2839	Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor. Frontiers in Immunology, 2021, 12, 793831.	2.2	16

#	Article	IF	Citations
2840	Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response. Nature Communications, 2021, 12, 7297.	5.8	25
2841	Soluble PD-L1 Concentration Is Proportional to the Expression of PD-L1 in Tissue and Is Associated with a Poor Prognosis in Esophageal Squamous Cell Carcinoma. Oncology, 2022, 100, 39-47.	0.9	8
2842	The Monoclonal Antibody Pembrolizumab Alters Dynamics of the Human Programmed Cell Death Receptor 1 (PD-1). , 2021, , .		2
2843	Disruption of Her2-Induced PD-L1 Inhibits Tumor Cell Immune Evasion in Patient-Derived Gastric Cancer Organoids. Cancers, 2021, 13, 6158.	1.7	17
2844	The Transmembrane Receptor TIRC7 Identifies a Distinct Subset of Immune Cells with Prognostic Implications in Cholangiocarcinoma. Cancers, 2021, 13, 6272.	1.7	1
2845	The spectrum of clinical trials aiming at personalizing medicine. Chinese Clinical Oncology, 2014, 3, 13.	0.4	15
2846	Anchoring a Xenogeneic Antigenâ€Guided Immune Activation System to Tumor Cell Membrane for Solid Tumor Treatment. Advanced Functional Materials, 0, , 2111499.	7.8	5
2847	Functional Characteristics of Kombucha Fermented with Lactic Acid Bacteria, Yeast, and Acetic Acid Bacteria Derived from Korea Traditional Foods. Journal of Dairy Science and Biotechnology, 2022, 40, 23-34.	0.5	1
2848	Mechanisms of Immunotherapy Resistance in Cutaneous Melanoma: Recognizing a Shapeshifter. Frontiers in Oncology, 2022, 12, 880876.	1.3	21
2849	A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy. Nature Nanotechnology, 2022, 17, 531-540.	15.6	125
2850	Expression of CD39 Identifies Activated Intratumoral CD8+ T Cells in Mismatch Repair Deficient Endometrial Cancer. Cancers, 2022, 14, 1924.	1.7	5
2900	Cancer immunotherapy resistance: The impact of microbiome-derived short-chain fatty acids and other emerging metabolites. Life Sciences, 2022, 300, 120573.	2.0	6
2903	Checkpoint inhibitors in treatment of metastatic mucosal melanoma. Chinese Clinical Oncology, 2014, 3, 37.	0.4	6
2904	Toxicity of checkpoint inhibitors. Chinese Clinical Oncology, 2014, 3, 31.	0.4	12
2905	Role of immune system in TNBC. , 2022, , 121-148.		8
2906	Dose Finding in Oncology: What is Impeding Coming of Age?. Pharmaceutical Research, 2022, , 1.	1.7	1
2907	Companion Diagnostics: Lessons Learned and the Path Forward From the Programmed Death Ligand-1 Rollout. Archives of Pathology and Laboratory Medicine, 2023, 147, 62-70.	1.2	2
2908	Computational Investigations on the Natural Small Molecule as an Inhibitor of Programmed Death Ligand 1 for Cancer Immunotherapy. Life, 2022, 12, 659.	1.1	4

#	Article	IF	Citations
2909	The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies. Cancers, 2022, 14, 2177.	1.7	2
2910	Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy. Acta Pharmacologica Sinica, 2022, 43, 2749-2758.	2.8	16
2911	Immune checkpoint inhibition in patients with inactive pre-existing neuromuscular autoimmune diseases. Journal of the Neurological Sciences, 2022, 438, 120275.	0.3	5
2912	Therapeutic Effects of Cold Atmospheric Plasma on Solid Tumor. Frontiers in Medicine, 2022, 9, .	1.2	13
2914	The roles of TGF-Î² and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors. , 2022, 240, 108211.		21
2915	ROLE OF MONOCLONAL ANTIBODIES AGAINST THE PROGRAMMABLE DEATH (PD-1) RECEPTOR OF T-CELLS IN TARGETED THERAPY OF MELANOMA. Eurasian Journal of Applied Biotechnology, 2018, , .	0.0	0
2916	Nanomedicines and nanomaterials for cancer therapy: Progress, challenge and perspectives. Chemical Engineering Journal, 2022, 446, 137147.	6.6	35
2917	Trimodal Imaging-Guided Photothermal-Immunotherapy of Triple-Negative Breast Cancer Enhanced by Ph-Responsive and Cancer Membrane-Coated Polydopamin-Caco3 Nanoparticles. SSRN Electronic Journal, 0, , .	0.4	0
2919	Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency. Advanced Science, 2022, 9, .	5.6	140
2920	When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents. Targeted Oncology, 2022, 17, 253-270.	1.7	5
2921	Review of the Clinical Pharmacokinetics, Efficacy and Safety of Pembrolizumab. Current Drug Metabolism, 2022, 23, 460-472.	0.7	6
2922	Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis. Pharmaceuticals, 2022, 15, 747.	1.7	18
2923	Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies. Frontiers in Oncology, 0, 12, .	1.3	19
2924	Adenosine-Deaminase-Acting-on-RNA-1 Facilitates T-cell Migration toward Human Melanoma Cells. Cancer Immunology Research, 2022, 10, 1127-1140.	1.6	4
2925	Resveratrol in Cancer Treatment with a Focus on Breast Cancer. Current Molecular Pharmacology, 2023, 16, 346-361.	0.7	2
2926	PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells. Frontiers in Immunology, 0, 13, .	2.2	4
2927	Application of molecular imaging in immune checkpoints therapy: From response assessment to prognosis prediction. Critical Reviews in Oncology/Hematology, 2022, 176, 103746.	2.0	1
2928	Recent trends in cancer immunotherapy: Pathways and inhibitors. , 2022, , 39-50.		0

#	Article	IF	Citations
2929	ICIs-Related Cardiotoxicity in Different Types of Cancer. Journal of Cardiovascular Development and Disease, 2022, 9, 203.	0.8	11
2930	Synergistic antitumor effect of a penicillin derivative combined with thapsigargin in melanoma cells. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	1
2931	Multiplex Immunofluorescence and the Digital Image Analysis Workflow for Evaluation of the Tumor Immune Environment in Translational Research. Frontiers in Oncology, 0, 12, .	1.3	12
2932	Dynamic Analysis of a Model on Tumor-Immune System with Regulation of PD-1/PD-L1 and Stimulation Delay of Tumor Antigen. Qualitative Theory of Dynamical Systems, 2022, 21, .	0.8	2
2933	Significance of the effects of chemotherapy on programmed death-ligand 1 expression in triple-negative breast cancer. Japanese Journal of Clinical Oncology, 0, , .	0.6	0
2934	Research Progress of DUB Enzyme in Hepatocellular Carcinoma. Frontiers in Oncology, 0, 12, .	1.3	5
2935	The structural conformation of the tachykinin domain drives the antiâ€tumoral activity of an octopus peptide in melanoma BRAF ^{V600E}. British Journal of Pharmacology, 0, , .	2.7	1
2936	Generation, secretion and degradation of cancer immunotherapy target PD-L1. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	5
2937	CCND1 Amplification Profiling Identifies a Subtype of Melanoma Associated With Poor Survival and an Immunosuppressive Tumor Microenvironment. Frontiers in Immunology, 0, 13, .	2.2	6
2938	The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 834-844.	2.3	11
2939	A 25-gene panel predicting the benefits of immunotherapy in head and neck squamous cell carcinoma. International Immunopharmacology, 2022, 110, 108846.	1.7	4
2941	Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study. , 2022, 10, e004879.		14
2942	Immune Response Regulation has Therapeutic Potential in the Treatment of Cancer. McGill Science Undergraduate Research Journal, 2015, 10, 37-44.	0.1	0
2943	Response assessment in neuro-oncology criteria. , 2022, , 491-499.		1
2944	Effect of Gut Microbiota-Derived Metabolites on Immune Checkpoint Inhibitor Therapy: Enemy or Friend?. Molecules, 2022, 27, 4799.	1.7	9
2945	Combined Blockade Of PD-1 and TIGIT is not Sufficient to Improve the Function Of CD8+ T-Cells in Chronic Lymphocytic Leukemia. Asian Pacific Journal of Cancer Prevention, 2022, 23, 2225-2231.	0.5	3
2946	Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Frontiers in Oncology, 0, 12, .	1.3	32
2947	Cancer: Immunology and Immunotharapy. Research Journal of Pharmacology and Pharmacodynamics, 2022, , 159-164.	0.1	2

#	Article	IF	Citations
2948	Design, synthesis, and evaluation of PD-L1 degraders to enhance T cell killing activity against melanoma. Chinese Chemical Letters, 2023, 34, 107762.	4.8	11
2949	PD-L1 Expression in Endometrial Cancer and Its Association with Clinicopathological Features: A Systematic Review and Meta-Analysis. Cancers, 2022, 14, 3911.	1.7	15
2950	Core immune cell infiltration signatures identify molecular subtypes and promote precise checkpoint immunotherapy in cutaneous melanoma. Frontiers in Immunology, 0, 13, .	2.2	8
2951	Identifying immune cells-related phenotype to predict immunotherapy and clinical outcome in gastric cancer. Frontiers in Immunology, 0, 13, .	2.2	2
2952	Escherichia coliâ€“Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer. Cancer Discovery, 2022, 12, 2280-2307.	7.7	23
2953	Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials. Frontiers in Oncology, 0, 12, .	1.3	0
2954	Macrophages in melanoma: A doubleâ€‘edged sword and targeted therapy strategies (Review). Experimental and Therapeutic Medicine, 2022, 24, .	0.8	9
2955	HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma. Frontiers in Immunology, 0, 13, .	2.2	5
2956	Anion receptor-mediated multicomponent synergistic self-assembly of porphyrin for efficient phototherapy to elicit tumor immunotherapy. Nano Today, 2022, 46, 101579.	6.2	9
2957	Use of heparin to rescue immunosuppressive monocyte reprogramming by glioblastoma-derived extracellular vesicles. Journal of Neurosurgery, 2022, , 1-11.	0.9	1
2958	Engineered T cell extracellular vesicles displaying PD-1 boost anti-tumor immunity. Nano Today, 2022, 46, 101606.	6.2	23
2959	Tumor-Associated Renal Disease: New Challenges for Clinicians. Advances in Clinical Medicine, 2022, 12, 7135-7141.	0.0	0
2960	Prognostic and immune-related value of complement C1Q (C1QA, C1QB, and C1QC) in skin cutaneous melanoma. Frontiers in Genetics, 0, 13, .	1.1	11
2961	Disrupting the Interplay between Programmed Cell Death Protein 1 and Programmed Death Ligand 1 with Spherical Nucleic Acids in Treating Cancer. ACS Central Science, 2022, 8, 1299-1305.	5.3	8
2962	VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes. Journal of Medical Virology, 2023, 95, .	2.5	6
2963	Endogenous DOPA inhibits melanoma through suppression of CHRM1 signaling. Science Advances, 2022, 8, .	4.7	8
2964	Tissue engineered cancer metastases as cancer vaccine to improve cancer immunotherapy. Acta Biomaterialia, 2022, 153, 299-307.	4.1	1
2965	ICBatlas: A Comprehensive Resource for Depicting Immune Checkpoint Blockade Therapy Characteristics from Transcriptome Profiles. Cancer Immunology Research, 2022, 10, 1398-1406.	1.6	12

#	Article	IF	Citations
2966	Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment. Pharmaceutics, 2022, 14, 2076.	2.0	10
2967	Current and promising treatment strategies in glioma. Reviews in the Neurosciences, 2022, .	1.4	3
2968	Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	4
2969	Neoantigens and their clinical applications in human gastrointestinal cancers. World Journal of Surgical Oncology, 2022, 20, .	0.8	1
2971	Chemotherapy in combination with anti-PD-1 agents as adjuvant therapy for high-risk oral mucosal melanoma. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	1
2972	A Therapy-Terminating Event: Programmed Death-1 Inhibitor-Induced Mucositis. Cureus, 2022, , .	0.2	0
2973	Firstâ€inâ€human study of <scp>ONO</scp>â€4578, an antagonist of prostaglandin <scp>E₂</scp> receptor 4, alone and with nivolumab in solid tumors. Cancer Science, 2023, 114, 211-220.	1.7	4
2974	Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma. Frontiers in Genetics, 0, 13, .	1.1	6
2975	Pembrolizumab leading to complete resolution of non-small cell lung cancer and microsatellite instability stable colon adenocarcinoma; two birds one stone. Journal of Case Reports and Images in Oncology, 2022, 8, 20-27.	0.0	0
2976	Risk of developing hypothyroidism with the use of tyrosine kinase inhibitors and immune checkpoint inhibitors. Cancer Epidemiology, 2022, 81, 102265.	0.8	2
2978	lncRNAs AC156455.1 and AC104532.2 as Biomarkers for Diagnosis and Prognosis in Colorectal Cancer. Disease Markers, 2022, 2022, 1-13.	0.6	2
2980	Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1. , 2022, 19, 1290-1301.		13
2982	Rational design of a Nivolumab-based ANTI-PD-1 single chain variable fragment that blocks the interaction between PD-1 expressed on T-CELLS and PD-L1 ON CHO cells. Protein Expression and Purification, 2023, 202, 106196.	0.6	2
2983	Evolving therapeutic proteins to precisely kill cancer cells. Journal of Controlled Release, 2022, 351, 779-804.	4.8	2
2984	Loss of LXN promotes macrophage M2 polarization and PD-L2 expression contributing cancer immune-escape in mice. Cell Death Discovery, 2022, 8, .	2.0	2
2985	The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. Life Sciences, 2022, 310, 121138.	2.0	14
2986	A single dose of heated chemo-immunotherapy for long-term tumor inhibition. Nano Today, 2022, 47, 101650.	6.2	1
2987	Proarrhythmic effects of cancer therapies. In A Good Rythm, 2022, 2, 16-22.	0.0	0

#	Article	IF	Citations
2988	Bioinformatic analysis identifies HPV-related tumor microenvironment remodeling prognostic biomarkers in head and neck squamous cell carcinoma. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	6
2989	Quantitative Radiological Features and Deep Learning for the Non-Invasive Evaluation of Programmed Death Ligand 1 Expression Levels in Gastric Cancer Patients: A Digital Biopsy Study. Academic Radiology, 2023, 30, 1317-1328.	1.3	4
2990	SLC11A1 associated with tumor microenvironment is a potential biomarker of prognosis and immunotherapy efficacy for colorectal cancer. Frontiers in Pharmacology, 0, 13, .	1.6	4
2991	Transdermal nanolipoplex simultaneously inhibits subcutaneous melanoma growth and suppresses systemically metastatic melanoma by activating host immunity. Nanomedicine: Nanotechnology, Biology, and Medicine, 2023, 47, 102628.	1.7	2
2993	Exosomes in Genitourinary Cancers: Emerging Mediators of Drug Resistance and Promising Biomarkers. International Journal of Biological Sciences, 2023, 19, 167-182.	2.6	3
2994	Comprehensive multi-omics analysis of the m7G in pan-cancer from the perspective of predictive, preventive, and personalized medicine. EPMA Journal, 2022, 13, 671-697.	3.3	11
2995	A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma. Nature Communications, 2022, 13, .	5.8	18
2996	The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy. Biomedicines, 2022, 10, 3154.	1.4	4
2997	Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. Cell Reports Medicine, 2023, 4, 100868.	3.3	16
2998	An Efficient Combination Immunotherapy for Antitumor Immunity without Accelerating Cardiac Allograft Rejection. Immunology, 0, , .	2.0	2
2999	Aptamer-Based Immunotheranostic Strategies. Cancer Biotherapy and Radiopharmaceuticals, 2023, 38, 246-255.	0.7	1
3000	Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens. Nature Genetics, 2023, 55, 19-25.	9.4	11
3001	Genome-wide DNA methylation profile analysis identifies an individualized predictive signature for melanoma immune response. Journal of Cancer Research and Clinical Oncology, 2023, 149, 343-356.	1.2	2
3002	Combined Immune Checkpoint Blockade Enhances Antiviral Immunity against Bovine Leukemia Virus. Journal of Virology, 2023, 97, .	1.5	1
3003	Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients. Biotechnology and Genetic Engineering Reviews, 0, , 1-14.	2.4	0
3004	The differential expression of toll like receptors and RIG-1 correlates to the severity of infectious diseases. Annals of Diagnostic Pathology, 2023, 63, 152102.	0.6	0
3005	Biomimetic, pH-Responsive Nanoplatforms for Cancer Multimodal Imaging and Photothermal Immunotherapy. ACS Applied Materials & Interfaces, 2023, 15, 1784-1797.	4.0	11
3006	Impact of Precision Medicine in Oncology. Cancer Journal (Sudbury, Mass), 2023, 29, 15-19.	1.0	1

#	Article	IF	Citations
3007	Cancer immunotherapy via nucleic acid aptamers. , 2023, , 317-346.		0
3008	ImmunoPET Imaging of Immune Checkpoints to Assess Their Cancer Therapeutic Potential. , 2023, , 1-34.		0
3009	An Immunogenic Cell Death-Related Gene Signature Reflects Immune Landscape and Predicts Prognosis in Melanoma Independently of BRAF V600E Status. BioMed Research International, 2023, 2023, 1-21.	0.9	2
3010	Data mining combines bioinformatics discover immunoinfiltration-related gene SERPINE1 as a biomarker for diagnosis and prognosis of stomach adenocarcinoma. Scientific Reports, 2023, 13, .	1.6	7
3011	High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer. JCO Precision Oncology, 2023, , .	1.5	6
3012	Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle. European Medical Journal Oncology, 0, , 70-76.	0.0	1
3013	Long-term persistence and functionality of adoptively transferred antigen-specific T cells with genetically ablated PD-1 expression. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	9
3014	The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade. Biomedicine and Pharmacotherapy, 2023, 161, 114436.	2.5	2
3015	Organoids as an Enabler of Precision Immuno-Oncology. Cells, 2023, 12, 1165.	1.8	2
3017	Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer. Frontiers in Oncology, 0, 13, .	1.3	3
3018	Association between Loss of Immune Checkpoint Programmed Cell Death Protein 1 and Active ANCA-Associated Renal Vasculitis. International Journal of Molecular Sciences, 2023, 24, 2975.	1.8	3
3019	A narrative review of genetic biomarkers in non-small cell lung cancer: an update and future perspectives. AME Medical Journal, 0, 8, 6-6.	0.4	1
3020	Characterization of the immune cell landscape in CRC: Clinical implications of tumour-infiltrating leukocytes in early- and late-stage CRC. Frontiers in Immunology, 0, 13, .	2.2	6
3021	Effects of KMT2D mutation and its exon 39 mutation on the immune microenvironment and drug sensitivity in colorectal adenocarcinoma. Heliyon, 2023, 9, e13629.	1.4	0
3022	Caspase-9-mediated cleavage of vimentin attenuates the aggressiveness of leukemic NB4 cells. Molecular and Cellular Biochemistry, 0, , .	1.4	0
3023	Modulating the tumor microenvironment improves antitumor effect of anti-PD-L1 mAb in breast cancer. BioImpacts, 0, , .	0.7	0
3024	Regulation of programmed death ligand 1 expression by interferonâ€î³ and tumour necrosis factorâ€îµ in canine tumour cell lines. Veterinary and Comparative Oncology, 0, , .	0.8	0
3025	Immunotherapy of Cancer: Towards a New Era. European Medical Journal Oncology, 0, , 76-82.	0.0	0

#	Article	IF	Citations
3026	Molecular phenotypic linkage between N6-methyladenosine methylation and tumor immune microenvironment in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
3027	Antitumor Therapy Targeting the Tumor Microenvironment. Journal of Oncology, 2023, 2023, 1-16.	0.6	4
3028	The influence of metastatic patterns and tumor load on therapeutic efficacy of immunotherapy in patients with metastatic melanoma as determined by quantitative PET-parameters using [18F]-fluorodeoxyglucose PET/computed tomography. Melanoma Research, 2023, 33, 199-207.	0.6	0
3029	Status and prognostic value of immunological biomarkers of breast cancer. Oncology Letters, 2023, 25, .	0.8	1
3030	Immune profiling and prognostic model of pancreatic cancer using quantitative pathology and single-cell RNA sequencing. Journal of Translational Medicine, 2023, 21, .	1.8	7
3031	Changes in Tumor Immune Microenvironment after Radiotherapy Resistance in Colorectal Cancer: A Narrative Review. Oncology Research and Treatment, 2023, 46, 177-191.	0.8	0
3032	Tumors evade immune cytotoxicity by altering the surface topology of NK cells. Nature Immunology, 2023, 24, 802-813.	7.0	17
3034	Anlotinib succeeded in rescue therapy for hyperprogression induced by immune checkpoint inhibitors: a case report. Immunotherapy, 2023, 15, 631-639.	1.0	2
3035	Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell, 2023, 186, 1846-1862.e26.	13.5	92
3036	Biomaterial-Based Delivery Systems for Chemotherapeutics. Biological and Medical Physics Series, 2023, , 105-178.	0.3	2
3047	The major clinical components of cancer immunotherapy (modulating cell-mediated immune) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 342		0
3062	Crosstalk between immune checkpoint and DNA damage response inhibitors for radiosensitization of tumors. Strahlentherapie Und Onkologie, 2023, 199, 1152-1163.	1.0	2
3080	Immunotherapy for Melanoma. , 2023, , 1693-1712.		0
3082	Natural cationic polymer-derived injectable hydrogels for targeted chemotherapy. Materials Advances, 2023, 4, 6064-6091.	2.6	1
3087	Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy. 3 Biotech, 2023, 13, .	1.1	0
3101	Immune Checkpoint Inhibitors and Systemic Side Effects: Overview for the Inpatient Dermatologist. Current Dermatology Reports, 2023, 12, 225-232.	1.1	0
3115	Roles of exosomes in immunotherapy for solid cancers. Cell Death and Disease, 2024, 15, .	2.7	0
3118	Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma. American Journal of Clinical Dermatology, 0, , .	3.3	0

#	Article	IF	Citations